var title_f1_50_1824="2D TTE 2-chamber descending thoracic aorta";
var content_f1_50_1824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from a modified two-chamber view showing the descending thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The descending thoracic aorta (T Ao) can be imaged from the apical two and four chamber view. Posterior angulation of the transducer (panel A) often opens the T Ao such that it can be seen in its long axis. Major pathology such as aneurysms can often be detected in this way. Anterior angulation in the apical two chamber view (panel B) demonstrates the proximal aortic arch (Ao).",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; rpa: right pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1824=[""].join("\n");
var outline_f1_50_1824=null;
var title_f1_50_1825="C1-INH deficiency diagnostic";
var content_f1_50_1825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    C1-INH deficiency diagnostic algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 657px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Bowen T, Cicardi M, Farkas H, et al. 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Allergy, Asthma, and Clinical Immunology 2010; 6:24. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1825=[""].join("\n");
var outline_f1_50_1825=null;
var title_f1_50_1826="Patient information: Nosebleeds (The Basics)";
var content_f1_50_1826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15461\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/21/16735\">",
"         How to stop a nosebleed",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/4/41026\">",
"         Patient information: Nose fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/10/19617\">",
"         Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nosebleeds (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nosebleeds-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H480410368\">",
"      <span class=\"h1\">",
"       Why do people get nosebleeds?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be scary when blood starts coming out your nose or your child's nose. But nosebleeds are not usually serious. They are very common. The most common causes are dry air and nose-picking.",
"     </p>",
"     <p>",
"      If you or your child gets a nosebleed, the important thing is to know how to deal with it. With the right care, most nosebleeds stop on their own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410375\">",
"      <span class=\"h1\">",
"       How do I know if a nosebleed is serious?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see a doctor or nurse right away if your nosebleed:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Causes blood to gush out of your nose or makes it hard to breathe",
"       </li>",
"       <li>",
"        Causes you to turn very pale, or makes you tired or confused",
"       </li>",
"       <li>",
"        Will not stop even after you do the \"self-care\" steps listed below",
"       </li>",
"       <li>",
"        Happens right after surgery on your nose, or if you know you have a growth in your nose",
"       </li>",
"       <li>",
"        Happens with other serious symptoms, such as chest pain",
"       </li>",
"       <li>",
"        Happens after an injury, such as being hit in the face",
"       </li>",
"       <li>",
"        Will not stop, and you take medicines that prevent clotting, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"        (sold as Coumadin&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?21/11/21685?source=see_link\">",
"         clopidogrel",
"        </a>",
"        (sold as Plavix&reg;), or daily",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have chest pain, feel woozy, or if you are bleeding a lot, call 9-1-1. Do",
"      <strong>",
"       not",
"      </strong>",
"      drive yourself to the hospital and do not ask someone else to drive you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410382\">",
"      <span class=\"h1\">",
"       Nosebleed self-care",
"      </span>",
"      &nbsp;&mdash;&nbsp;With the right self-care, most nosebleeds stop on their own. Here's what you should do:",
"     </p>",
"     <p>",
"      1.",
"      <strong>",
"       Blow your nose.",
"      </strong>",
"      This may increase the bleeding for a moment, but that's OK.",
"     </p>",
"     <p>",
"      2.",
"      <strong>",
"       Sit or stand while bending forward a little at the waist.",
"      </strong>",
"      DO NOT lie down or tilt your head back.",
"     </p>",
"     <p>",
"      3.",
"      <strong>",
"       Pinch the soft area towards the bottom of your nose, below the bone",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef62213 \" href=\"UTD.htm?16/21/16735\">",
"       picture 1",
"      </a>",
"      ). DO NOT grip the bridge of your nose between your eyes. That will not work. DO NOT press on just one side, even if the bleeding is only on one side. That will not work either.",
"     </p>",
"     <p>",
"      4.",
"      <strong>",
"       Squeeze your nose shut for at least 15 minutes. (In children, squeeze for only 5 minutes.) Use a clock to time yourself.",
"      </strong>",
"      Do not release the pressure before the time is up to check if the bleeding has stopped. If you keep checking, you will ruin your chances of getting the bleeding to stop.",
"     </p>",
"     <p>",
"      If you follow these steps, and your nose keeps bleeding, repeat all the steps once more. Apply pressure for a total of at least",
"      <strong>",
"       30 minutes (or 10 minutes for children)",
"      </strong>",
"      . If you are still bleeding, go to the emergency room or an urgent care clinic.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410389\">",
"      <span class=\"h1\">",
"       What if I get repeated nosebleeds?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Frequent nosebleeds can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breathing dry air all the time",
"       </li>",
"       <li>",
"        Using cold or allergy nasal sprays too much",
"       </li>",
"       <li>",
"        Frequent colds",
"       </li>",
"       <li>",
"        Snorting drugs into your nose, such as cocaine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, repeat nosebleeds can be a sign that your blood does not clot like it should. If that is the case, there are often other clues. For instance, people with clotting problems bruise easily and may bleed more than you would expect after a small cut or scrape.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410396\">",
"      <span class=\"h1\">",
"       Nosebleed treatment",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you end up seeing a doctor or nurse for your nosebleed, he or she will make sure you can breathe OK. Then he or she will try to get the bleeding to stop. To do that, he or she may have to put a device or some packing material up your nose.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410403\">",
"      <span class=\"h1\">",
"       What can I do to keep from getting nosebleeds?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a humidifier (a machine that makes the air less dry) in your bedroom when you sleep",
"       </li>",
"       <li>",
"        Keep the inside of your nose moist with a nasal saline spray or gel",
"       </li>",
"       <li>",
"        Not pick your nose, or at least clip your nails before you do to avoid injury",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480410410\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/4/41026?source=see_link\">",
"       Patient information: Nose fracture (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=see_link\">",
"       Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/50/1826?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15461 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-39486C3A7C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1826=[""].join("\n");
var outline_f1_50_1826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410368\">",
"      Why do people get nosebleeds?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410375\">",
"      How do I know if a nosebleed is serious?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410382\">",
"      Nosebleed self-care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410389\">",
"      What if I get repeated nosebleeds?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410396\">",
"      Nosebleed treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410403\">",
"      What can I do to keep from getting nosebleeds?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480410410\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/21/16735\">",
"      How to stop a nosebleed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/4/41026?source=related_link\">",
"      Patient information: Nose fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=related_link\">",
"      Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1827="Withdrawal syndromes with antihypertensive therapy";
var content_f1_50_1827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Withdrawal syndromes with antihypertensive therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1827/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1827/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1827/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1827/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1827/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1827/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/50/1827/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt discontinuation of successful antihypertensive therapy can result in one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatively rapid, asymptomatic return of the blood pressure (BP) to pretreatment levels.",
"     </li>",
"     <li>",
"      Slower, asymptomatic return of BP to pre-treatment levels.",
"     </li>",
"     <li>",
"      Rebound of the BP with symptoms and signs of sympathetic overactivity (a withdrawal syndrome).",
"     </li>",
"     <li>",
"      Overshoot of the BP above pretreatment levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most commonly, discontinuation of antihypertensive therapy leads to a gradual rise in the BP to pretreatment levels over a period of days to as long as six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some mild hypertensives who withdraw medications can remain normotensive 12 months or longer off medication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; concurrent institution of comprehensive dietary modification (weight reduction, salt restriction, and avoidance of excess alcohol intake) can delay or even prevent recurrent hypertension in up to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18068?source=see_link\">",
"     \"Can therapy be discontinued in well-controlled hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WITHDRAWAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal syndromes has been reported most frequently with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    (but can also be seen with transdermal clonidine), and are thought to reflect a rapid return of catecholamine secretion that had been suppressed during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Patients who concurrently take a beta blocker may be particularly susceptible; the sudden surge in plasma catecholamines leads to unopposed peripheral alpha-receptor-mediated vasoconstriction because the beta-receptors are blocked and cannot mediate vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abrupt withdrawal of beta blockers may also lead to a withdrawal syndrome, presumably due to increased sympathetic activity related to adrenergic receptor upregulation during the period of sympathetic blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of sympathetic overactivity depends upon the relationship between the rate at which the antihypertensive wears off and the rate at which the receptors downregulate (the latter has a half-life of 24 to 36 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, a hyperadrenergic state is most likely with short-acting drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ), since receptor upregulation will persist after the antihypertensive effect has disappeared [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. In comparison, withdrawal syndromes are relatively unusual with longer-acting agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and beta blocker withdrawal are somewhat different:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary clinical manifestation following abrupt cessation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      therapy is acute, rebound hypertension above the pretreatment level [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5\">",
"       5",
"      </a>",
"      ]. Rebound hypertension usually occurs after abrupt cessation of fairly large oral doses, but has also been noted with transdermal clonidine [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to a rise in BP, beta blocker withdrawal in patients with underlying coronary disease can lead to accelerated angina, myocardial infarction, or sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5,6,11-13\">",
"       5,6,11-13",
"      </a>",
"      ]. This can occur even in patients who have no previous history of coronary symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent withdrawal symptoms, these drugs should be slowly discontinued over a six to ten day interval, cutting the dose by one-half every two to three days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. However, the protection is not absolute since rebound hypertension has occurred after gradual withdrawal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1827/abstract/7\">",
"     7",
"    </a>",
"    ]. If such withdrawal symptoms occur, re-institution of clonidine will usually provide immediate relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101254469\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt discontinuation of antihypertensive therapy can occasionally result in a withdrawal syndrome, characterized by rebound of the blood pressure with symptoms and signs of sympathetic overactivity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of sympathetic overactivity depends upon the speed at which the antihypertensive effect fades and the speed at which adrenergic receptor upregulation dissipates. Thus, a withdrawal syndrome is more likely to occur when short acting (oral)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      or a short acting beta-blocker is abruptly discontinued. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Withdrawal syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with underlying coronary disease, beta-blocker withdrawal may be associated with angina, myocardial infarction, or sudden death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Withdrawal syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      or a beta-blocker is planned, the dose should be slowly weaned by halving the dose every two to three days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/1\">",
"      Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension. Br Med J (Clin Res Ed) 1986; 293:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/2\">",
"      Nelson M, Reid C, Krum H, McNeil J. A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs. Am J Hypertens 2001; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/3\">",
"      Nelson MR, Reid CM, Krum H, et al. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). Am J Hypertens 2003; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/4\">",
"      Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA 1987; 257:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/5\">",
"      Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 1981; 102:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/6\">",
"      Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/7\">",
"      Vanholder R, Carpentier J, Schurgers M, Clement DL. Rebound phenomenon during gradual withdrawal of clonidine. Br Med J 1977; 1:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/8\">",
"      Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med 1987; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/9\">",
"      Lilja M, Jounela AJ, Juustila HJ, Paalzow L. Abrupt and gradual change from clonidine to beta blockers in hypertension. Acta Med Scand 1982; 211:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/10\">",
"      Krukemyer JJ, Boudoulas H, Binkley PF, Lima JJ. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. Am Heart J 1990; 120:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/11\">",
"      Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/12\">",
"      Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1827/abstract/13\">",
"      Rangno RE, Nattel S, Lutterodt A. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. Am J Cardiol 1982; 49:828.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3835 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1827=[""].join("\n");
var outline_f1_50_1827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H101254469\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WITHDRAWAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101254469\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18068?source=related_link\">",
"      Can therapy be discontinued in well-controlled hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1828="Pretibial myxedema in autoimmune thyroid disease";
var content_f1_50_1828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pretibial myxedema in autoimmune thyroid disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Terry F Davies, MD, FRCP, FACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1828/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/50/1828/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretibial myxedema (also called localized myxedema, thyroid dermopathy, or infiltrative dermopathy) is an infrequent manifestation of Graves' disease. It is not restricted to the pretibial area but may spread to the ankle and dorsum of the foot and may present on the elbows and knees and rarely additional sites. It occurs in at most 5 percent of patients with Graves' disease, many of whom are older and nearly all of whom have had both hyperthyroidism and ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/1\">",
"     1",
"    </a>",
"    ]. It forms the third component of the classical Triad of Grave's Disease.",
"   </p>",
"   <p>",
"    Pretibial myxedema also occurs, very rarely, in patients with no past or present thyroid dysfunction and in patients with chronic autoimmune thyroiditis. The incidence of pretibial myxedema has declined probably because the diagnosis of Graves' hyperthyroidism is established earlier and antithyroid therapy is initiated sooner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretibial myxedema is characterized by nonpitting scaly thickening and induration of the skin, most commonly as one or a few well-demarcated papules or nodules several cm in diameter. They may be violaceous or slightly pigmented, and often have an orange-peel appearance. The lesions are usually asymptomatic, but may be pruritic or even painful.",
"   </p>",
"   <p>",
"    The most frequent location of pretibial myxedema is over the lower legs, especially the pretibial areas or the dorsum of the foot (",
"    <a class=\"graphic graphic_picture graphicRef75580 \" href=\"UTD.htm?21/57/22417\">",
"     picture 1",
"    </a>",
"    ). Rarely the fingers and hands, elbows, arms or face are affected.",
"   </p>",
"   <p>",
"    The lesions usually appear over a period of several months and then stabilize or, in some cases, regress spontaneously. In occasional patients, however, the lesions progress to involve the legs, feet or hands completely, resulting in a form reminiscent of elephantiasis. The disorder is associated with high serum concentrations of autoantibodies to the thyrotropin (TSH) receptor. Patients may also have other signs of severe hyperthyroidism, including clubbing of the fingers and osteoarthropathy of the phalanges of the hands and feet (thyroid acropachy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretibial myxedema results from the accumulation in the dermis of glycosaminoglycans (GAG), especially hyaluronic acid, secreted by fibroblasts under the stimulation of cytokines. The cytokines arise from the lymphocytic infiltration, which is best seen in early lesions. The resulting characteristic pathologic changes are mucinous edema and the fragmentation of collagen fibers. Clinically, one sees nonpitting edema of the dermis, due both to the hydrophilic nature of these substances and secondarily to compression of dermal lymphatics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/2\">",
"     2",
"    </a>",
"    ] and fragmentation of dermal collagen fibers.",
"   </p>",
"   <p>",
"    The etiology of pretibial myxedema is not proven. These patients characteristically have higher serum concentrations of TSH receptor antibodies than patients with fewer manifestations of Graves' disease, but there is no direct evidence that these antibodies or T cells that specifically recognize components of the TSH receptor are important in the pathogenesis of the dermopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the demonstration of TSH receptor protein expression by normal dermal fibroblasts raises the possibility that TSH-receptor antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antigen specific T cells initiate the inflammatory response, which stimulates the production of glycosaminoglycans by these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, IGF1 receptor antibodies, also present in patients with Graves' disease, have been shown to induce hyaluronan synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/5\">",
"     5",
"    </a>",
"    ]. Cytokines such as tumor necrosis factor alpha and gamma interferon induce GAG release from fibroblasts and may be secreted by Th1 type T cells activated by TSH receptor antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. Since normal skin may express TSH receptors, the presence of the antigen specific T cells and TSH receptor antibodies are the hallmarks of the disease. What determines their presence in the characteristic anatomical locations remains uncertain. Similar questions remain for the orbitopathy of Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An etiologic role for TSH receptor antibodies and TSH receptor-specific T cells could also explain the occasional worsening of dermopathy after trauma, surgery, and radioiodine therapy for hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/7\">",
"     7",
"    </a>",
"    ]. Among them, trauma to the pretibial region may be the most common precipitating factor initiating an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and it has been seen occasionally after thyroid surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pretibial myxedema is usually apparent from the location, nonpitting nature, and distinct borders of the lesions, in a patient who has longstanding hyperthyroidism or had the disease several years ago and has Graves' orbitopathy. Chronic lymphatic and venous obstruction of the legs, chronic dermatitis, and cutaneous mucinosis can cause similar skin lesions, and a punch biopsy of the skin may, rarely, be necessary to establish the correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with pretibial myxedema do not seek treatment because the extent of the lesions is limited and they are asymptomatic. Severe disease is most often encountered in patients with longstanding untreated Graves' thyroid disease.",
"   </p>",
"   <p>",
"    The usual indications for treatment are pruritus, local discomfort, or the unsightly appearance of the lesions. However, it is reasonable to treat all new lesions in the hope of preventing them from becoming more chronic. Treatment starts with minimizing risk factors, such as avoiding tobacco, reducing weight, and normalizing thyroid function. High potency topical corticosteroids with or without occlusion or intralesional corticosteroids are the best approach. We use the topical application of a glucocorticoid ointment covered by an occlusive dressing (eg, 0.02 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    under plastic wrap) nightly or every other night.",
"   </p>",
"   <p>",
"    In an old prospective study, nine patients with pretibial myxedema were treated with intralesional injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide. Complete resolution was obtained in seven of the nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/11\">",
"     11",
"    </a>",
"    ]. There are no more recent trials of treating this now uncommon disease. However, this regimen will often lead to regression of the lesions, especially those that are no more than a few months old. Once the lesions regress, the frequency of glucocorticoid application can be reduced. Resistant lesions may require systemic glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Long-standing pretibial myxedema may be quite resistant to all therapy. A number of case reports have suggested that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    may be helpful in resistant cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/12\">",
"     12",
"    </a>",
"    ]. This drug prevents the proliferation of fibroblasts. In another case report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and plasmapheresis were found to be helpful in a severely affected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/13\">",
"     13",
"    </a>",
"    ]. Surgical excision has also been tried, but as described above, such trauma almost always precipitates a recurrence of the disease and should not be attempted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is documented about long-term outcomes in patients with pretibial myxedema. However, in a retrospective study of 178 patients followed for an average of 7.9 years, the following was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1828/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpitting edema was the most prevalent form of dermopathy (43 percent).",
"     </li>",
"     <li>",
"      The pretibial area was most commonly involved (99 percent).",
"     </li>",
"     <li>",
"      Virtually all patients had co-existing ophthalmopathy (97 percent).",
"     </li>",
"     <li>",
"      More severe cases, treated with topical glucocorticoids, occurred in 54 percent.",
"     </li>",
"     <li>",
"      Overall, 50 percent of patients had moderate improvement or complete remission, while 50 percent had minimal or no improvement. Patients who were untreated had a tendency for better outcome, but one could not conclude that topical corticosteroids were ineffective, because patients with the most severe disease were in the treatment group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretibial myxedema is characterized by nonpitting scaly thickening and induration of the skin, most frequently located over the lower legs, especially the pretibial areas or the dorsum of the foot (",
"      <a class=\"graphic graphic_picture graphicRef75580 \" href=\"UTD.htm?21/57/22417\">",
"       picture 1",
"      </a>",
"      ). Rarely the fingers and hands, elbows, arms or face are affected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretibial myxedema results from the accumulation in the dermis of glycosaminoglycans (GAG), especially hyaluronic acid, secreted by fibroblasts under the stimulation of cytokines. The demonstration of TSH receptor protein expression by normal dermal fibroblasts raises the possibility that TSH-receptor antibodies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antigen specific T cells initiate the inflammatory response, which stimulates the production of glycosaminoglycans by these cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual indications for treatment are pruritus, local discomfort, or the unsightly appearance of the lesions. However, it is reasonable to treat all new lesions in the hope of preventing them from becoming more chronic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment includes minimizing risk factors, such as avoiding tobacco, reducing weight, and normalizing thyroid function. High potency topical corticosteroids with or without occlusion or intralesional corticosteroids are the best approach. We use the topical application of a glucocorticoid ointment covered by an occlusive dressing (eg, 0.02 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"       fluocinolone",
"      </a>",
"      under plastic wrap) nightly or every other night. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/1\">",
"      Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore) 1994; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/2\">",
"      Bull RH, Coburn PR, Mortimer PS. Pretibial myxoedema: a manifestation of lymphoedema? Lancet 1993; 341:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/3\">",
"      Ajjan RA, Watson PF, Weetman AP. Cytokines and thyroid function. Adv Neuroimmunol 1996; 6:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/4\">",
"      Kahaly G, F&ouml;rster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998; 8:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/5\">",
"      Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004; 89:5076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/6\">",
"      Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/7\">",
"      Harvey RD, Metcalfe RA, Morteo C, et al. Acute pre-tibial myxoedema following radioiodine therapy for thyrotoxic Graves' disease. Clin Endocrinol (Oxf) 1995; 42:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/8\">",
"      Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 2000; 10:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/9\">",
"      Davies TF. Trauma and pressure explain the clinical presentation of the Graves' disease triad. Thyroid 2000; 10:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/10\">",
"      Syed AA, Jones NA, Perros P. Medical image. Acute pretibial myxoedema following thyroidectomy for Graves' disease. N Z Med J 2008; 121:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/11\">",
"      Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol 1975; 111:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/12\">",
"      Engin B, G&uuml;m&uuml;��el M, Ozdemir M, Cakir M. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol Online J 2007; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/13\">",
"      Heyes C, Nolan R, Leahy M, Gebauer K. Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australas J Dermatol 2012; 53:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1828/abstract/14\">",
"      Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 2002; 87:438.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7826 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1828=[""].join("\n");
var outline_f1_50_1828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7826|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/57/22417\" title=\"picture 1\">",
"      Infiltrative dermopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1829="Lunate fracture and Kienbock";
var content_f1_50_1829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72808%7EPC%2F52781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72808%7EPC%2F52781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lunate fracture and osteonecrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T1- weighted, axial magnetic resonance image of the wrist shows a curvilinear region of increased signal (arrow) traversing the lunate that represents a fracture. The decreased signal intensity throughout the lunate, when compared to the subcutaneous fat or adjacent navicular bone, is consistent with post-traumatic osteonecrosis of the lunate (Kienbock's disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lunate fracture and osteonecrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T2- weighted, axial magnetic resonance image of the wrist shows a curvilinear region of increased signal traversing the lunate, indicative of fracture. Moderately increased signal from the marrow of the lunate is consistent with post traumatic osteonecrosis (Kienbock's disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1829=[""].join("\n");
var outline_f1_50_1829=null;
var title_f1_50_1830="Prophylactic cranial irradiation for patients with small cell lung cancer";
var content_f1_50_1830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylactic cranial irradiation for patients with small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Elizabeth H Baldini, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1830/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/50/1830/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of small cell lung cancer (SCLC) is one of rapid tumor growth and early dissemination. Because of this, the therapeutic approach is different from that used for patients with non-small cell lung cancer (NSCLC).",
"   </p>",
"   <p>",
"    Although the tumor, node, metastasis (TNM) staging system is recommended (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ), patients with SCLC are typically divided into those with limited versus extensive-stage disease. Limited-stage disease is defined as disease confined to one hemithorax (ie, disease which can be included in a \"tolerable\" radiation field). About one-third of patients present with limited disease, although many of these patients probably already have subclinical metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy is an integral component of the treatment of patients with limited stage SCLC because of the high likelihood of early dissemination. In addition, radiation therapy (RT) is important because local tumor progression occurs in up to 80 percent of patients with limited-stage disease treated with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain metastases are a frequent problem in patients with SCLC, and brain imaging (preferably MRI) is indicated for patients who present with either limited or extensive stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/2\">",
"     2",
"    </a>",
"    ]. Prophylactic cranial irradiation (PCI) for patients without detectable brain metastases can decrease the frequency of subsequent intracranial relapse and improve survival for patients with SCLC.",
"   </p>",
"   <p>",
"    The role of PCI in the treatment of both limited stage and extensive stage SCLC will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRAIN METASTASIS IN SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a significant rate of occult brain metastases even in patients who are diagnosed with SCLC but do not have neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/3\">",
"     3",
"    </a>",
"    ], and patients who have a good response of their other disease to systemic chemotherapy will often develop brain metastases as the sole site of their initial relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/4\">",
"     4",
"    </a>",
"    ]. PCI has been extensively studied as a way to decrease the incidence of brain metastases following chemotherapy and to prevent the associated morbidity and mortality associated with brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limited stage SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of PCI in patients with limited stage SCLC has been established by the results from numerous clinical trials. PCI increases overall survival as well as decreasing the incidence of brain metastases.",
"   </p>",
"   <p>",
"    Although there is some heterogeneity in the results of these trials, the value of PCI was established in a meta-analysis of seven randomized trials that included 987 patients who achieved a complete remission with chemotherapy and received PCI between 1977 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of brain metastases was significantly decreased with PCI (relative risk [RR] 0.46; 95% CI 0.38-0.57, without PCI), and there was an absolute decrease in the three-year cumulative incidence of brain metastases (33 versus 59 percent). Furthermore, mortality was decreased with PCI (RR 0.84; 95% CI 0.73-0.97), which corresponded to an increase in the three-year survival rate from 15.3 to 20.7 percent. In this meta-analysis, 12 percent of patients in the PCI group and 17 percent of patients in the control group had extensive stage disease. There were no differences in the relative risk of death or of brain metastases when the data were analyzed according to stage of disease.",
"   </p>",
"   <p>",
"    A second meta-analysis that evaluated 1547 patients from 12 randomized trials reported almost identical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extensive stage SCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI also decreases the incidence of symptomatic brain metastases and prolongs survival in patients with extensive stage SCLC who have a response to systemic chemotherapy.",
"   </p>",
"   <p>",
"    The role of PCI in this population was demonstrated in a phase III trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/7\">",
"     7",
"    </a>",
"    ]. All patients initially received four to six cycles of chemotherapy for documented extensive stage SCLC. At the completion of the initial chemotherapy, approximately 75 percent of patients had residual disease in the chest, and 70 percent had residual evidence of metastatic disease. Overall, 286 patients with a response to chemotherapy as judged by the treating physician were randomly assigned to PCI or to observation without PCI. Radiation doses and schedules ranged from 20 Gy in five fractions to 30 Gy in 12 fractions, depending upon the institution.",
"   </p>",
"   <p>",
"    Patients treated with PCI had a significantly decreased incidence of symptomatic brain metastases at one year (15 versus 40 percent without PCI, HR 0.27, 95% CI 0.16 to 0.44). The median overall survival was increased in patients treated with PCI (6.7 versus 5.4 months, measured from randomization), and the one-year survival rate was significantly increased (27 versus 13 percent, HR 0.68 95% CI 0.52 to 0.88). The risk of extracranial progression did not differ significantly between the two groups (89 versus 93 percent at one year).",
"   </p>",
"   <p>",
"    Treatment with PCI was generally well tolerated. The most common side effects were headache, nausea and vomiting, and fatigue or lethargy (43, 36, and 10 percent, respectively). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The results of this trial provide strong evidence that PCI can decrease the incidence of symptomatic brain metastases in this population, and this approach can improve survival. Additional trials will be required to elucidate the optimal regimen for PCI in this clinical setting as well as whether there are specific subsets of patients who are more likely to benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIATION DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher doses of radiation are associated with better control of brain metastases, although this benefit must be weighed against the risks of toxicity. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Indirect evidence supporting the efficacy of higher doses of radiation in reducing brain metastases comes from the initial meta-analysis that established the efficacy of PCI, in which the dose of radiation was broken down into four categories (8 Gy, 24 to 25 Gy, 30 Gy, and 36 to 40 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/5\">",
"     5",
"    </a>",
"    ]. A statistically significant trend for improved control of brain metastases was observed with increasing total doses of radiation. Similarly, a retrospective analysis of PCI doses demonstrated an approximately linear dose-response relationship for reduced brain metastases with increases in dose that ranged from 0 to 35 Gy in 2 Gy fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of radiation dose has been studied in two large randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most extensive data on the impact of radiation dose come from a multinational phase III trial, in which 720 patients with limited-stage (LS)-SCLC and a complete response to their initial treatment were randomly assigned to PCI at a dose of either 25 Gy in 10 fractions or a dose of 36 Gy (administered either as 18 fractions of 2 Gy each or 24 fractions of 1.5 Gy given twice-daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/9\">",
"       9",
"      </a>",
"      ]. Among the patients randomized to the 36 Gy treatment arm, 78 percent received once daily therapy.",
"      <br/>",
"      <br/>",
"      The two-year incidence rates of brain metastases were 23 percent for the higher radiation dose and 29 percent with the lower dose. This difference was not statistically significant (HR 0.80, 95% CI 0.57-1.11). However, the higher dose was associated with a significantly lower two-year survival rate (37 versus 42 percent, HR 1.20, 95% CI 1.00-1.44). There was no obvious explanation for the increased mortality in the group treated with higher doses of PCI.",
"     </li>",
"     <li>",
"      The RTOG 0212 trial randomly assigned 265 patients with limited-stage SCLC and a complete response after chemotherapy and thoracic RT to PCI with either 25 Gy in 10 fractions or 36 Gy. The 36 Gy cohort was secondarily randomized to receive their radiation either in 18 fractions of 2 Gy or twice daily in 24 fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/10\">",
"       10",
"      </a>",
"      ]. At a median follow-up of 25 months, there was no significant difference in the incidence of brain metastases or overall survival between the treatment arms, but the study was not adequately powered to evaluate the impact of treatment on these parameters. This trial did provide important information regarding the long-term neurotoxicity of PCI. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Long-term toxicity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial irradiation can be associated with both acute and long-term toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxicities associated with PCI include fatigue, alopecia, scalp erythema, and to a lesser extent, headaches and low-grade nausea, all of which are usually self-limited. Fatigue and alopecia are the most prevalent short-term toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of cranial irradiation\", section on 'Acute reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long-term toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term toxicity, especially delayed neurocognitive impairment, is a potential concern, particularly for patients with limited-stage SCLC.",
"   </p>",
"   <p>",
"    Long-term toxicities are difficult to assess and quantify, and the data pertaining to these are limited. Potentially devastating neurologic and intellectual disabilities were seen with earlier treatment techniques that used concurrent chemotherapy, large fraction sizes (3.0 to 4.0 Gy),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high total dose, all of which have been shown to be associated with severe late neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Less devastating but significant impairment in cognitive functioning was also demonstrated in a CALGB study following simultaneous treatment with chemotherapy, thoracic radiation, and PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of severe deficits appears to be minimal with modern techniques for PCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two early randomized trials that evaluated PCI included neurotoxicity as an outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/4,16\">",
"       4,16",
"      </a>",
"      ]. In the first, patients underwent neuropsychological examination and computed tomography brain scans and then regularly during follow-up after randomization to either PCI or to no PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/4\">",
"       4",
"      </a>",
"      ]. No significant differences were observed in neuropsychological function. In the other, cognitive functioning and quality of life were assessed both before and after treatment with PCI or control [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/16\">",
"       16",
"      </a>",
"      ]. Although significant abnormalities were present prior to randomization, neither study demonstrated adverse effects attributable to PCI.",
"     </li>",
"     <li>",
"      The RTOG 0212 trial randomly assigned 265 patients with limited-stage SCLC and a complete response after chemotherapy and thoracic RT to PCI with either 25 Gy in 10 fractions or 36 Gy. The 36 Gy cohort was secondarily randomized to receive their radiation either in 18 fractions of 2 Gy or twice daily in 24 fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/10\">",
"       10",
"      </a>",
"      ]. Detailed neurocognitive and quality of life assessments were carried out on the study population. Baseline assessment prior to PCI identified abnormalities in multiple parameters including language, visual and spatial scanning, attention, sequencing, and speed. Further neurologic impairment was observed at the 12 month assessment, but chronic neurotoxicity was significantly less frequent in patients treated with 25 Gy compared with 36 Gy (60 versus 85 and 89 percent, respectively, p=0.02). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As treatment for SCLC becomes more successful, the potential for long-term neurotoxicity due to PCI will be more relevant. Research efforts to minimize the neurotoxicity of PCI have included twice daily fractionation (1.5 Gy twice-daily to 30 to 36 Gy), hippocampal-sparing whole brain radiotherapy, and the use of alternative systemic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1830/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"       \"Patient information: Small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with small cell lung cancer (SCLC) who achieve a complete response to their initial treatment, prophylactic cranial irradiation (PCI) can decrease the incidence of brain metastases and prolong survival. Using modern techniques, this can be achieved with a tolerable level of acute and delayed neurotoxicity. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Brain metastasis in sclc'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Radiation dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with limited-stage SCLC who achieve a complete response to induction therapy, we recommend PCI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with limited-stage SCLC with evidence of significant tumor regression but less than a complete response at the completion of chemotherapy, we recommend PCI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Meta-analyses have shown that this approach can prolong overall survival and decrease the incidence of subsequent brain metastases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Limited stage SCLC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive-stage SCLC with evidence of tumor response at the completion of chemotherapy and a good performance status, we recommend PCI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). PCI improves overall survival and decreases the incidence of brain metastases. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Extensive stage SCLC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who achieve a complete response to initial therapy, our approach is to use a total dose of 30 Gy in 2 Gy fractions or 25 Gy in 2.5 Gy fractions. More abbreviated courses of therapy are an option for patients with an incomplete response to initial chemotherapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/1\">",
"      Cohen MH, Ihde DC, Bunn PA Jr, et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1979; 63:163.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed on April 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/3\">",
"      Hochstenbag MM, Twijnstra A, Wilmink JT, et al. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 2000; 48:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/4\">",
"      Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/5\">",
"      Aup&eacute;rin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/6\">",
"      Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/7\">",
"      Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/8\">",
"      Suwinski R, Lee SP, Withers HR. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1998; 40:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/9\">",
"      Le P&eacute;choux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/10\">",
"      Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/11\">",
"      Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/12\">",
"      Johnson BE, Patronas N, Hayes W, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol 1990; 8:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/13\">",
"      Herskovic AM, Orton CG. Elective brain irradiation for small cell anaplastic lung cancer. Int J Radiat Oncol Biol Phys 1986; 12:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/14\">",
"      Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980; 6:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/15\">",
"      Ahles TA, Silberfarb PM, Herndon J 2nd, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 1998; 16:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/16\">",
"      Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997; 33:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/17\">",
"      Wolfson AH, Bains Y, Lu J, et al. Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy: report of a single institutional phase II trial. Am J Clin Oncol 2001; 24:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/18\">",
"      Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1830/abstract/19\">",
"      Mehta MP. Models support prophylactic cranial irradiation. J Clin Oncol 2006; 24:3524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4631 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1830=[""].join("\n");
var outline_f1_50_1830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRAIN METASTASIS IN SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limited stage SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extensive stage SCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIATION DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long-term toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1831="OCT in acute MI";
var content_f1_50_1831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    OCT in acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 473px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHZAdIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oieviqgD7V/wCGq/A//QK8Sf8AgPB/8erV1/8AaK8N+H/7N/tfQfElv/aNlHqFr+7tn8yCTOx/lnOM4PBwR3FfCtd/8WdbXXYvBUsWn6jZx2Xhu00/feQ+WLhoi4aSI5O6Mk4DcdDwKAPpb/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7q1H9orw3p2haRrN7oPiSPTdW877FN5dsfN8pgknyifK4YgfMBntmsr/AIar8D/9ArxJ/wCA8H/x6vkLU/Eepan4e0XRLyZX07R/O+xxhACnnOHfJAyckDr0rHoA+1f+Gq/A/wD0CvEn/gPB/wDHq1fFP7RXhvwrr11o2vaD4ktdSttvmw+XbSbdyh1+ZZyD8rA8HvXw3aW095cxW1pDLPcSsEjiiQszsegAHJNd78ftUk1z4raxq0mlarpK3iwPHa6pbGCcKsKJkpk8Eocc9KAPpL/hqvwP/wBArxJ/4Dwf/HqtaT+014R1fVbPTdP0bxJNe3kyW8Efk2675HYKoyZgBkkckgV8RKpJ4Gav6LeXmkavY6nYOsd5ZTpcwuwDBXRgynB4PIHBpXKUW9kfZ+rftNeEdI1W903UNG8SQ3tnM9vPH5Nu2yRGKsMiYg4IIyDiqn/DVfgf/oFeJP8AwHg/+PV8f6xc3Os6tfapqEqve3s8lzOyqAC7sWY4HA5J4FVRAue5H1pcyLVCfY+39A/aK8N+IP7S/sjQfElx/Z1lJqF1+7tk8uCPG9/mnGcZHAyT2FZX/DVfgf8A6BXiT/wHg/8Aj1fO/wAHbybTT4z+z6JrWqC98PXWmk6bamfyHm27Xkx91PkbJ5Psa89WOJ1yoI+po5gVJt2TPsr/AIar8D/9ArxJ/wCA8H/x6tYftE+HD4VPiT+wfEn9ii8/s/7R5dt/r9m/Zt8/d93nOMe9fDv2cHoTWr/buqHwj/wjAmX+yPt39o+UYxnz/L8vdu6428YzinzITpSXQ+t/+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+LTGw/hPFMpkNNbn3VqP7RXhvTtC0jWbzQfEkem6t532KbyrY+b5TBJPlE+VwxA+YDPbNZX/DVfgf8A6BXiT/wHg/8Aj1fOfju7u5PhN8PNMudD1mxGl/bt13d2hit7jz5RInkufvfKOeB7Z615tQI+1f8AhqvwP/0CvEn/AIDwf/Hq1df/AGivDfh/+zf7X0HxJb/2jZR6ha/u7Z/Mgkzsf5ZzjODwcEdxXwrWx4j8R6l4i/sv+1Zll/s2xi0222oF2wR52KcdSNx5PNAH17/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH3V4p/aK8N+FdeutG17QfElrqVtt82Hy7aTbuUOvzLOQflYHg969A/wCEo1f/AKETxJ/3/wBO/wDkqvhT47a2viX4o6vrMen6jp0N4lvJHBqEPkzBRBGoYrk8HbkEE5BBr6L/AGjIdQ8eeL9P8DaJbXt4NPsZtVuo7Ro1IlKlLfcZHVcBjk8k7X4FAHsFv4uuP7X0yw1Lwxremf2jM1vBPcvaPH5ixSS4PlTuwysT87cZrmvih8a/Dnw41+30jXLLV57me1W7VrOKNkCM7qAS0inOUPb0rO8FeKW8YeGfhXqk7Mb4arJb3gb7wnj0+9V8+5I3f8Crwv8AbW/5KnpX/YFi/wDR89AHqv8Aw1X4H/6BXiT/AMB4P/j1WtJ/aa8I6vqtnpun6N4kmvbyZLeCPybdd8jsFUZMwAySOSQK+IK3vAeox6P458O6nNDPPFZajbXLxQLukcJKrFUBIyxxgDI5oA+wdW/aa8I6Rqt5puoaN4khvbOZ7eePybdtkiMVYZExBwQeQSKq/wDDVfgf/oFeJP8AwHg/+PV8mfEW6a/8f+Jb17S6szdalcz/AGe7j8uaIPKzBXX+FgDyPWudoA+1f+Gq/A//AECvEn/gPB/8erV8U/tFeG/CuvXWja9oPiS11K22+bD5dtJt3KHX5lnIPysDwe9fCtbHi7xHqXi3xDd63rkyz6jdbPNkVAgO1FQcDgfKooA+vf8AhqvwP/0CvEn/AIDwf/Hq1fC37RXhvxVr1ro2g6D4kutSud3lQ+XbR7tql2+ZpwB8qk8ntXwrXo37P+oT6L8U9J1iHR9X1eKxWZ5bfSrU3E214XjBC5HGXGckUAfR/wDw1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fF08MkE0kM8bxzRsUdHUqysDggg9CKaFY9BQCVz7o0D9orw34g/tL+yNB8SXH9nWUmoXX7u2Ty4I8b3+acZxkcDJPYVlf8NV+B/wDoFeJP/AeD/wCPV8keG9c1Tw7/AGp/Zc8cH9pWMunXO5FbfBJjeoyOCdo5HNZPkYGSw/ClzI0VKT6H2b/w1X4I/wCgV4k/8B4P/j1aunftFeG9R0LV9Zs9B8SSabpPk/bZvLth5XmsUj+Uz5bLAj5Qcd8V8Q+RHxjd7gmvQPBd7La/CX4h6fHomtXUWpGyH222tTJbW/kSmR/Nk/h+Vhjg++OtJSvsOVJxV2fRP/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8aCFGUEA4PvSG3yu5W496OZB7GXQ+4dR/aK8N6doWkaze6D4kj03VvO+xTeVbHzfKYJJ8onyuGIHzAZ7ZrK/wCGq/A//QK8Sf8AgPB/8er5H1XXdU1Hw/ouiXc6SadpHnfY0CAFPOcO+Wxk5IHXpWK0bqMlTj1p3RDhJbo+0v8AhqvwP/0CvEn/AIDwf/Hq1df/AGivDfh/+zf7X0HxJb/2jZR6ha/u7Z/Mgkzsf5ZzjODwcH1FfC6qWYKoJYnAA5JNejfGi9ur1vBq3ei6zpLWHh200xhqVoYDNJDu3PHn7yfMMHg+wpkn0b/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH3V4p/aK8N+FdeutG17QfElpqVtt82Hy7aTbuUOvzLOQcqwPB71lf8NV+B/8AoFeJP/AeD/49XyF4u8R6l4t8Q3et65Ms2o3WzzZFQIDtRUHA4HCisegD7f0n9prwjq+q2em6fo3iSa9vJkt4I/Jt13yOwVRkzADJI5JAq3/w0V4b/wCEq/4Rv+wfEn9tfbf7P+z+Vbf6/f5ezd5+373Gc498V8Z+A9Rj0fxz4d1OaKeeKy1G2uXigXdI4SVWKqMjLHGAMjmuu0y6a/8A2k7K8e1urM3XiyOf7Pdx+XNEHuwwV1/hYA4I9aAPt7/hKNX/AOhE8Sf9/wDTv/kqpdJ8Uy3mvw6Rf+H9X0m5ntZbuJrxrZkkSJ4lcAwzSEEGZOoHf0r5u+MdtYXHxL+Jn2290W1uU06yktVvYA9zNIsanZavvBSQ4AyFfqOK910Kea68UeBJ7q2ntZ5fDN68kFw26SNjJp5KsT1YHg5oA9BooooA8A/bW/5JZpX/AGGov/RE9fF1vBLc3EUFvE8s8rBI441LM7E4AAHJJPavub9qy+0vTvBOg3WvaR/bOmx60nm2P2lrfzc21wF/eLyuGIbjrjHevmrQvHvg7SvFw1PSfBVxo0Zhigia31hpXtX3sZJlaSJzlkKrgAEBSQctkAHA6Q8Gh+JoG8Q6RLdxWVxi602Vzbs5U4MbHBK8jBGM9RXZ/GDxjpPjCx8LT6eLwX1taSxXSXEwk8kGeRkjG2KNThSMFflClVwNpJ5v4malp2s/EPxJqeimU6deahPPC8jZLhnJ38qpAYksFIyoIBJIJPM0AFFFFABRS45qxHBjlwPpSbSLhBzehd8LRxSa/YrdarJo9sZAJL+ON3aBe7BU+YnHGB610XxDuLK4u9MtdK1KzvtI0+1NraLbicvEm9nJlaWKPc7M7t8owM4GABXMAHBJxj0p33hyOMcVm5nVHDJO7YgA2DHTHTFJtHPb8RSqM+mB69KUkAZU8CoOi2mo057Dn2PWl5CjAwaVQcnAzxzkUZwAMgc0DS6nffD7WtLttNsrbUtX/smXTtdg1di0M0guY0QAonlq3zjacBtq/OfmFcPqdwt5qF7dxxmKKeeSVI+6hmJA/WoDzzyWzzTgoGcnn0FU5aWMo0rScu4xWwPl7ijd6A04g4yMn+lMYkDPc9c/0pGmqA43ZAPXntUcsa7WJxnHBFSDABJz+HpTSeApOKaM5JNWZ3Xiy40218EjT9H8U2urSXc0F3qBmjuluJpUQqiKHiCKkYdxneS3XgAKPOKtSoWjAB6HvUQt3PpWikjjlRknZENFSPGyDJ6VHVGbTWjCt/wPrOn+H/EMOparpR1WKFWMcAmEW2THyvlkcHaecFSCQM5HBwK91ufHXg5vEsnlaf4b/sn/AISONVI0CIY0k/6w/wCqzngc/wCsHO3A4oEcP8ZvEel+KvFNrqWkSXk27TrWO4lupvMdplhVWBJjQkgjBbGGILDAIA9D/wCGq/HH/QK8N/8AgPP/APHq5uDxd4YsNJis7Ky0KTytDl2vcaNHNIdQ+1OY8u8ZZsRbepKHoc9K5zWta8Lj4kLqv9i2+raA0EDTadbu9hHJMbVBJtKqCgExZsKMHGBwaAPbPhZ8a/EfxH+K3hHSNcstIgtobq4u1azikVy62dwoBLSMMYc9vSua/bW/5KnpX/YFi/8AR89Wvgj4i8Hav8YfCkHhjwL/AMI9erNcO91/a813vj+yTgpscADJKnPX5cd66D9pzW/DGjfFOD/hK/CP/CSebo1t5H/Ezls/IxPc7vuA7t2V69NvvQB8v2NheX5nFhaXFyYIWuJRDGz+XEoyztgcKB1J4FdJ8OPE2neFdUnvb7TLi8uWj8u1uLe7WCSzYnmRN0cgLYyAcZGSRg4I7fwH8QvCOlaf4h059CvdJtdRtdRDtb6jv89ZI3EFsSYGb5QwVWJ27vnYHoPGqAOu+LWraZr3xH8QapoTSvp93dvLHJISTJk8sAVUqD1CkZHQk9a5GiigAoopyqWOAMmgErja7D4dQaRLeXZ8Ra3/AGdZxosi2zCcR3zhsqjvCjlFB5J2k9hgncOaSABQW+9U5IPAXFQ59jphh29ZF/xTdSap4n1XUL28tr+4url53uLZHSKRmO4lVdVYDJ7gHis8rgAf3adycHHPpRxhsgbqzbudUKairDWPzHBB+tAwFOMZoHOGKg/Q0dDyoP4UD8wyRyOQP1r0vwj4j0e00bQri81M202ix6lHJpxglZrwzowQoVUpzuCtvZcBO9ebBcIRjI9aByuBx7GmpWJnS51ZjIwVjAwQcY5pQM4yBz2xmgrkblJ69jQRnvnHrSKStoSBENuzE4cdOOtRYB//AF1EpO7A6e1SYPB/rRaxPNzdCSCNPtUBE32U+YuZgCfK5Hz/AC88deOeK674kXGmx6Tp2l6D4htdX062nlnLeXcrczTyhfMmk82JVUHYgCKzYxkliSa4/wBCMDtTJoWlUFccHB5qoytozKrR5veiUaKs/ZXBwSv51DJGyHDVomnscsqco6tDKKK2/BE+nWvjTQLjXBE2kw6hbyXglj8xDCJFL7kwdw25yMHPTBpkGn8OPE2neFdUuL2+0y4vLlo/Ltbi3u1gks2J5kQtHIC2MgHGRkkYOCNDxz4ss/8Ahc174r8LDzoItUXULZrncyyujhwxG1GCkj7vUA4znmuig8Z+Gbu1s7fUrDw+iTw6nHetDokUbr+6f7HtZIwVO8j5kwem88U+78beGoIb2LT9P8OsIY9LWyaTQoXYkQqLwsWi+Y7twO/PqvPNAG7/AMNV+OP+gV4b/wDAef8A+PV6B8APirrnxN+Kf/E+tdNt/wCztGuvK+xRum7zJ7Xdu3O3/PMYxjvXzumseENO+IniG8ufDi+IPDctxcDT7RLuWyCIZsxOCo3YCDG0j+LnkV7l+zHrfhjWfinP/wAIp4R/4RvytFufP/4mct55+Z7bb98Dbtw3Tru9qAPqqiiigDwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAooooAKeiM7YXrRGhdgFHNXoolWPgjPQ+9TKVjalSdR+RHFGEwefrUg64bkD9KcOc5P4DtTtoJPTj1rJvud8YJKyGDgjp681Iqg/SkIBx+RIpVTjA7GpbLSEUEEgEE+npSyAdTkk88dqkA2k45PUGnbT5Rzxxnp1qbl8uliFF9uT2NKwI29gPepVXAynHrxnFT+QH+TlmPOQcUnKxSp3RSVW3E4wT3pTG2CWA444NWGhKfeGM9jkU4ROEJ27lJ657Uc4KmVSvzEd/SmYJB/XIq7KGycqxJ9cfLUDJwNgDN0OO9NSJlAgAAGOOKQY74x9Ke24Akj9KQBduc8Y9au5m0MHUgDOaTAAPtj86cOOv3h7YpCfmPBAPamR0Ggj+LkHvVeWLA3L0qyR83HU9qTB59RTTsZzhzqzKFFTzx4+ZelQVqnc4ZRcXZhRRRTJPVf2XP+S7eGf+3r/0llrq/wBtb/kqelf9gWL/ANHz1yn7Ln/JdvDP/b1/6Sy11f7a3/JU9K/7AsX/AKPnoA+f6KKKACiipYozIfYdTRsNJydkJHGXJx0HU1bRFVMKOfWgLtwAOMU5fpmspSud1Kkoeockcfdz+dKeW+Xg4/KkIAII6EY5pyHAySeKg2XZiDAPOeKUA9RzS54ww9qXB44wM8E5pFJBgY5xj3FKuOCuAM/eFOCZA4LHvT0Rjxjn2NJstR1GOjYIPOP5Um1goHJP06CpmUlQQDj+v1p/l5QAjaRz17VPMXyFN1KNh+g96iYfeJwe/NTOMFcj8aTy3khcpubby3HStEznkuiIYjg8bfTnv+NScbiDyB7VHGCwGAAeuakHzdDyKb3JhewBWbPIpcAPkg49qfHGWOc9s5+lTFNxAPPpjvUORtGF0VxycEgD1puwNwwBFTsmGIbqOoNMIAHbGO/NNMTj3KE8Ww5XlM1BWkw5GASO4qncReWcrytbRlfRnBWo8vvLYhopaSrOYK+gP2Kf+Sp6r/2BZf8A0fBXz/X0B+xT/wAlT1X/ALAsv/o+CgD7UooooA8V/asvtL03wToN3r2kf2zpsesp5tj9pa383NtcBf3i8rhiG464x3r4t8WX+k6nrc114f0X+xNOZVCWX2p7nYQACfMcAnJyfbNfXv7a3/JLNK/7DUX/AKInr4qoAKcASQB1NIKs28YC72/Ck3YunBzdiSOIRkAHL9/r6U8nDAY70uCSSD+lIoGOaxvfc9FRtokPC5+bjjpShflGNuD60RksMc5NSxRh2JHbsKhu25rGN9gVM4ORn2FTxxEuSOgHrxSIPmKqQR9eKtwwiVsDjOAD2rKUrHRGALEgLEt8uOCD09af5KnIwQR6elXbeNE5AZ0Xg9voP89q0bO0fA2xNsCljnouPUnpXJOtym6gZUUPCgoW29Gz1FW7e3WRFkj3humATyPTpWhYi2eUfI4YDI2Akj2HuK0rbRJB/qQ5kySOowOxOPw+tc1TEKO+hooHJ3kLFASIzzwvfr0x3qsbSRVVmGCSDkHII9f/AK2K7i48NzgK6kKc5YBcY+vr/wDXpZtCiXywgnJUclULdu1KOPglZMHSucGkBJOQWbPp3Poe1MazwSR90HkdQK7C40VFQATOwUklgoBU89ax7jS3xvhl8xVOSRzkc9q6KeKjLZmbpHPumMgDI7sOPwqu8RVm+UkdOBW1c2x8oCbp2cd6pyQsg5+bbwR0PrXXCpcxnTuZwD88frTGB4P65q065DHtxz6c1FsO7HPHet1IwlDoQEAAetIRgdsk048ZJ6+1NbgEY596tGDQFQGHrVWdNrZX7pq5bwy3EgihRpJD91VGTTLiJkJjkGHB5UjkGnGVnYyqQ543sUKKc6lWwabWxwNWPoD9nvW/DF78TPA9hpHhH+zNag837Vqn9pSzfattlMr/ALphtTcxDcdMYHFdV+05rfhjRvinB/wlfhH/AISTztGtvI/4mUtn5GJ7nd9wHduyvXpt968q/Zc/5Lt4Z/7ev/SWWur/AG1v+Sp6V/2BYv8A0fPQB4FMytK7RpsQsSqZztHpnvTKKUUAORS7ADvVyMBVwpwAeh7mo4E2ruIPvUgG3jPA5rOTvodtGHKrsUnavzYJ7il6n1X0pGHHJwCeop2SCMdqg3XmKBjoKdnoBxSLnjJ6celTDH3i319qls1irjME+mcU8AnnGM9hTgCSB2xUiRtxjg46E1DZooixx4bax4PrT0T5+4A6kDt/nNWIYTJhSvA7+/tV6O2baG4IQZJ4wP8A69YSqWN4wKAhAK5Kkeufb0p5gjMYDAqwznjOR6+1bNvY+c0YMUpyc/u0/wA5+tLc2iiMgB4mOchlwScVzuur2NPZnHSx/vmH3cevGaI7trbzY1VW81dh3Dp9KkuVZZnUjODzVBgd5J659a9KKUlqedVbg/dJFJ79PpUsEbSPhVJHbaaiXhuM/Suk0bTcgS3CSKpGflTPHr+lRWqKmrsdCm5uxVjtmRAeY2HA96ZJEwZducHtnpXTSWXyM6Mkygk5jOf0PIqpNZNKsjx7gB1VuwxXDHEJs9B07I5142AIcH+dRFSDn+EcfSta8hDAuiEccGs2YESlVyRkDp0rqhPmMJxsVmbnofxqIoGUKRwenvUkg2ZA4Peo8gDg9Oa6F5HJPsylKhRsdu1R1clUODx9MVUIx1raLuedVhyvTYSvqr9mTW/DGs/FOf8A4RTwj/wjflaLc/aP+JnLeefme22/fA27cN067vavlWvoD9in/kqeq/8AYFl/9HwVRkfalFFFAHgH7a3/ACSzSv8AsNRf+iJ6+P8AQNJi1aedLjVtO0qKKPzGmvmk2n5gNqiNHZm56BTwCTgCvtX9qzxDqnhXwToOs6Dc/ZdSttZTypvLWTbutrhG+VgQcqxHI718tRfE251fxSNf8e2sniLUIbUW1nKjw2ptiGLB9ohZHILNjch5OecDABx/iHQ7vQPEN7o9/wCWbq0lMUhibchx3B9CMHt1qMEJ8mM+tWNTuYL3Vbu8tUu0juJPMAvLkXExJ5YvIETcS2TnaPx61X9s54496ym7ux3UI8sb9WKB84zzTiowWPftimg9T07Yp2c7RyemKhnQrWHRglTzyfWp4l42nK4OeRUaRndgDgjrirkUfmDc2A/RQehHPaspyOiERY4wXZwyqMdCK27O3CoGbPoRjn/CoLe22sD8pYYByM/jXUaXpcgeGRkYhm2opX7x9APb34rzsRXSW51wgVbC3aD95MCXfO1Qu846cdvbNdJpGh3V67OUCQjlixP7wjvz6decVt6Z4ditAkk7vJKSdoLcIO2ByK6PyZJYv3h2KoORjhf8+teBiMdd+4bbGLa6DZWaqr4mkTlsKDu9eeg5rSSJFjMUMGE7Zbcev8vxrnvEXjLQtAAiaYXdyMgxwDdj6kniuYufi+Sriz0qNG6q0shOD3OAKzhgcXiVzKLa89DOVaEXZs9M+zsQ6uinAJ/1Z6j+LNRTwO5IlhVlkB2gjt65xXlKfF3WAUMtnbbQckAEbvetbTfjDIJEGpWACE4JjJ6HvzWksoxkVflv8yViIPqdXfWNqdiNAYxgjd1x6DtXN32gymV3tCr/AC45G3P5V2uheIdF8TRg6dcKkg6qVCuOnOD/ADqxf6cYlDhchf8AloCD6/lXPGtUoS5ZKz7M2UkzySfTEjnlEmAwPzIRgN+HT15rJvbZVykQbK5DqBkr+FemarpyXYKkBJlPynODwfbvx0rj9Z0+SKYuGMchwWHQHnr6Hvx6V6+GxfO9XqEo6HF3FuY1+cbHB6H/AArPkAXhsHuPetzUZPJz5xCvnlfSuancvJxzntXu0LyVzgrtQGuwwAAc0x3wcjqDTWyOAcH3pdnTfy39K60kcDk2WdNvLixu1uLOQxTrna47VHI7ySs8rF2J3MzHJJ9aQg7cnggdRSFduMYJzjPrU2V79StUrdCCcBkDDgjjFVq0HXPy8YHFafg3xfr3gbV5tR8MX32G9lhNu0nkxyZjLKxGHUjqinOM8VrBnJXhZ3Oy/Zc/5Lt4Z/7ev/SWWur/AG1f+Sp6V/2BYv8A0fPVv4I/FLxj43+MPhTTfE+sfbrKKa4uEj+ywxYkFpOoOUQHozcZxzW/+038QfE/gT4pwf8ACKan9g+26LbfaP8AR4pd+ye52/fVsY3t0x1qznPnzwx4Ql8RWjPZ6tpMV8RMYdPmkk8+YRR+YxG1CqjGcF2XJBx0rnYE3NnsK7nTvG+m/wBn6wda0jULnXNXnllvtUs9QitnlSQ5aPaYHCKSSW2bd2cHjiuPhCrGFIyTyamTsjWjDmlqAOOvQ9MGnYDZ59sUAbgCDgY6Y6UhyScEfWszt23HKPlzjn/PanE8rkZzTQT0456ilUdj2PapLXkPTJJPrxirEY3uu0cHr7+1RbRkZ/SrUIwB8mR6Dt71nJnRTQ+GISKwQnOevalSIK2AR1xux7Vat0cDI3AHkDrnPWtqzsRIrLwWbiMEgfj1z79a5KlZQ3OmMLlGytAzqGJAOMjGT+tddbaCrCLyEkA+6zzptQn0A7/lVXTNOnik2NtRWP8ArO5+v/6q9A0iyEsELQ4LxgoZWBJ9T9a8bG4txfus6IxsjIsdJdUYBIvLxj+Mjtxyce/asrxBpCEBjds4Ax9wKBx7j+tdze3ukaJGJNQuS8q4/dgZYjJwAv41wvi34i2V2yxx2En2fJXLHDccYP8An0rjw31irPmhFtf13CU4rfY8u1aE288gbjBPpzWUpyAevrW2htNR1ZjcSvDbMrPzjPCk4/OseNcnpwePbFfY0nZWe55NZc0rrY6Pwd4butcvB5CMyR/M3Ga9gj8PSpDGFRWkCgA9Dj1968p8JXcujx3F5BcvEygDaOAeeh9a9D0DxxI7x2968bbjhSOmep7defb69q+fzRYipNuGsUehh0oQS6kt1olv5rtFEwYcttODuHp7Hr1/KuU1Xd9o2ygZT5VZhgkenv8A0r0KXUbS+hb7OVkAA4UkFeOeh985/wDr1wuuyxzmRmG3ORuznPvmuPBzm5WmdD2OS1LeQ7KcDjJx156isWeU7m6irN3d48yFTnBwHHGaoMx6Ny1fUUYWWp51Wpd6Eedw6HJ70n147c04nnFIzY4z/wDWroOR+Y0Lt7cGoLlB95enerDDjPG2mOuQ3fI4FVF2ZlUjzRsUq+gP2Kf+Sp6r/wBgWX/0fBXlfgb4g+KPAf27/hFdT+wfbdn2j/R4pd+zdt++rYxvbpjrXv37MfxB8T+O/inP/wAJXqf2/wCxaNc+R/o8UWzfPbbvuKuc7F656VqcB9VUUUUAeAftrf8AJLNK/wCw1F/6Inr4rAycV9qftrf8ks0r/sNRf+iJ6+MLcfvl9qT0KiuZpFsDBVQOQME05m5IHUd8UiEA88EHnHrSnhwR1AxWB6a20AYyB1NPAz16mmkD5TnmpBk9cAY60maJEibt4KqSAc4HNatlEweE4LAEZA449f0NZtqFz95gB+VdJpFrJdiPZhgzcqCctxn+Wa5MRPlWp1Uo3NPTrV5JohEhAbO0L/D7/XAr03w5oqaXAtzdfvLiRSUGOIx6D9PxrM8C6YiuHKEJHnG4Z2jJ5/p+NdgsqESSz48iIEg+o5/wr5PHYpzk4R2OvYrXl3aaXYNqGp3CwIgOS3Vj2wP0rxTxn8RdR1gzWtgxtNNPGE4eQf7R/pWd468Tt4i1+SZ95tIhthhBwPqetcyszJIXWNOOMMuQCe/1r3MtymNFKpVV5fgv+CcFevf3Ysi3MZBIy7iTnLDg06SRp3LEHJHAXpUsrpEzjazSnqx4APt7VWDYHHUH0617i11ON+7o2TRyOBtBJjByVFCO5YfPs5yGOTj8etMyCGPTHYd6Q4Hv3osO/mXLO6mtLhJrWRo5wflkVtv516n8P/iVJ5yWGvsjbzhLp+OfRv8AGvHz17UZIbBPWuXFYKlio8s18+qNIV3Bn1JqVtFdqjw4KEblZWB7g/iK5DxhfWlppjy3TotwoKojAfMemPcVw3hPx9caBpNxYXcb3CEbrcMfuH0Pt3rkNX1O81vUJJrhmkd2yqDJ2+wrw8Lk1WNX94/dXXudk8ZGMdNX2GaleyXk5kY8DgAnOBTPORYfKhjBkDZM3f6AelbFp4S1GSFJ5oTFG3QtwSMelWv7MitVKtCGK5BbPJ+n+e9e68RRXuxd7djnjRqzfNLS5zkcDkBivU4yaUxDOBz25rTuF8uQg8ZUdelUZAN+cEAHrWsZuWoOkokROAfXOCO1RgcgcAdKkyWJLE4qNsDn0POatGUu4mOFqvdDOG7dKsbwSCelNuADGw6nGauLszGpFSg7Ho37Ln/JdvDP/b1/6Sy11f7a3/JU9K/7AsX/AKPnrlP2XP8Aku3hj/t6/wDSWWur/bV/5KppX/YGi/8AR89bHnHgcS7pFFXcghscEetM0+2aVZJAMhMD6k1M6bGwykVjOSbsd+HptQ5u5EecfXPHtQpxjt/SlHDYHI9aQFifbk0i+o9cEZHX6U8H5flFMBGSBx7Zp65ZeACfXPSkzWJLEu5geNvfJ4rXgty0OWb16dCPrWfaqN4BGR16GujsIPNtnCBcMpxxz19PpmuOvU5TtoxDS7WSS4ySrZBJdyACK7jwxopeZZWQsHPMhx0Bzkfl+lZGg6c092ibGCCQwkMxwT6cde9etaXYJBaRxuVAODkfwp0x9f8APevncwxbXuxOpe6jE1TTInt0uPljgiySy8Z9ye1cP4i+I/kW/wBi0PcCnBmGB2OdvH05qb4w+KQ7f2Lpr7I1P711OFJH8NeSSHa5KdDgAjjtzXVlmWqrBVK+vZf5nPWruOiNK4u7m7u/tEksskso3E7iTkd/5GqF6pJ3b1Y46gcn6/y/CgyFoircv2NQShxgE5AGePSvoIQ5XoclSV0RbSQSOAKtwptQMxxgZquDhB8pGc5PqK0bWMTRXDYyqpu6VU5WWpFGKv5kTTsEaPBAYdz09f8APvSNdvEy+VtBXO04HGasrZvLEAUfIBKOF4YAdKn/ALAumG8rhOOTxWLnTXxM3cKj2K9lrd3akLHIwU8/KetWtR1dtSC+YArAYOBwT61SurPyFKgfMDzxyKqgFWJo9nTk+dLUXPUh7smPyrDI/HIqBuKkY5GTwKi53Dj9K3SMpsbk4OR82aTPbHanEkHgc03pnPWqMWHJxQDjoDnrR3Gf0peCOevWmIqTDEh4xnmve/2Kf+Sp6r/2BZf/AEfBXhNyP3a5OSK92/Yq/wCSp6r/ANgWX/0fBWsXdHDVjyyPtSiiimZniv7VniHVPCvgnQdZ0G5+y6lbaynlTeWsm3dbXCN8rAg/KxHI718a+IvEereLtdn1jxBd/a9QlVVeby0jyFAA4QAdAO1fWv7a3/JLNK/7DUX/AKInr41tU+TI65qZPQ1oK8yYYLbvUdqcnAHQGm54AAwR19KkRuV56ce1Ys9CO4IckHGSeg9KehHtyMUqyAg5GfotPTaxxnGOntUNm0V5k0AGzJXOcfNjrXZeHIESBnZ9gGdpI6+v0rk7JSFbOBzjg+orsPD0Mk0Nuihv37jn/ZDYx+PFedjZe5Y7aKPWdAgNvpOTjMhKqoYj5QBjn8TXOfFrW5tI8PRWlmBG96hSRyRlU6HHfnI/WuysI2MsFuuCI1HQcAkZP45JrxD4x6m+o+LDbJEVt7L9wmM/MTyT/n0r5zLKP1jFJy2WrHXnyxbOJEn2PL2rks+V3Mo46dPfNV5AyqG3qS5JIByR9amkjMdvnJJLH/6+PbBFQhyrLkDABOB0Jx3/AEr7WPdHmS7MiZ2ZRuZiBwAT0pOOOKXHetDTNMlvleQfJAp2lz3PXAq5SUFd7GcYubsjPHU5PXpzinHr2xXY2Gi2hGZoJFjIBjJ2fP8A99sp/IVlXVjF5zW8kD20wyQCuCR+HB/CudYmMnZHR9XkluYOfwx3qzpzKL63aQAqrhmHTIB71DcRNDKyNjI79qaG210Ncy0MIvllqdt8R9LtX1K41fSr+0vLC5fchRsMmQDtK+3T8K73wD4e0ePwjaanaxxTXzj94z9Q3cfSvDdzbQGwQOOK9h+CN/8AaLS/06VmLRkSR+wIwa8PM6VSng7Rl8L/AA2O2hOMql7anU6hC0lu0mA0igSBieuP/rj9a861LcqygR7XTOfl6npwO3Y/jXqwt2kidPK4OV4I54PX9a841+FIb+dnU7iyD5T32jP6V5GXz95xPQlqjhLrIyhGT3Lc8/4HiqrHcBknJ9ex/wAa0r0Jlm2EA4wByBz0rLkUr93v0J9u9fU03dHDPQixjgnOe2KjZcjPYD86kfJwdoH41EfbsO3FdCOaQ0hRgEc+lN28YI5GaceRk9QaO/XORxVGTSPb/wBnz4g+J/EHxM8D+G9X1P7Rouneb9lt/s8SeX5dlNGnzKoY4Ukck57811X7TnxB8T+BPinB/wAIpqf2D7bott5/+jxS79k9zt++rYxvbpjrXln7L/8AyXjw1xj/AI+v/SWWup/bV/5KppX/AGBov/R89bnls8QglZ2eZyTJIxdiOOc058kDDcnqTUUCnywBwetOIyuQc9DzWD3PShpBICOmKcOuccj0NN3ZHHTOKEY5yRjsfpRYpNXHhRkdTxmpEUjBB9ai6NuIznvmnqeenSpZcWjXslD2+4xZOQN2f0/Kur0y1UEMhJXhmGcHrXMaa4azkQEBR84wB1ruNOia4iiZ1AQr1BAwBzn8q8fGzcT06K0Ok8DabFcXksjIQY/lXuMnJJ6+gArsfEepR6Tot3fyER4BWMdyeg/nUXhK0htrS4miVldgGy3uMficCuO+MN8wsdPtEdRucvhuRgdM89znP1r5yK+tYpRexcmeP6rIZJiZHEzEnc2zp7fnWe8jMjdlfG70p92oVgNm0Dkn1P8A+qo4trFQflHue+K+4hFKKPMnJuTQ+zQyN5YUs/ZQOT+ldFpfhh7yw1R3Yr9kh8xsDODn7p9+v5VS0CxeV/PwWToqZxu/I9K7HTGn0cySW0bi6xjyViUq/oG3ODj8DXHisRKL5ab1OijSXLeSPODbyGfYV2hTgZGM81taUiLKEHSVdpI5APbqOK3PEGrtr0jR3QW3mQlisdssRUnrkDg+ma5eJ5bS8SNiYyj5wvPX/Iq1OVaFmrMIwVN33PYvB2g6bL4YM0kBZlkOJWPPHAHFY+vrGrFY0UIBjCnr2xW94D3W+jXcN3Cyxv8AOmejZ/8Ar1heIpYTPN9eMc/p+FfNwlJ4mSbvqdq0RxOorHnc6gEAnisO6j25OCAc4/w/Stx01HU9WttN07TJLl7u5S0gfeESSVwCE3H5QfmHU1kalaajYajdWmoWMsEtpcvZztu3okyEhk3DKkjB6H3r6ihTmoqTR51XEUnLkvrsUcYOAcA/jTWOD7DmnFTtPHtTMEjjvXQjF6bDSOgHJpCASD0FKMkEnimsc9OM1RkwP3ucnilHJOOnamgFmIzTh0UH36UxIZJzCfpX07+zH8QfE/jv4pz/APCV6n9v+xaNc/Z/9Hii2b57bd9xVznYvXPSvmRxlSBxmvcf2Kv+Sqar/wBgaX/0fBVwOXELVH2pRRRVnOeFftg6bfav8O9GsdKs7m+vZdZj8u3tomlkfFvcE4VQScAE/QGvlfTPBV9ajU38XJqPh+00+1S6lWawY3Dh5RGgSJ2jyC2eSwACnqeK+qP2wdSvtI+HejX2lXtzY3sWsx+XcW0rRSJm3uAcMpBGQSPoTXyjZeONbee7l1qc+IYry1FpcQ6xPNMHjWTzFAYOrrtbkbWHU+pynbqXDmv7pV8VaLJ4e8Q3ulSTpP5BHlzBCgkjZFdG2noSrKcds1ljOOwq7r2rXWu6vd6lqAiW6uX3ERLtRFAAVFHYAAAewqkvOc9D69+RWL3PQp3truSbeqk/Ump4IhJIF3EE+vFV1PJz0yMmrKYOMLg9vxrKVzphZly0t1cnk5IGeenIGf1r0HwkQ9xo53FoxcOMYxjhsH9P0rgrUkKST2BJ/H/6xrufBl4bYxSKgZBNkNjgEcZH5tXkZhd03/XQ7qSPX4i0d0wOdyHhs9fqP89K+Y/FlxLP4k1MzklhcyE+v3q+mITm+zu3JsWQgcAHA/8Ar14J8XtJGl+LJXQ7orsecpwMbjww/MfrXm5DOKryg92jLE35LnEyO2F3FsdOT0prFg2WPNOYbtzAdRkgCogdvNfXI8yTsx+0EMRwO1dnZ7LHR7UlPlK7huGQz/KefbLqfwrit3XI7dK6zSrhbzS41ILCIFJBjO3PQj3+UH324rlxabir7XOnCtcztuajC0tji402XU7toVubiRrho/LDAMAMexHJz/SodVtIvKiS3kZ7SeD7VZNJjfGRnKk/8BIPrwfWh1W5WJbyzupDHGIvPsn/ANcg4UNkY6YHrxyKdqN60m0G3W1dYvs1tbZyYkIILN6cE9cEk9OK4FzJq39fj/lpudmjOa1v5o4pW2ndnJXoD7e3X86yjt98+pre8WSh5YYSo84fvHPQ8gADHbpnHvWDgcCvTw7vTTPPr/GxQoJbnOK9G+B7k+KZ1QkQtCVJ6d+AT/ntXnagFM5UjuvevTfgcT/bl3CAoQxK27I6g/4ZrlzR/wCyz9DTDr30erC0G2YZKhTg9Rjk/wCJrzDxRLCNQlLcoZ0Q54zhSf8A2avUrg7La4lbGdzNufoRzXkWpT7rqZZfuNMSWfHAxgke+a+Xy1NzbPU6HNah5CpIoGJsgrkcH1x7cCsiVioAcdOTite/hJLEg4zncPTjr+NZlyRGxQfjx14r6ui1Y5ahRLbUPIJ/pTCSe3bn3qZvXIz6f0qI/dY9B19660cckNJBH/1qvaNo2qa5dPa6Lp97qNysZkaKzt2mcKCAWIUEgZIGfcVRwpcZz+Her+j6xqmg3TXOiale6dcOhjaW0naFmXIJUspBxkA49hTM3fc9S/Z98KeItD+OHhi61vQNW062eS5jWa7s5IUZzaTEKGYAE4BOPY10X7XHhzXPEHxTsf7B0bUtT8jRYPN+xWrz+XunuNu7aDjODjPoa539nzxX4i1z43+GLTW9f1bUrVJLmRYby8kmRWFpMAwViQDgkZ9zXRftceI9c8P/ABTsf7B1nUtM8/RYPN+xXTweZtnuNu7aRnGTjPTJrdbHmS+JnmHh7wC99a2UGp38+naxqFzc2djYtZFyZYFG5ZmLqYssdgwrHOcgCuJX/VKxPLAdq6rR/Hes2FmolhstRvI5p7q2v73zZLi2lnUCV1YOAxOA3zh8NyOc1yqgBFU9hzWcrdDro8+vMKgy3H5GnBcYyMHv7U0jC5A6GlYE/wAXXqag6EGMkds9ql5Zhn1we1RjhgRn2zT04UHOCKTLib/h6NWln2gfMhIB5HHP9K7jRIMafDNEV3KVBAOM5+X06Vw3hyUx6jAM5XO0gehHSu48EvmyuI/mZASB8oOMEH1+teHmN1d+h6dHY9U0MsukI+MlkDYz3+n415F8YJJZdbhUHCRxDYGOB64H1r13T3U6cY2KMcHO3gf/AF+leRfFM51hjJsKMBtTOMEjAP5142VP/ar+oVFozzW+lcuoYkhcgZz09efWolw5VQvBIHJ/rVy/g/1J3DJiUkY7/X1qg2FI74wa+0g046HmVLqV2dzbCWy06OGBWW4uCkaHsAeMj3z396luY9ItrmaJ7C5uIoJPKn1BZiGV84JVOhGexpumy2d9obRiaVbtGR4HK9GAwQx6jsQfWpZlW6vTc3mj3ks7MGkW3ciCZv7zAA4/Akda8a7Une/n07en9bnoPVKxQ8RwTWsrrK6Pc2MgQSnjzIypIz+G3j/aI9KzL/bDqNq5GQDtLf3trdfc4rZ1S5e7vZBNMn2m4kMlyI8MI1wV2Drzg49sDvWDrc6y32AB8jckdiTkgfy/CunD8zsn2/r8TOel2e92s8Oq6PbzxLnI2uD2IFcdrVsoQ7MbeSPVgP8AP86j8Oa9/Yi/ZbpC1hOAzS9fLOD/AA/h+lW9R8q/DTwSKUPzYBxj8Pxr52FGVCq/5eh2J3Og+AfiC00nXzbax4kgazvtShtrbw6Lbzna5Ij2XG4jEYBwdwPJHqBWX+0l4hs9Zv5oNH8SRLZWOpTW1x4e+zeQ8d0pcSXG5RiQM247icjd6k15jrul2j3DzPGDIwBLFiO2Bxn6ViSWlvCd8abeTjkk/wA6+vo4iMqaXkeJPBVFVc7q17/iQDoSAQM0zIXOOSe/QCpXyckADJxx61FyBz261aNZEZXaM8c80gUAnFPJIHTANIw5IUe/WquZNDFBySBgetHTgcDrRjcMH05xRnqO2Kog1dD8Oa1rxmGhaRqWpCDBm+x2rzeXuzt3bQcZw2M9cGvcf2R/DmueH/ipff29o2paZ5+jT+V9ttXh8zbPb7tu4DOMjOPUV4hofiLWdAM39h6vqWmefjzfsdy8Hmbc7d20jOMnGemTXt/7I/iPXPEHxUvv7e1nUtT8jRp/K+23TzeXunt923cTjOBnHXAqoHNiOh9f0UUVocx4B+2t/wAks0r/ALDUX/oievjW1PyEcdelfb/7Vvh7VPFXgnQdG0G1+1alc6ynlQ+Yse7bbXDt8zEAfKpPJ7V8a+IvDmreEdcuNH8QWn2TUYlVni8xJNoYBhyhI5BHeplsa0HaaKG44JBwRzQoI6Hk0h+7jvSggMTz1rI7+uouFxznPQe9WonCqSCASKqnJORyM1MhAI6c9eaiWprB2Zo6c4jY7xlWwCOldhoknlq6hsxl1IAH3TlsH9f0riIGwdoPy9Tx056102g3Pk5aTeVJ2BgN3PavOxkOaLO+jI9r0i9S4WznHOBtYehHr+tch8aNE+26Rb38SkyQuOoxweD/AENXvCVyJLOS23RmQESLk8FsAde2a7JoIta0WS0nUOWBVlP8XGK+UhN4TEKa6P8AA1qRTVmfKDIyq7K4A54HpxVdvm3Ejkc8dBW74t0d9D16+sSjbI5DsY/xL2rHK5Z2RdqdeSOP8a+8pTU4qa2Z49SLTsR8ngnOO3pU1rdz2swkhbB6Eev1qJ0KH5wRnkHoDQOcZq2k1ZkK6em5vweJRGkgNsoZ+pUKe3qRmom1/aB9lt1Vh91pMHHvtxg/jmsQ5BI4NBOQPXuTWX1en2NPrFTuOmleV2klZnkY7mYnJJpyjPAweKYpIHHUVIcKgIOZCck+la+RC7ktoF3b2dUdTwPwPNex/BXTmtNEu9RI/eXLlUP+yMDP5k8V5TodlPqep21lZRgzTNsz1wT3P+e1fRul2SaPolpp0BGy3QBiDyxx16+vPNeBnmIUaapLeX5L/gndhodSDxJItrp3mmVSEjJHfjGOR+FeU3CN8ty7EKcYGM5baCc/iR+ddx4su83H2SJmkWQoXyw5XJ4HueT+ArhtbgntUeSVxjbhADzgcfjz6+lefl0OVa9Tuexh3lwjySkfIjSEhQe3b+lY9wQWZs5JHX8akncsCSCM89elV5DuODjgdfSvpacOU4qkrkUg5BB+tNcDGe55xTnOcYJz0PpUbAA/zrdHNIRgVyR1PQelKB75x096TPXjk8daGwoIU4xmqI8z0X9l/wD5Lz4b+t1/6TTV1P7av/JVNK/7AsX/AKPno/Z7+H3ifw/8TPA/iTV9M+z6LqPm/Zbj7RE/meZZTSJ8qsWGVBPIGO/NdV+038PvE/jv4pwf8Ippn2/7Fo1t9o/0iKLZvnudv32XOdjdM9K6DyXqfMcTfuEBOM/40vbGQTnimJG0bSxSDDxsVIJ6HvTueSfXNYtanfCTcUxwOTjpkcmnZOB3GaaPm6Dk/pS8cDnikaoX7o9RUkYO4Y5APNR4+vPepUIXGM8DNSzSO5o6dKIJopshSjB+D6GvRfDx8mSQhFVfM81cYwVbB6emCRXmMDKzDoc8cnqf8K7XQ7/CWTMUMaZjkzyCP/rZz+FeTmFJyjoehQkeq6bNiyVY2JVPlDMeox1/PP5VwfxTtd0cUqpneNhA7MM8/wA+K6LT9ZWS2eF23MDhNpySP8eM1jeJrK816wlgijd2X513YHIPb1NeDhIujiFOWiN5xvFnlE935sRRSdoGAAO3XH4VQRSxPWtqK1FnckTCMAglHJBVsDpjsfrVW+sntmJPzRkZz3HTqO3avsITinZHl1Kcpe9LoFhfPY4KENGTyK2ZNbtp7ZopFCK3JCou7Oc9eDXMg9cUjbRhST0zj3pToRm7vcI1nFW6HRx6rbQKsVsix5H3yBwfX/69ZfleWzGQF0OSrRtxnnBqigOw8jHvTonZSNhbjriiNFQvyle25rXR0DSxpp0MVtMs0u0tIM5257flU+jarJbO9vEd0LA5XoC3HP4YOBWZZT2okU3D7S6nDr1B5wDn+lQzjyp2ltn8xlbk4rB0lK8JI357WkjrvsJ1loLe3RlnOWZM5xz1/Ks7xFpa2Cn5Crg7cY4qfwPqi2viCGZHZd4Kyg45JzyPbpWprt5Bq0rW8ALoCTvHUD3/AErg5qtGsofZWpurTjc8+ILHHTnrSMpCAsCVPQit24sAwzGowSCSDyaoTxhPcZ7HOO9epGqpbHLKk0Zzx+/AOKjK4GAcnpVmcEMSB1JOM5zURAOfXnitkznlFXIgeDz9aaQQQRjnin8ZPHBOAKCcgd8VZla42Q4UkDjrXuH7FX/JU9U/7Asv/o+CvDJyVjYd+lfTv7Mnw+8T+BPinP8A8JXpn2D7bo1z5H+kRS79k9tu+4zYxvXrjrWkNjjxLvJI+qqKKKs5zwD9tb/klmlf9hqL/wBET18XwNiUY78V9oftrf8AJLNK/wCw1F/6Inr4rHBoeo4uzuXRzjOcU/GxsnkHnrSRYKbs8mnO4zwoz6+tYdbHpK1rkmzODnFPBRCFXknIPfNReYNhDMSPagOccgACoszZSS2JlJ5xwfStOwuRCwzvZj0GfT+vSsgcEHqParaS7irZO5eTng1nUjdWNqctTrtB1We0voZQx8l+Cuegz2HsTn869d0u9WQiWHO4bRIquMr3DfQ9seleA2U4z1IB4GT07/zrvvC3iGW2Bg4kfjarfxjPI/n+NfP5lg+b3orU7acrqx3HxA8GQ+LraKeB44r1AAkhYfMO4P8AnivBvEHh3UtDu3hv7SRQjbQ23KfXd0r6IsL1Gt47ixbzbY4DKVO9DxkEe3StOaK21nT3s58FJoyjBhkkH1/zmuHBZpVwf7uSvH8jKrRUz5LuExhkVlibpu/XnvSygFQqE8ZwpHT8e9eqeJ/hRdWb+doUi3MSfM0b/f69h0IrzvUtPksC8eoW8lvMMhRt5J7ZBOQPevqsPjaOISdOV/z+44Z0XG7ZljH8QPT6U6OEzyrHCMsfU8VIhjY7pR/DgKg28447VfstL1O7RHtLCYjlxKikFvx/wrplNRV27GcafNpuUUAt5SLhCRgggMM+lSWyeaU8lN85O2OFVJyT3P49q63RfBWu6swt/sDWtvnLzTICw78d/wAq9V8LeDtK8NYlQebe4CGR+SOpyOw7V5eLzWjh1a95dl+p008PJ+hjfDbwifD9pLqOpp/xM5AFWPGRGp7fU/pXW6nfRWNsxc7y3ygAZY56Af5/KmarfxWMZnnJ3n7kSAlm56AdSetcZeanciPz5ixeT5go+7Gnp/8AX/CvmX7TGVHVqdf6sj0IQUVZEOrXFrYTz3EirJcyZb5jwCev1xjjrgdOtcHq1+10xaVnZd28E9M8/wCJ/OrWsX/mysJYyp559cngmsK4fLgZBUHhfSvo8HhuRJy3Mqs+iC5mBUBTjsxI61Tk55GSfr0okckEjg9KYzHAz34wK9SMbI45zuDnHbj2NNJPrwKDnHIGOuKZnAB4+tWkYykHOOmBUdzgREg57VIcleTVe7+VgvtmrirsxrStBnpv7Ln/ACXbwz/29f8ApLLXVftq/wDJU9K/7AsX/o+euU/Zc/5Lt4Z/7ev/AEllrq/21v8Akqelf9gWL/0fPWx5x4NbH5iPWrG7BHuOoqkh2sDV0ggfSs5rU66Erxt2H+470qYJBA4pgyyg8Z96cMjr1zn8KzZ1J9R2QSPanKxyemDTcA/eIBpvQ/oaVir2J/MUKmxSHGQT/WtXTbpvKkjQk5+YjGckcVhpzkj6fWtbSXCTxhyo9Q3TB96yrRXKb0JNs7rwwHu7mGRnYZBIO3uOo/SvUbAIttHLENwIADcHGeOQOnpXlWjXptWkhOCVO5SOK77Q9QCSNFKy7ZBksGBBz/InmvkcxhJyv0PRWxxnxB8OizvW1C3wbac4YAZ8tzxn2z6+orgQSXVJzvB+VN46gHgk5HOOM+1fRV3EssD2s0fnROvRxw646fX/AAryLxp4Ul0yEyW0bzWXO1kAzHz/ABY574z7V3ZZj1NKlUevQxqQ6o4aW3DykQ/L32tjgfXvVd0yoGQRk4NWisiMMlNm3ngdKikSLkLkcZDY4Yf0r6GLOOUV2IELIHwvBGDkZwKdGQuRjJPHBxT2jaTDPICzDj8KWOMiENuIY8Ek8Y9KptEKLuQuSGB49+KmmJMzi3ZihwTn+v40yTZtBBY47k8e9WNOjH2jO7DdBjkHiiTsrjim3YfZq+7zFjO5cHLdDz19K9K8KaOyaXLK+DLPtCqy8qnf6Z6/gKyNA8PtMiSXJcRZ4hcHLDPp2FdK14tpGrAlCo+4Oi+1eDj8T7X93TPQo0+VXZg6nYxRPIygq4zgbs81yeq27Q4LLhnyCR611V3ei5meeQ8RjPI/L9ea5+5/fysZG3ZzgE9OOtb4Vyj8QVEmjnioUnOR7EVGTgjkcCr1zGF4H3jzxzx/jVSRSpGSMZ4r1oyucM42ICSo3cD0oxx1wTz0pW+96/hQcdQOfX8K0MLFa7boO/U17t+xT/yVPVf+wLL/AOj4K8DnO6Q46DgV75+xT/yVPVf+wLL/AOj4K3irI82rLmm2falFFFMzPFf2rLHS9R8E6Da69q/9jabJrSebffZmuPKxbXBX92vLZYBeOmc9q+bvDfhOM+MJrT4dahZeLbRbETXeoXegs4sx5nzbbaQOZHwqgYVid5AAwSPfP21v+SWaV/2Gov8A0RPXxVQB1HjkJH411lYtHuNEia4Mken3EJheFTyAUP3cgg7egzgcYrFHOM/nVNDtYH0q6pBBK9eoNZyR10JXVhyAhegHbmpVDOxVFzgcsaiX5iN7bVFS+Y5QrGNsXoD1+vrWbOuLQ1xjjgjoTUikrgjkkZ5qMEYGBjHtTs7RzuHfFJotPqWo5AFAHB7jPatKG6BjxvZX69e9YodiPlx64FWI2wcg7c9AD1NYTppnRCZ3Xh7xDLaSrPM4lRMZxlZACeoI4b6HmvQdN8T2V9OoeeLzc/LLEOvuy+teHw3OwADBjPDKeg57GtCG5G5JdnbaxU4z7d+K8jFZbCo77M6Y1Ln0TbXMhRZobhJlIztAxj65/lUd8Y7naNQ06GbH96IMc/jxzXj2k641tZgRziCYHarq5wP95MkH2Iro9M8cXixkR3lmYkTO+QNuJ9Dt4H+eteLPLqsHeJejOzm0zRyyySaVakqR0hTINTG5RUYWtsQF6bVwq/iBiuWj8dt84mmtzMF24SViMdydyc/gao3niQz72t75XwNxCoVB9cnHFZ/Va70ncaSOxlvCnyvIoIAxtwT+nH61iahrj28gUJ5IbrcOPlQDvjOc+wrlbnW7gW2zzIVMhD7lm35H1xjNYt5r0mFAuAWHGGQNx2wTk/4V00cuk3qNtI6i7dILxrh2uLlmUsbl2xt+gHQcngVxWo6tJcOyu4EKHAH3cDJxx1JxVe71Oa6J+03ErED5d3Y/Qde9ZN1ICN4JLHoSxP1r2cNhOT49WZzqaaBfTu8zblIbqPb6VRb7hPUDr7U53G5T8o46g1A5JO3JAHrXqwjbQ5JyEODnnNMfp8vTpk0Zxn0IxkUdABjvnmtUc7Yg5OCMcfjSdAP5UY+X8etKCcDcAF9+tMkRm2licbQK0PBumaFrGrzQ+J/EX/CPWQhMiXX2GS73yblAj2IQRkFjnp8uO9Y91Jn5RwDzx+lVa1granDiKnM+VdD6L+CPh3wdpHxh8KT+GPHX/CQ3rTXCPa/2RNabI/sk5L73JBwQox1+bPat/wDab0TwxrPxTg/4Svxd/wAI35Wi23kf8S2W88/M9zu+4Rt24Xr13e1eVfsuf8l28M/9vX/pLLXV/trf8lT0r/sCxf8Ao+erOcw/BHh69XRNauLHQIvEnhWKa7t7e6h0UzXeouUKxlW2s9ui/LITlcZI+Y8DyeCTcgB6gVTqSF9jg8YPBzUyV0aUp8si6QMDGc/zozggY4pOMLtIOe1KRnk9ayPQ9AJIJz60YyAR170cEknignavOMmgPUcnU5BNWrZlUgsAw64b0qov+TUqE8nt7VElc1pux09lc7THcN90fuyo5I4rdsLhygIfnoCePfiuKtp2B2I2Eb+HpWraT7gctheqjAIz/jXmV8Pc9CnUueu6JqUrAQXylS3IyRyPXOetbBO2He4BGMb+uPXd0rye21fy3KNI67ANjKc8/pXUaT4geNPMmIbOApwM8cDJzXz2IwMovmSN00xdc8F6ZqiSSQN9mu9ufkxgn6dPyxXn+p+CtXspN0UCTAH70eM/98nn+deqPeQ3Bb7OzA43bozuz9RxgfT8qmguJmj3cMAucKRzxyCOvetqGPxFBWvddmRKjGerPDzpd6kuJbOTc3OPL5p0fhzVZNoFpIqn++MDpXtEktvKG82L5/8AaXP40jXNlFgCNY844CnaK7P7YqdIEfVovc8tsfB960jLdIka9TggsPwrvNH8N2VlErW8RDch5HGWPHJHHFa7X6bQ0UIfbypVePxx/jVa8nuZIjOJY4Rt+YPgn6D0rkrY2viNJOyNIUow2Rn3l3FaSlIn3biSp287fT+dc/qLlnM05IKHO3PXvn+VaN5NBbqV2kqUGGPzHcegX8647Up3eVgSignGRnkZrqwlHmdxzlZBqN0LgsvROh9/b86z3nyChA3dMnoalnYgloQQV6+w/wAaoStxgknHOT7+lexSgkrHNOQkkp2lcY7AVUJzjccYzx71LLwSFPY9aiZs4rpijlm7iDAK4AJzUMx2KWz34561NuwR6+3r/k1Su3y2wHO3qfetYK7OatNRjc6PwLonhjWftv8Awlfi7/hG/K2fZ/8AiWS3nn53bvuEbduF69d3tXv/AOzJonhjRvinP/wini7/AISTzdFufP8A+JbLZ+Rie22/fJ3bst06bfevlWvoD9in/kqeq/8AYFl/9HwVueYfalFFFAHgH7a3/JLNK/7DUX/oieviqvur9q3+w/8AhCdB/wCEr/tL+xf7ZTz/AOzdn2j/AI9rjbs3/L97bnPbPevi3xZ/YH9tzf8ACI/2p/Y+1fK/tTy/Pzgbt3l/LjOcY7UAY9TwSY+U4x2qClFJq5UZOLui8ATnORjn604ZZdoGQemKhhk38MeRVpWEQypBf+VYvQ9Gm1JXvoWGjFqqu5BmIHy+n1qscyNknk85xSKTI2XJZifzp7EBSFI29/Un2qEreptdSXkJnP3Qc5/yaeGK9cHnntQi+XH5jcMeFHaowck9z1xRuF7EqyFjkdD2qwshIDdR19M1U3HOM0iuVbHP40nG5cZ23NVJmVQEbaOpB5qc6hPgKZsj+6cED8elZCSEtnkADHHen+aSuGBGDjd3rJ0k9zVVDWluzLtVn2ADg4/PGPemm4VUQhyHI+bc5Oayg+WI5wO+OtJ5mCS3Q5GKn2KH7U1o7r5ZUYR4bGWfkr6Y5qm0+0naSAfvMT1/z6VVDsoIU9RzTS3Uc/WqVJITqE4mYr8zkLngkd6jklBCnIPeoSxyD1/CkBAGSeG9K1UUZOp0HyEHkc9selIzZGMZzx61GXUnk4HYCkJG3FUkZuY/naSD0phycYzj+VKOeB/KkOT9SOaaE9Q+7nnPH60yZgoy+D7UpJAJOOKpyuXbnpVxjc56tRRQ0nJzTaKK1OA9V/Zc/wCS7eGf+3r/ANJZa6v9tb/kqelf9gWL/wBHz0fs9/8ACD/8LM8D/wDCPf8ACSf8JJ+9+3fbvI+yf8eU3meVs+f7+Nu7+HOea6r9pz/hB/8AhacH/Cef8JJ/yBbb7J/Yvkf897nf5nm/8Axj3z2oA+VaKfNs81/J3eXuOzd1x2z70ygC1bSZG3uOn0qYFgeaoqSDkdRV2GQOuT24xWclbU7KFTmXK9xenKnJ6cU7g44Oe1C9fbrTWwCBj6YqDo6ASRxjjNSqzKPQZ+maYcDnBz60gLZGc5+tLcadiZWYLvAwOlXYJ2ZcrhTwOe9Z+TnIB9ealjbLErk/Ws5RujeE7M1VdmJKl84OCD1q7aai1sQN4BJO4EZC1iJK3GD9OM05W3NuPyjr8w4rCVJS0Z0Kp2O2tdWKwB/Lww/5aAHp+GM1pR659oVVRCq5zvPA/XpXA29y20LmPGepB4rSTUAVMe8Pnk4PGK8+rgo32N41TuINVjMZdpmdWHQoMnGemSeKiuNd+cuiq24EBcDA7Hn2rh5r0gqS+Qe3Xjp3x/Wle4ycbhnuGbH4VksBG92V7U7eHVZ/ssjnb5RwAAc7T6//AFqqSaijF43LojMMlRggfriuYt74xqYyybX4DN6+lTm/khhMJfC8sQMDJ9cdzS+pqL0Q+e5oyuglyS5ByTI2doHYVz+qSI0nc4524wPwFLc3zvvXPz4AGRgD/PrWdNLvO8nnPzD1967aFFxd2ZTmiN2ZiwI6nntUMsgJIyWP16UrsXc5BA/h44qFuMDHbiu+KOWUhrNk9iPc0hBPOevYUZHUA8U1mEaM7HJrQwb6sjndYxx948DPaqNOdi7Fm60yt4qyPMq1Od+QV9AfsU/8lT1X/sCy/wDo+Cvn+vqr9mP/AIQf/hac/wDwgf8Awkn/ACBbn7X/AG15H/Pe22eX5X/A859sd6oyPqqiiigDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKAHKSpBHUVajkV+TjPcCqdOBIOQeaTVzSnUcGXk+9k8e4qSMKZCWP7sHJ96rRTBsButSlgV2kj1zWLTO+E01dDpX8xyzL7KOuBQuCfXvTF4P8Aj60pIU7T0PNFug1LqyQEjO4fWhWHGCcduOKSMb+FPPTHrTWHZT3x+FIq7tckDY4PGO4NBbHH9aY2QRjP4UpJyARjtzSsPmY4kjqCMfjSk7lAY8jjiow3bOeexpcgnCn8KLBzXHMV6YOfajfkcmmkkjbn8e9Lu3Hn5scAmiwcwbjtx26009OQMdzmgE5yDx6dKaxYEgnOadiWxQdx4HH0pDg4xSjAGeD7ZpDkAZxgUyeg5hxt70hYAYLcfypu9QMlsD6VUkctwOFFNRbIqVVDVDppS/A6D9aipKUDJwK2S6I4ZScndiUU+SN432yKVb0NMptOLsyT1X9lz/ku3hn/ALev/SWWur/bW/5KnpX/AGBYv/R89cp+y5/yXbwz/wBvX/pLLXV/tq/8lT0r/sCxf+j56QHz/RRRQAU+NyjZWmUUDTad0XlkDKpBGOmD2pcfLgAZ6/SqaMUbI61ajkDjOQD3FZONjsp1VPR7j+vUk04DB5HXrTFLbstgADI96cBk9/wqWbp3F+U+v8qch64IpvAGMDFIQSOfXODSKvYmjOcnP1qYSAthTwOme1VuBg4NPD5GM8/WpaNYysTxuBx8zE96k38qQX2jpmqmQGO85J704kgYJXHpUuJanYsMxPzO5YY5IGcGlEgGd2dhzjIP8qqhsDANJ8u31Ynjn+lLlDnLcNwEYFmwvpTrm4DNywJ/OqTN8uASwFDMWOTk0civcPaO1iyJtqZYc7uPaopJWduSOemRkVEWbPPGfSlZsdwQaajYlzuO35xuJ4z2xmot2e2fWjI5wee3pTHkWPl85Pp3q0jOUrK7Y5n2gljgVSnl81s4wo4ApsshkbJGPYVHW0Y21PPrV3P3VsLSU+NGkcKgyx6CkZSpIYEEdQa05Xbm6HONr6A/Yp/5Knqv/YFl/wDR8FeAV7/+xT/yVPVf+wLL/wCj4KQH2pRRRQB4r+1b/Yf/AAhOg/8ACV/2l/Yv9tJ9o/s3Z9o/49rjbs3/AC/e25z2z3r5u8Nan8MtH8aw32knxMsEUcP2OTVLW2uPKufMO+R1WRF2qmzbnOGJJBwAffP21v8Aklmlf9hqL/0RPXx3ouh6trs8kGiaXfajNGu947O3eZlXIGSFBIGSB+NAG18V57G6+Jviq50q6+2WU+p3Esc4ChX3SMSVKswZck7Wz8wwcDOBylbt14P8TWj2yXXh3WYHupDFAsljKplcZyqgr8xGDwOeKfqHgvxTp1rcXOoeGtbtba3AM0s9hLGkYPQsSuB+NAHP0UUUALU0U20/MMj1qCik1cqMnF3RdRgcnJIPbPSnMQQMbif1qkrEHIJFTJP2cAj1FQ49jphXTVmXUO1gxPQcfWoid3IJ49KaJgy7c55/GnsRkjgdvpUWsdPOpLQTcucfmcU9zuyQeKZGcHk5HQUfLjkZNAJuwHgdOD36UuQCBzn1pW2lQB+nFIBkkgjb9KAt2FXIPOFHuDRhtuQSc++KQ8E4Ht1603b/ABfpSH5BkjilHAx1HrRnYpyMH3qF5lGMcmqSbM3JR3ZNg7DtBzjFRSTKP9oioXmd++B6CoqtQ7nPPEdIjnYsck02iirOZu+rCnJ99frTaVThgacdGgPfbzwzo0+mHQYbGORLeWUX+p+YvnQSqgKSkEDFuw6D6/MTjPlPhaLwlDrcy+M31t9L8g+X/Y/lecJty4DeZ8u3bvzjnOPesvVNbvtRjhiuLmZ4IU8uJHctsX0Ge3t0rMrvxuJp1W1FXffqZwi1ufRXwR/4V1/wuHwp/wAIP/wl39pedceZ/bH2byfK+yT5x5fO7ds9sZ9q3/2nP+EH/wCFpwf8J5/wkn/IFtvsn9i+R/z3ud/meb/wDGPfPavKv2XP+S7eGf8At6/9JZa6v9tb/kqelf8AYFi/9Hz155oZvw11rwBpth4os7W71Oxmv7DU4mub+0gkc2xjcQxI/nKPNI2kqFG98KGAHPiNbWl+FfEOr2LXulaDq19ZqSGntrOSWMEYyCygjjIz9amTwX4pfU5NOTw1rbahEgkktRYSmVFPRim3IBx1xQBz9FauseHNb0SGGbWdH1LT4ZyVie7tXiWQjqFLAZx7VlUAFKDg0lFAFmOcEYfr61YDArkd/Ss6nBiOhqHBPY6IYhx31L7Nu6n6mhc9Tkg9vWoEuFIw6kHHUVIjqxG08DtUNNHTGpGWqZK+3IzSgc9iB7dKQHBOBn685pgbOOgOemak1bVyQ529Dk9KCSBn36YpBgE5XJ9PSmgHeRnIPvRYdyQnGDxn2Jpu/K8jHPGaQnAyDn04xS54OetFhXAvkMoJ9+aTjIHKj0pQeDgD8qR2VRlmA/rQF+rHZb6+lJIxKcg47ZqCS5UZ8tTn37VWZ2bqfwqlBvcwniIx0WpYlnCgKhBx+lVmYsSTyabRWqSRxzqOe4UUUUyDZ8HaeNW8VaTpzSiFbq5jhMh/h3MBn9a9R8WaPo2q+GWubHTUsbCws0kt7xZVaRpS6iSC4OBmTLMV6fKowpByPG7WUwXCSgElTng4q1q2r32rXLT6hcyzytjLSMWJx6k8n8a9HD4mnSouM9ddvuM5RbldG74KXwOr36+Om8RsBs+yHRfI5+9v8zzf+AYx/tZ7V77+zH/wg/8AwtOf/hA/+Ek/5Atz9r/tryP+e9ts8vyv+B5z7Y718q19AfsU/wDJU9V/7Asv/o+CvPbuzQ+1KKKKQHgH7a3/ACSzSv8AsNRf+iJ6+R9B8QNpGieItPSAudXtY7XzRJt8oLPHKTjHzZEe3GR97Psf0H+KGk+DdZ0C3t/iHJYx6St0skRvL02iecEcDDh1ydpfjPqccV5h/wAIH+zz/wA/nhv/AMKN/wD4/QB8+R/FqVdbu9RfSndp9Xg1UKbw5XyreWHZnZ380Hd224x3GLa+PpIdGsLBrJ5Ba6PeaSXNwfn+0SySeZjbxt3gbe+3qO307/wgf7PP/P54b/8ACjf/AOP0f8IH+zz/AM/nhv8A8KN//j9AHxVRX2r/AMIH+zz/AM/nhv8A8KN//j9H/CB/s8/8/nhv/wAKN/8A4/QB8VUV9q/8IH+zz/z+eG//AAo3/wDj9H/CB/s8/wDP54b/APCjf/4/QB8VUV9q/wDCB/s8/wDP54b/APCjf/4/R/wgf7PP/P54b/8ACjf/AOP0AfFVPDsOhNfaX/CB/s8/8/nhv/wo3/8Aj9H/AAgf7PP/AD+eG/8Awo3/APj9A02tj4wWdgMHB7Upn45X8q+zv+ED/Z5/5/PDf/hRv/8AH6P+ED/Z5/5/PDf/AIUb/wDx+lyor2ku589/BS0sdS/4Tz7fZW919l8J39zD58Sv5Uq+XtkXI+Vhk4YcjNebGcY4U5+tfa+n+FfgPp32n+z9Y0S0+0wtbT+R4olTzYmxujbFx8ynAyp4OKq/8IH+zz/z+eG//Cjf/wCP0cqH7Wfc+MTcHsorebw3qJ8A/wDCXedbDTf7T/srygT53m+V5u7G3G3bxndnPbvX1h/wgf7PP/P54b/8KN//AI/VseFfgP8A2V/Zn9s6J/Zvnfafsn/CUS+T5u3b5mz7RjdjjdjOOKOVCdWb6nxATk88mivtT/hA/wBnn/n88N/+FG//AMfo/wCED/Z5/wCfzw3/AOFG/wD8fpkHzr4702xtvgx8Lr22sraG9vP7U+03EcSrJPsuVCb2Ay20cDPQV5pX2/c+FfgPc2FnY3OsaJNZWe/7NbyeKJWjg3nL7FNxhdx5OOp61V/4QP8AZ5/5/PDf/hRv/wDH6APiqug8X+Fb7wr/AGL/AGhLbSf2tpkGqweQzHbFLu2q2QMN8pyBke5r61/4QP8AZ5/5/PDf/hRv/wDH6tX/AIV+A+o/Zv7Q1jRLr7NCttB5/iiWTyol+7Gubj5VGThRwM0AfEFFfav/AAgf7PP/AD+eG/8Awo3/APj9H/CB/s8/8/nhv/wo3/8Aj9AHzr+0fptjpHxn8Q2OlWdtY2UX2fy7e2iWKNM20ROFUADJJP1JrzSvt/VPCvwH1e/lvtV1jRL69lx5lxc+KJZZHwABlmuCTgAD6AVV/wCED/Z5/wCfzw3/AOFG/wD8foA+f/2XP+S7eGf+3r/0llrq/wBtb/kqelf9gWL/ANHz17r4C8JfBvTPFljeeC7nRH1+PzPsy22tNcSHMbB8RmVt3yFuxwMntV/4oeGvhXrOv29x8Q59Ij1ZbVY4heas1o/kh3IwgkXI3F+ceozxQB8Z+GvH8uhWPh+3is3c6TPfT7luCnmm5hSIfw/Ls2k55zuxxRdePpJ/Ci6Mtk0bDS4NM88XHOIrqS43429/M27c8bc57V9O/wDCB/s8/wDP54b/APCjf/4/R/wgf7PP/P54b/8ACjf/AOP0AfMPjbx43iiPW0awa3/tLWDqwzceZ5XyMnl/dGeGHzcdOlcRX2r/AMIH+zz/AM/nhv8A8KN//j9H/CB/s8/8/nhv/wAKN/8A4/QB8VUV9q/8IH+zz/z+eG//AAo3/wDj9H/CB/s8/wDP54b/APCjf/4/QB8VUV9q/wDCB/s8/wDP54b/APCjf/4/R/wgf7PP/P54b/8ACjf/AOP0AfFVFfav/CB/s8/8/nhv/wAKN/8A4/R/wgf7PP8Az+eG/wDwo3/+P0AfFokZehOKeJ27gH3r7P8A+ED/AGef+fzw3/4Ub/8Ax+j/AIQP9nn/AJ/PDf8A4Ub/APx+lZFKclsz4zFwMEFT+dek+BLWxuvg38Tr+6sbea8sv7L+zzvGrSQ77hlbYxGVyODjqK+g/wDhA/2ef+fzw3/4Ub//AB+rVt4V+A9tYXljbaxokNlebPtNvH4olWOfYcpvUT4baeRnOD0pcqL9tPufFRuhj5UxTDcNggADNfZ3/CB/s8/8/nhv/wAKN/8A4/R/wgf7PP8Az+eG/wDwo3/+P0cqB1pvqfJ+t+GtR0rwn4d8Q3M9s1lrv2n7MkTN5ieRIEfeMADJPGCeOuK5vOTX2/ceFfgPc2FnY3OsaJNZWe/7NbyeKJWjg3nL7FNxhdx5OOp61U/4QP8AZ5/5/PDf/hRv/wDH6q1jNyb3Z8V16V8bdNsdO/4QH+z7K2tftPhKwuZ/IiVPNlbzN0jYHzMcDLHk4r6K/wCED/Z5/wCfzw3/AOFG/wD8fq1qHhX4D6j9m/tDWNEuvs0K20Hn+KJZPKiXO2Nc3HyqMnCjgZoEfEFFfav/AAgf7PP/AD+eG/8Awo3/APj9H/CB/s8/8/nhv/wo3/8Aj9AHyV498KX3gjxZfeHtVltpr2z8vzHtmZozvjVxgsAejDt1zXP19v6p4V+A+r38t9qusaJfXsuPMuLnxRLLI+AAMs1wScAAfQCqv/CB/s8/8/nhv/wo3/8Aj9AHyh8MraC8+JPhO1vIYp7abVrSOWKVAySIZkBVgeCCCQQaPibbQWfxJ8WWtnDFBbQ6tdxxRRIFSNFmcBVA4AAAAAr60tPBnwAs7uG6tNS8PwXMLrJFLF4mkV43ByGUifIIIBBFF34M+AF5dTXV5qXh+e5ndpJZZfE0jvI7HJZmM+SSSSSaAPiWvoD9in/kqeq/9gWX/wBHwV6r/wAIH+zz/wA/nhv/AMKN/wD4/XYfC/w18K9G1+4uPh5PpEmrNatHKLPVmu38kuhOUMjYG4Jzj0GeaAPT6KKKAPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAK9A+L3iHS/EH/CFf2RdfaP7O8M2Wn3X7tk8uePfvT5gM4yORkHsa5Dw6dKXXLJvEIvDpAlBuVswpmZO4XcQMnpya9D+NmtaFrmmeDZ9CvFk8qwlhNqlrHALaMXEmxGVZXKtjsSSRtYkljgA8rooooA6jxB4tfWPBHhTw41osSaB9r2ziTJm8+USHIxxjGOpzXL0UUAFegfHvxDpfir4sa7rOg3X2rTbnyPKm8to922CNG+VgCMMpHI7VzPg1Lp/FOmLp+oWemXZmHl3l5IscMB/vszAgAeuPpzXU/Fu4uL3V9Miu76HUvsln9mXUf7QgvJ7zDsxklaKR9vL4VWJIVV680DSbdkeeVreFdVfQfE+kazHB57adeQ3giJ2hzG4bbntnGM1HEqRFXRQexyM0cAHPBxWftDqWF7sn8T6hL4h8TavrLQCBtRvJrsxBtwQyOX2574zjOKzVt2Y8FfzqwOSNpzTlG3cAM55+lDmxqhE7P4S67pfhxvGo1i7+znUfDN7p1t+7dt88mzYnyg4zg8nA9TXBCAldykEV618J9U+xaZFHp+t2OlXKa3bz6n9ovEtjcWATlfmI81Ad+YxuJ3D5TXmupNBJqV5Lp6hbNp5GhTHRCx2jH0xTbsrmUYJzcbGY0bKcEV0x8Vyj4Y/wDCHfY18r+2P7W+1bznPk+Vs246d85/CsFvp1PGKVcc5Ug0cxXsU2U8UlaBjDk5UBffrUMluApZTwBmhTRMsPJK6O28Z+IdL1H4T/DrRrK58zUtJ/tH7bD5bDyvNnV4/mIw2VBPyk474rz+vWfHlxqcXw6tdP1DXtM17fLBclotVtpVsAsZRYIIVfeMh/3hCBcqvXBY+TVZgFdR478WyeLf+Ee8y0W1/sfR7fSF2ybvNEW7DngYJ3dOenWuXooAKKK3/A8+gWniGG48WRXc+mxKz+VbRLIXkA+QOpdMpn7wDAkDAIzkAHQ/HvxDpfir4sa7rOg3X2rTbnyPKm8to922CNG+VgCPmUjkdq+yPFevazd/F/R/B2m6nLpFjLpUuoz3MEUTSysH2KiGVHUY25Pyngn2I+Pfjtqmm6z4xtb/AErUBfCXS7PznSGOJVkECAqFR2AIxyvG05XnGT7l4i+P/wAL/EVxZ3GqaB4oa7syxt7mAJbzRbuoWSO4VgD3GaAPZNYtry01D4fW+pX51C6TWZQ10YViMg/s+9wSq/LnGM4ABPIA6DC8UDPxT1Tkg/2NYdP+u97XG+Cfiv4R8X+MfA/hrwlpusWf2TULi7zfKpDL9iugxL+Y7M5aTJLcnkk5rtfEib/ipqn/AGBtP7/9N72gCtcSMzFU+XjBotY/s8hMrbh9aszmKJTlRn61lzSM8mQfzoA1JLqOE5TA+hqqb0kHCtwfWqh67WIPc81KuVwQOaAElZ5RtPHtVeNVU8dqZcX32e5WEwXDsy5BSMsPxIGPzoidnbJSRQf7y4FAF6Zv3O4evWse4nbBUHrx09jWxFCZY2xjHoDWbqFk0RJXk4wRQBlK3GGOMHH+eaq3Fu8bmazJEmclOx71ckglWTcnQ9QKlgjD4G3rjjHH4+lAEFhOLgAfclUYKHj8jV2OAyOM4H4dKV9PSQEoVSUdGB60unXTCZoL1Asi4wx6GgDK8WW6pb2+3OWY9sen+NQOiReHbVFz5kvOPxq343lVXt0yAAC34cf4Vh2N2bponcnyYxsRSOgoA1bGNliT5T83JrQ8xpomZSiADHqfyrOhutq4UfLnjFPilz5h3cbuPQjpQBjXhNrrMd04LJJxKMcHnrWnc3CxxSSwYwmdy+1GoBJjFHtG8nDH1rSn0+KMP5Tbl2dOueKAH6dMWjVg2CQOBVlwCrHcNx4xisbw/PE8dxbs3zwNwPVT0xWtI+cED/JoAiO0kFuo6d+9ROm3djgnHQ+31p+OSEwBnP6Ush2RqCDnOeKAKT71I3Eke575oDlVAyeB1P0p0mGYk/h600rkegA+n+e1AFa4xswTgeo5rOQf8TjQeSf+J1puf/AuGtCXIXA5Pv2rKu5Ht7nTruK3kuPsmoWl28URXeyR3EcjBdxC5wpxkigDutT8ReK73x58T7Ox8TTada+GrS3urKAWtu8RLQeY6yloy5UlTyGBGfbFdJ4L8QTeKta8B65c2620994c1CZ4lztVjPYZxnnB6j2NcFrPiXwBqWs6lqWo+CfFjXepeX9uC3qJHciMAIJIluwjAADgqR+ddd4K8aad4s+JmkQaVpF/pkGn6HfII7lYVXa01kFCCKRwAAnQ46jHsAeuUUUUAeLftV6MPEHgrQdMOpabpYn1lP8AS9Sn8m3j221w3zvg4zjA9yBXzX4f+Gem2/jJLTWfE/hjVbGCKK4aPTdZiUXZeRkECySFAG+UlsZIUjGSwFe/ftrf8ks0r/sNRf8Aoievi2OR4pFkidkkQhlZTgqR0INAHR/EzR4NA+IfiTSrNIo7S01CeOCOOYTBIg52LuBPIXAIJ3AghsEEVzNTXdzPeXU11eTSz3MztLLLK5d5HJyWZjySSSSTUNABRRTgpJwOTQAlTQw5kXzAwXvjrirUMCRBWOGfuCOlLK24/Mc/U1m530R2Qw3KuaYm0JgIMf1pAATkYGOaAOvzdOMZpOSyg9PXHFQbv0FTng/Lnn0obkDgEetJ3yOc+lLwTg460B0sKpBzngj1FNIG/G3p+tOK9ufwpeccfmOKB2vuAByMYGaawGdw/lTiRxgDGOaSToTgfUUhu1iE7ScEc1KBtUEDn36VAWJbnjirO3p04HaqZlT1bsIuDyG69jSkYBIwCTQoHP8AhQ2M5XoKk16EFzvYKV3EHg4quI3PRGP4Ve2gAYPBo43DA6CrUrIwnRU3dszyCDggg+9JV94w4Ifj0PpVSRCh55HrVxlc5qlFw16EdexT/CXQ4tcfS/8AhLb43C60mgk/2Ou03L/cP/Hx/q+uW6jHCnOa8erSbX9Ya5Ny2ragbg3IvTKbl9/2gdJc5zvH97r71Rkd3bfDfSF0uKfU/El3b3Z0qTWJIYNMEqLClw0JVXMy5clSQCoHqRWcfh2snji88PxeJdEsYobOK9jvtZm+xRypJHFIq/xYk2yj5cn7rc8VyL6xqbrh9RvGHkG1wZ2P7ksXMfX7hYltvTJJ61XvLu5vp/Ovbia4m2qnmTOXbaqhVGT2CgADsABQB9C/BLwAvhX4weE74eLfCetGSa4h+z6RqP2iVc2c53ldowo24z6kete4eLDJ/wALT1Pyyf8AkDWGcf8AXe9r5Y/Zc/5Lt4Z/7ev/AEllr6k8YsV+Kepgd9FsP/R95QBFMwAG8gn61Wc/PlTnvS+W0j5AyvqaslVCqAoJPBOaAIIo5GfheCOue9XEhbGCf1q5ZKq/MR19qtrGpUsRz29qAM9oVSM56kHiqgTy2EgBx0YdiPWtSVTtyBzkDFNaFRH2+bjBoAS0iWSBVIG7B6d6p3qxqcNIB7NzirltPFFbnfIqJHwxY9K4vW/G9jYXcy2aC5ZzncTgDj86ANJpAx2rGzDruRc4qWGONvnVsA+lef3vjTU7xj5cwiTsIxgfnWHPfXEzhpHdmPVtxJoA9bJK5C52n2NVr0WwtZXu28tUGQxwMfT1+leaWV3MMDfIPfNQ6xfTCBt7sSBnk5xQA7xV4j+23Yij3OEGwEdKu6C5miUJjII6d64mzheW4TapZmOAAMmvV/DGkLpWnZuRi6lG4jGdgPQfWgBEiCD5sZ9/rSRSDywhxwxyD9alnwpGPlU849Kz7vKyxunXoR6igDRsogWVnOWXkEnpW2gKRPJkY2/d7E/5zXNxXAA64IyeT/n8q0rK5WRdrccZ25oAy9OI/tmUiLyiwOWH8Q9f0rpEB28cjH/16qpHFDK0qAEt+hqfzlCEKVC44wM5FACSqFIK43dT+f8A9YVVkYsQOMeoFSS3KYPzAZ9CapysWyUyB+X+eKAHGTLHPHHWmmT5sggLnOD/AJ96iklCEgYx+VQSPgZBx24oAkmbn5iPSsuaXYM5xx6danllLDhhjHJzjn/Csy5copPU4/OgCjePulJyfT+ldl8Azu+KQJGD/Y13/wCj7WuFnJyOT61237P5z8VD/wBgW6/Lz7WgD6WooooA8A/bW/5JZpX/AGGov/RE9fFVfdX7Vn9h/wDCE6D/AMJX/aX9i/20n2j+zdn2j/j2uNuzf8v3tuc9s96+LfFn9gf23N/wiP8Aan9j7V8r+0/L8/OBu3eX8uM5xjtQBj0UU5VLMAoyTwAKABFLsFUZY9BV2KPyhjGG7mnwxG1YHIMnRlPb2pJGDZJB9aylLm22O+lRVNXluAOGApgHXpz0pM884p4AC/NS2LWoZ568EelOGPl44+vWl2j2zjihR8+Mn/69TctRYmPlPJp6KSoLY64FKAu3PpQAx5xjHNJstRGlcYOf1pAMYOCT2qZVGc8Edx6UOrcEN+NK5XIQ52huAO9IzDbnn16YzTpBtIyDk1A5+UKTjmqSuYyfKSSPBJKDDE0S9xvzmlBBOB1+magiGGJHT61ZU5AAI+tNqwqbctxgwSeOP50/seSf6CnsrR4AAz169aRQT14FTc1UehEPQDnHX1oYcAD8akKZx1z3FIwJyMc4p3JcdCMnaOMZ7Ypdm8EHvS7evQH2pDnt1xjNMm3coyIUOO3rTKvum9SpHPSqbqUbBrWMrnDVpcmq2GUUUVRieq/suf8AJdvDP/b1/wCkstfUPjPd/wALWv8AH/QGscn/ALb3leE/s9/8IP8A8LM8D/8ACPf8JJ/wkn737d9u8j7J/wAeU3meVs+f7+Nu7+HOea9+8Ux+Z8VdSH/UGsP/AEfe0AMgbYvzL/nFMfLMAo781bEPf8KfbxDeOB70APtQSAoXOO1aHl7UGeo7VEpUDsoNEs4QjJ4oAWZxty3GBjFYGt6vaabbl7ghnP3Yx1NQeJfEdvpqtGrb5yOB1xXlOsXk9/cPJKzO7HvyBQA/xB4hvdTuCryMkXQRpnA+tYkNhJeThjuOQAMmul0Lw3c6riQoscC8F2zj8K9F0XRbPTosxxh5uokcdP8ADvQB5/pPgq8lQGaVLYEZAkBJ/Ktm28GR523MxHoypkV21wFCHd06YHP+etJb26MPmBy2cckHFAHKv4FCLmG7Rh7IR/U1Q1HwG0tu3+kRAsP7prq3vYrHekjSNhzjZz8vrU0V7FJC0v2pGhHJDkAigDkvCvhVfDtpJPcPFLcc5c5+Ue2amuLx0djBDkE5VicYH+FWtQ1X7Yxh0+2aaEH5pHO1T9Kz767ukDeZbEEHkA5x+VAFS/huLhUcSiMH+6uefxrOFwUvEhuSGO3gjvVtromLMUT4PbHtVFbWR5/Pl5PRQOwoAW4nRZGA6dcCpobhSVZOCOw7UyS0DNnBAx0FPjhCEEHB785oA1Yrrzk2ljuxx7/41EsreYEG7GOR2HNQJjOR6Y9qfC3zbvUYOOOlAE5cAt8xz9cVF5qg43ZPbdTJ13MMMeO+aiGMdhjjofrigCWeXCkcHjoaql84z+HJ/wA9KVsAli2e2M1E5wCDgfTigBWYgEDjv9OKzLskFmJPXORV5iT0wB71UmAwMjp39KAMe4Zs7eCR1wa7r9nsMPim27odGusc/wDTe1rjJI8Ee55/z+Ndx8AgP+FqE5yf7Guvy8+1oA+k6KKKAPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAUVpabZiSIzbwJAfkXHXFZ8aF2AAJHfHYVpyTRlgEGwAYGP4ayqN2sjrwsI355dCOZgzHzF+YHnFM5yR0/rTiRuOeff1po5IIGAKlHQ9WLgFhxwPWlAAPU5x608ru7cD3pMDHPWlcrlHIeOmc08gh80xfvYzjHpTxjByD+PNSzWOwpwTx2pyqw6AYA5B60+OLkdDzirkUCowXBz0BA61nKaRrGDe5XVVLoV5LHpmrLQtlmLJnIPB7H+VXFsXj+UkLIcbQ3B/wAatxQF9wbexK5UDt+f9Aa5pVl0N1A5a4V1m6DA/IVVcgPym/rweK2NatXguXDhUUcgc8ZrDnJLjGDkV20nzpM8/Ee5ccoBJKgrnnHpVu1iLMcLu44Peq8SbygVTn0ro4LIJAuRtYjBJ65qa1RQReHpc2pkCL5wMDI7dxR5WRu5OOcVqPb5dg0eCTkdBmoTEyZxwoGSOn/66zVW50umZ7rh+xJqNicjjP8A+qr0sYXaWxk9h1qtjoRnb3q4yuZygQbMc55pH9Se1SuMnnp3qPr9wfpWiZjJdBnPuM1HKgeMc/MOlSEHgMcf1ozggZ61SdjKUU1ZmeaSrF0m2QkDAP8AOq9bJ3VzzpxcHZnqv7Ln/JdvDP8A29f+kstfWHiDn4p6sB1/sbT/AP0fe18n/suf8l28M/8Ab1/6Sy19Za8cfFTVv+wNp/8A6PvaZJZVMIVLda56fVlPiE6NbsftSwC4ZiPlVC2K35iGJAz/AI1zWqaNfLrcGraNcQx3Ii8iWKdCUmTORyOQQaANtLBHTzJXkkJ6/NisPxHLbaZp7SHLTuMxoG4Hua1YdXeytH/tmBbZwpO6I742GOx7V5p4h1JtRv3l3fu+irnoO1AGJDLJPK/nOzuzEsxzXX+GPDJulE9ypWDPAPBNV/Cnh/7dL9ouVItEboR9413jyizh2SPs28AD0oAURJDGkUaqkaABUAxipoyiIWx0Pes6S/DH5fmA55NZV/4gCH7Lbfvp2PAUEgfU0AdHcSwbt80ioi5xWYdXSdmiskO37rSkYH4VQtrXcgkvpDLLjlScKKlcoDtBAI/hUdKALaFY0ZUAbccMSBzWZ/YmnGdpxCfMbnG75R9KkEpEh2g9+TTZZtrNtIGP4gTQBHIBC2wbVjXpgYx7VWvSJQ2AxxwD7U9v3i5Ybj2J681DIThgWz9eaAKbSFG54B4GTk1A3yuBxzwR0qS5UknHGef1qmjArjjjj60AWZAViIUf/XqmC28FB9B6UM74YK3HQZqWMMS5LEAjtQA63G9fnGDwMDkVLhV/u9DznGaiG3aAAc47mm+eAMHHHGD0FAErnkjOSPU4qEqQrZAA9M/5/wAikafLkfNgcUya4QDCjnpwKAGEhWyWyT04qE4I5A9+nNDyM3Cr9c1BtnJJxhemfagCRpOCT0PfHWqtxIOQDx6fnU3lzlcAYz15pklq5Xnr0xjigDIlmc52gDrXc/s+OzfFRtwIxo11j/v/AGtcg9qFJyOeldp8A4xH8VMD/oC3X/o+1oA+k6KKKAPFf2rP7D/4QnQf+Er/ALS/sX+2k+0f2bs+0f8AHtcbdm/5fvbc57Z7183eG00Q+MJm+HHiTVvD2lLYj7Xcaxe2treyt5mTHbvuRMkCPqy/xZOOD75+2t/ySzSv+w1F/wCiJ6+LY0LuqKMsxwBQCV9Dq/G0l1qHi7WtUmgtIGuLpnZLK5juIl3ANgSRkqxwRkg9c9OgwHfeScDPTPrxVkvNbRmHaoQHO0gdcdahciTBI25rnUm3dnpqnyR5VuRjqeMelOUYHQGkZeOvvSgYAyO/amJJkiL0KnJz61IoHO4c9fSowBnJ5ApysAACKlm8dBxVSevT2609E+UcY55oVd3AGfer1vAQwJBA9upPpWcpWRrGF2TafFknGN2Ox6c9612hhnWE2sDmVQAQpzu/l/KktLXcryADZwoB/i/LtXZ+GNEe6hUsjBG+ZpMAA+wwPp+leTisSqfvM7YQ0OYtLCS5kEcdvJNOMAqh5B69cYA/nXbaN4aeK1aa8AabggR4yoPPLf4V2um6JDbRqlshV+u0cAHuc/THXmp9W1HSvDdrLc6ndYjz9wEbjzjIX8ua8Otj513yU1v95V1E8K+J+mx2NzEYowiyDOQmM8eo4NcCJ1WCSLyY2ZmB8w/eX2HtXovxY8Y23iOaGOzgkiij6O7Ak/8AAR0rzfA3A55619XlsZrDxVVWZ5eLlefunU+AtEfWNU2kfu4sE/L156H9a9RvfDU0ZVDDwcg9++OO5ry3wfrlzoDGWBgokYYBHBPr616npHj+S6lRL61Qo/yqYySMDjP615OaRxLq88NYo7sM0oJI5+90EsxQKUB5XK1g6ppb25bzNzRnoe4r2hfserxb7eRZMDkEgkVzev6I0QYhS653AdVP5Vw4fMJKXLM6GlI8klts4MhznGx8cGs+5XbyOD0I612N7p4JcRFhuGSnbr/OuXvBsmKN8x75HT2r38PWU9jnqQsZ0q4YlRx3FQsT261YmICDbyahcgc9Sfwruick0RnOOcDHHFAX+7g+/pQ33+D2pucE8nmrMWJKu+PHft9a0fBf/CLDVZf+E4/tv+zfJPl/2P5XnebuXGfM427d/vnHvWeuCvNVLldsmex5rSD6HJiY3SkfQnwR/wCFdf8AC4fCn/CD/wDCXf2l51x5n9sfZvJ8r7HPnHl87t2zrxjPtXvniAgfFLV8850XTxj/ALb3tfJ37Ln/ACXbwz/29f8ApLLX1L4wdk+KOphc5OjWH/o+9rQ5C6WIwwOOnWnwOZM8k+npmqZujIgKgAgd+Kz9Vvzp1hJOzgyEfKB60AZnxD1mNQNORgQOZO/4frXC6Xo11qEvl2LkBBuw5+VehHNRO8l9fMzks7t1IzkmvTdM01dM0yJRgysQX470AZ+hXt0ljHbGBcxjDCNufqM+tJrGrogCbWMx4CMOT9aLyxxcNNbzNEx4IGef85qO0tkiYvOBIx7uMigDPgsri7Bm1OcxwnpGpq7aQwxEm1jCA8bycsRS3QjzujRVHsKjSXjCAHn1oA0CPn+aR857Nx0pk5CgBemex5NQKpKnPLcDI79//rVHJJt5HPuR0oAkd2PDDI+v9Kqz3SxSMM8k9R3ps8hQD5mYY6Dj/PSmR232oswBOOoGOKALCTB0O1shuc/5FISrLkYB9vWq/kiIEA84xTDKAOSwI5HHtQBHI2DwQMe3BOapTgI2cEk96tFuW+QnPfHtUEuGjAzyQTigCq79QPbHFOjmZWHzHA/z/n61GyD7uTVqOHaOnI6/5/CgBpbIPc+hqu2WYlOnbjFaDW42fKo9ckVGkJZfukgjgAcDNAFJkZhycD8+akt7dQ64yx/LFTGMDocjvU9qhQBiMA8daAHxW6ZA4B9u9K6qoOQSRTmkAGDn8ec0x+V455zxQA1TlvmNQ3BBAA5+hpTheDnp6fp6UyeQMpAHHuO350AZ12DknAPHNdT8DMf8LUXHT+xrvv8A9N7WuVmYFSvQ9q6n4Ftu+Ko45/sW7/8AR9rQB9G0UUUAeAftrf8AJLNK/wCw1F/6Inr420yUwXQmCBtoPX34r7e/as1n/hH/AAToOp/2bpup+RrKf6JqUHn28m62uF+dMjOM5HPBANfHHiDXm1/W7jU10vStL80Kv2XTLfyIF2qBlUycE9Tz1qZ6xaNaHxplOe4WZ87MMByQc1CDk56Cl35Odq49KYxBOBx2rFK2h6EpX1Y7A753HtUigMckAY5prZxt3Aj9akXlAdgx0BpMqK1G7AOmB3xUiAlgMZ9MUFPm4xjtU8CZbDKcdfoKhy0NYw1H28Z3qAMMePxroNIsHvFKRFmlPQdFyQKz4LYOcoxLLycjoM4Fdl4b08osZSLLzHYhboRnGR+Ix+dedi6/JG6O2lA6bwr4U3zr5rH7LEoLnHXA5/z7139pHBarv2pb20YLdlAUd/rxnNWoIfIgitFG1Qq+YRj5m/8ArV478U/GTXskulWEjJYxEKzoRiUj6dhXzFKFXH1eW5cpE/jv4lyvK9hoLeRCCVM6E7n919BXmFxq09wCbxpJpM/ec7iM855qhJMeclsjuTnP51CHwcMOPzr67DYGlh48sV/mcU62ugt3I0rLu3HHHP51FJksgKqMAD5R1/8Ar1aFnPPZm5iikaGNgjsFJCk9MntUKRMvzlWCdVJHBrti0lZHNKLbL0NxGrZky21cAYGPb3rXtdcW2VhBnywudu3Azxz6f41zGWXnDKDyKN/Qdz3rKdCM9zaNdxO207xebII0bSGQjlskAceg616doniCz1axZpZFcIBu46ZPB/SvHfA+hQa9qz2lxP5QCFgyjqa6C80S48K34mhnM1q+VbnBx/L8a8THYXDTn7KLtPf1OyjOclzS2Oh8RLC7u8IIJzt9/f8AlXBaqqvuJVdxOBt71oXV/IhYkE7jjGSSB7j8az7xVaMuB944z6VrhKTpWTZpUaZhMOMn7yjk+tQN7jOOavXMXy5wRj0PX/PNUyuWIX73fmvYg7o8+pGzI34AyRu6nFG3C0pUEBc9eKQYxtIyfWtDG2o0EH6e1QXAJQEjkfyqdRjpnjvSTDdE/wBOKpOzM5x5ou56L+y5/wAl28M/9vX/AKSy19V+J4zJ8UtVx20bT/8A0fe18/8A7PfjL+2PiZ4H0T/hHPDdh9i83/T7Gx8q7n2WUyfvZNx3bs7m4GWANfQ2vAn4p6vjn/iS6f8A+j72tjzSrIjIgLAYPpjivOfGer/ar9oVDeTGdo46nua7rX7sxq1vESDtJcg/pXmkke67KHDbjknvQBu+BdI8+c3UifIhyBj+Ku/nhZkJbB4zzUWiWkdjpcEAVQQu5vcmrFxIqQsGOSOlAGLMgjBI5C9yOazrltybRkNnAI7c1Jdu0ibA6g9Mnt/nrSQIqxlm3F+nTrQBVlXIIIwB0Hr/AJ5p0SIoBPB/Gp1TjOCpPbHtTZwqLkZUjr3oAmCDZyeOufX3qGZIgMADI7Dmq4uJMEbiSfpzU0I7jhs8ngGgDPvLWRwvljjqe3HpVmytgifMMluoz/nmrhQjggnp+dPjUljgZJx1oAzNV+UBkHAO09sVlFyQW/iHqPxro7+MsrDaOelY3kIrlQoA6kdf896AIEJ9OneiWAhQ3Poea1VtESPKINx9eKSWBXj9GoAwcEMNwJ+vSrcSgleMcc1Bcr5WDsxzxkVNFJlQRnjOBQBdUB16DOfriqrRlU+XjA7/AOefpUiSkrnofXPSo0dzyRkEY5PX/PNAFd1A/wB4ce9PQ4CYBGR1FOmBYDDYPbpTUbC4K59MigBZFJIx0Bz6UcjI7/Xmng7jlQCMdBzTJB6HA60ARSgkgD8AOPrVef7pOKnLhgc5B9+1MuPuk85B49e9AGTKMNwM5yMetdX8CMf8LV4GP+JNd9v+m9rXKzA579cgnviur+BYA+LBC9P7Guh/5HtaAPo6iiigDwD9tX/klmlf9hqL/wBET18f2n7u1jPyNuycEA45r7A/bV/5JZpX/YZi/wDRE9fJ3h3Sb3XDJb6daRN9nh86aWa4SCKNMgbnkkZUUZYDkjJIArOom1ZHThZKMm2zNcgN9zHJPAphUk8fxVa1Wxu9K1G6sNTtmgu7eQxyxMRlCPccEehHBqvxtOCQM5qNjpupDscY6mpUX7oDYxz1qBThvvZHfjrU6sM4JHFSzaDTHINzjcRj19q07KINcRr9Pc1WgjUEnftQmtGxjClzkHaMDjOc5/8ArVzVZaHXTiaGhxeZdJE4KrJ8uD0JJOB/WvYvCGnwq7yPtdbTCIuQQHUHnPueev8AOvLfDNo02oWyxAcygjDdcH0+oNeweFo1GkIVyqzzM0hP8WcDp9AK+bzWp0TOpaRF8aa6NG8OyTbS11dbvLGOVyDnj1A/Uivm7U2bzSOueSBnr7g16j8Yp/P1iyjhlZkt0zhOxJz+PBFeUXUjyzYncb8n5jnn+tehk1BQpc/VnPWdlYpZO4ntVqytmuHxkhOm7GcH+pquOmRxz35rqYbGO3sVklDGBB82Pl3nj5Qfcnn2FexWq8i9TlpU+Z3fQteG7xNFM8kBtZ41AMlvcyIUkIPdCefwzUOuXrazGiRC2iijOI44IwqrnqPX881et45bUJBdanZWM0wVltTbnYoOCA5Awvbrn3qhqVibS4mlaH7PcQN5dzEo3KwPAYD3OOnqCPSuBODqc/X+v+G0udetrdDlZVwSNpVskYPalSPKnAy2MHI6e9aWvRpHclkO45wW9cHrj34qhBG3neW3SQf04/pXoxnzR5jklC0rHZ/C+e2sNRmuru4hRVUIVdsE7vTP616R4j0j+0As8cyCHGflIwRXh13blmRtuJDkELzn/ORXqHwv1IXEVxpbsWK4aCN+wxj+eDXgZnh5J/WoPXt5HbRlb3GjJ1fSoYMBAGXb1+vSsCKNGZo2QblY7SR0ya7zxZCIpyu0IdxBQHp+FcbPGyXgdhkv94joD7/hVYSq5w1ZtJamJdRfNKgzwc4rNKgcjk9+OlbV/ayGUuiPtI3EdSOO9ZdwjJgcjcOeOhr16Uro5KiKK54xQxwT3zz9KewcOAFPT6CmlCMjPB7V03ORpjCMkAZ3dKUrhhn24pGHGF4PHWgbsg5BIFMk9E/Zd4+O3hn/ALev/SWWvrLXOPilrDf3dF08/wDka+r5O/Ze/wCS7+Gvrdf+kstfVXipynxF19gcY0Kw5/7bX1dB5LOO1S9Y217cHl2JGfrXI6SGuNWhDfdLc4/z9a39WyNCcvjJmxkewrH8LRNLrUCggfNnANAHrZ+6pz06Gqt7IBE3UfXrT5JgExkYHpWdcyb1HJPtQBz18227UB2UEDODV2NiEXdgrjr704xRvIJNozx1qSQbm28AnOfzoARwSvDYyaZMQI2JBJA9KteWPL/zzVC/z5e3af0oAqJiSQjnIPpzWtawAj/AVQtodoUkgAdq1LN8hgeg5BoAkaPaRtGPcDFMDFCcscjp+lWGKlhjn1OOlU7wqZQq8jNAFeSYH7vOfTrn8KrRxB7hGfO0dh/WrLKMHbycdSahJwdxUAZoAsXTncijkdOmMiqnRug/H1p9yRuQdSPfpn/IqrKzgAL+PtQBW1AAZBwQfxqvbqJMLnBXnA4FTXBLKTk7uvGTzVWHEZHbsTjFAE7qy5POelIFY4bgjqCe9OV+CDz6YqVvlRcYPuKAIVj4HPJz+WaR0yvXtg9qkY8E8DP+fWnSheD79KAIF+Ukg55zjmm9UwOOB04qYdByD+NR7Py5xQBUyASR0680MMhs+nABqSZeCwOR70xRuB55oAz3wG9D0NdL8Ccf8LUBH/QGu/8A0fa1zNzwDj09etdR8Cv+SpL/ANga7/8AR1pQB9G0UUUAeK/tW6z/AMI/4J0HU/7N03U/I1lP9E1KDzreTdbXC/OmRnGcjnggHtXzFN480/Xn1a31rRbLQrHUrCG1z4c09UWN4p/NVzC0ihyeVPzjjb6YP0R+2r/ySzSv+w1F/wCiJ6+O7dCbYNx+JxUyly6m1Gn7RuJs+Ndbi8QeKNQ1K1glhtpSkcSSgb/LjjWNS2ONxCAnHcnrWKDgZwPpUrqFwC6n6c01sAZzxn0rK9ztUORWuIpbLcYBzTkxnknPamrgvgdaDwCWpFrRGpZqjPgnBxgYOcnvW7HDG9tOmSXAX5fXpn9M1zVnIN4wvbrXWaWSyAlQcrtwRz9f5V5+JvHU9Ci1JHT+DoNk1gy7QdzIwU/M+MkHrx1P5V6bpRURWKq+UCsAD1II9frmvM/Dck1pfQhcIRxk/wAJHOOPUfzr0bTJlVrfAjz5RXHQEDgV8rmF3O7OlrQ8d+I0v/FXXrSqZHJfaCD8uCf8K8/mOJWxkL7gV3/xJk8vxTfqyDAkC8DOcgMc1wl1ne5ZSuWzyMdeR9OOa+qy7+DH0Rw4gh5yvPIx+ArtmkbU9IijVl+5+7Ve5yc/jnPvyK4hs7dpyD/OtLR9SazJjcB4W5IPGPet8RSc0nHdGdGoouz2Z1OpNa6jdXF019Dai7VftMU0LM6EY3eWQOR+vrUmsX8VzLcXaRv5VyYoII2ba0iIVy2e3Cdff2qEa1p0kHO0zbceY4Vs/XKE8fWs6fUrRZXkaZriYjG4k9PQH0/KvPjSldaPT/gf5I6m13KWuYxEhySoJ/TA/lWPHuWQbeD6+h9a0Ly4iunDnCMOgAyMVDkAtkowzyM4r0qd4xsznqJSldFlmjUQgRlXf5nZWyR24/Otm2uDZMjRSfvBnZIQF9MZ+nP51iwan5Em5EQ4AG7GSuB2J/GoZr0yrudFK9getYypSno1oaKpGPU66116Oa+je6Mt1dk7ZGcDCc9vzroNYhhiuXLw5zhg3Tj/ADmvMraQQN5sPQtgc4IPHX6V6teXKXcenzbWkDwLlVOSCBj/ABry8ZRVGcXHZ3OijNzWpi3yxywqFykjdT6iuU1JAoZR8pDEk9frzXY6mES2kctxxgL27VyF4SRlmAG0k9/1rbBsdUx3G45Jxk9CKifCnIJAP61K4bDMyngnkdO1Qnad31yK9eJwSGrgn0x1zW14M8Rjwvqc14NE0XVy8Ji8jVrX7REuWB3BcjDfLjPox9awzg45696C4wDt4Bz9atGMknoz3j4KePv+Ep+MfhWx/wCET8JaN5c9zN9o0jTvs8zYtJxsZtxyp3ZI9QPSvd/FcPneP/EeCRjQtP5/7b3tfKX7Lxz8d/DJ/wCvr/0llr661Zd/xH8QqWADaHp4Of8ArtfV0nks858QxmPwqj7efPbJHfgVynhGZ49ciLscNkDJ6cV1t/LHceFrtN4Z4ZgxA7AjH+fpXEaU6prEGOPmwev+etAj1QMfLOcljnn0qOZ/3ft0PPSqMFxMG2OvGcHHWrQwVB4z2oAgBZpOT0PFTRjnHfGcUqKwIA5z1qWGI856dsCgCOeSXaqgYHQ0xrdjgsOc9auxouQCAR2zU8i5Ruh+lAGeltvU9FI6VPDFtyQOnNPBxnB981WaQtlQfl6H3oAhluC0hXBA9T9KRRktg/lUzxBgCT+H40pjwmRyfcUAV+NpAIqIfcyckqeD3qxIuFOSScZqvnBPIz34/wA9qAI9hZDgH73TBpknIIYAY71M/KlsjPXp71XlJGSvOeo/H/61AFZ+SV/n/n3qlLGVwTyD/jVqUkykHGAD2qCbIbcRjJH4ZNAERBxyOT2/yKlXJG89Cc4zn6VFCpJIPHscZNWYgAvIJPf0oAgkOFcAZI5yRR5q7R/U/lTpkABK8E9R1rP+aMFhkj09aANDcoJ7HvkU5iSMgcDFUhKHjDAbe+KkQrjII6cA0ASMR5ZG6opQAAegIJ5p5JAweg64PWonb5W+nWgDNvGwpIyOeRXU/Avj4qLxg/2Nd5/7/wBrXJXRBlHIAzjmuv8AgaMfFNPX+xbs9Mf8t7WgD6LooooA8L/bB02+1f4d6NY6VZ3N9ey6zH5dvbRNLI+Le4Jwqgk4AJ+gNfG93pepaVdvY6rYXdleR4ZoLmFo5FBGRlWAIyDmvsf9sHUr7SPh3o19pV7c2N7FrUfl3FtK0UiZt7gHDKQRkEj6E18aXerahrGoSXer313f3cgG6a6maWRgBgAsxJOBUz2NqDtNCOrKPmUKOwNRkkhsEYoXOSR6UD3HbqO1ZI7W7jgMAY/DNHBCgj9KXJzgY9aTP5enpQMsQkgqFXLe1dr4akDgyoCy5wyt2OO1cVExG3B4BzwK1NN1B7e9XJHlHCk9BjPFcWKpupFpHbQko7np3nRafskaIyROQw2jGT6j3xzXYWMrKtuQyOquVyAQSpORx9P5V59ZBb6BoiS0q98nCkep/wA9a6/RZJZtKiWQ/OoXcGGCpHqenOP0r5TFU7LXc9Dc4j4tW8ttr0kzR74ZkV3bbnbj5cfXgfnXB3amaRlKMrcDHXJIFe0/EDTW1jw6l1EVE0I3D/d6MM/hXkuoW5FzhRIsAIjwudmSOD7jj/8AXXt5XiFOjGPVaHLVizCKMuQYfXkjmmcjBKgA9OvParBCrMr4ZIt23cf54qOVGAAJzxuznjHtXspnE0MYuFTf90jIHUc+lH3uVJLD1pG9Dn8emaZ0J/u1RDYuCeT+NDc5Y4603ovPOKQkHofwp2JuOY7umQOelLuBBAGPf8Kb2PrSZ6gdqLCvYs23JY7eO3ua9NsHZtE0/fkN0yjYOfc15nZuY5lKklhXrekaeBYadAwwUjMznvyM15GaSUVG/wDWh6WE2ZU1SJY48SFhJ9eOnf8AOuS1aBfLQqQN+QR7V1/iJ9wyT82egIz7H9a4nU5MFl2k7eDx/n3rnwN2kzeqZjqyhS+GxnjGarPjHBOM4I9Kt3Lb23DnHAHvVaT5eAcf1r2YHFMrkcjnPNIXAjf5T8oOKcchieMgd6hum2wlT1yBWy1OWb5U2eufs2eHNc074w+ENT1DRtStdNufP8i7ntXSGXdaTMu1yMNlQSMHkDNfSPi6dofihqgXo2jafn8J73/Gvm79mzxHrmo/GHwhpmoazqV1ptt5/kWk908kMW20mVdqE4XCkgYHAOK+k/FMSzfFXUgxI/4k1h0/673tdB5J5lAjw6vqunTPhZgWj3exyMVzRDQ3ecYKtnOeRXqnjHw60sSX1mpNzbjkDqy//Wrzm4UXaNK3yy/xoQBg+v0oA76wX7RaxXKkMrDkjtWlHErqARk9q4jwlq4tH+zTEmBj19DXoCY2BoyGDfdYdDQBSceVMFyeuAO4qxvUIRG2SfvZ61HJGrXG9Ru25UsOgqNjPFO2SjxHocEEfWgCwDgk9OcHtRJOqQ7T1qu7SEkAIuPfoKkjiPBbOelAFNLlZVJU/J6+tV7y9t7EQm6lEYlmWCPIJ3Ox4X/PpV2aIRsdowM1y2psb3xtodjgGG0jl1CTjjdjyo//AENz+FAHUpkArjkcc881m6p4l0nTNX0/Sb28VdRviFt4RGzmQltoGQCBk8cmtkKVUHHXvXlV7pDeKNF8c+JIR/pkdwllo8meUFoRJIy/7z4A/GgD0/G5cnrjk4qi/GQAQBxTtE1JNc0Sx1S3AEV7Ak4Veikj5l/4CwZfwpZlxyQuRyPrQBEGJbkgg56VBcj5h1x7Guf8ZatqWnjRrTQksmvtT1KHT0+2K/loZMgE7SCOQORnjPFVrvUPFWj6rosOtP4dv7XU72OwH9lfaFkidzhSwlUZHsMnigDoHTMmRwe49aWePdCGA57dsVc8nKkNgPkrg9QR1FRsu0EOQTnOAKAKKRsoztPPpQgwFbAz24qUkqSp6f5H9KZLJFGwBbcAew60AMlGQcgflVO6wihBtycdavIwkOYwF9z24qrLEWJkI3An5T7DvQBnpui3JntkEn6U55jsbaCSD0yB+VPuIzuLYGAeuOxqGXjJ/h9qAHR3O5BvG0nt1pxlDKdvzDuQKqmUg8HgdRntVae5jVQzMqkc470APuDknO7GOprsPgaMfFJB6aNd/wDo+1rhPtcbJtDDOSPSu2+BDl/it1z/AMSa6/8AR9rQB9IUUUUAeAftrf8AJLNK/wCw1F/6Inr4sRtrg190ftW+HtU8VeCdB0bQbX7XqVzrSeVD5ipu221w7fMxAHyqTye1fKjeAb7wz4sh0LxvoOqyald26y2djpt3AJJSzlQTIBIqqAkh6E/KM4HNA07anHng4zyeKFBJweM1p+JrTT9P8SarZaRem+063neOC4ODvUHg5HB9Mjg9RxWYR1P8NYvTQ9BPmXMhVIINBAz7jmmA/KRx9af0A7+uO1A07omjJEg9c8+lWWRt6NnYpHPf8f5VSBweTVhXyuw/UZrKSOmElszv/D+oI0CSFgoLLHJtPBbsfxrrLDUnicNExCudrBuFx37/AExXk2iXqwTeVMx8iQYOP89q77Tb7y4Gt8ZSTG/5c7vQj2r57HYXlk3Y9KlU5onfWUgcPbsQ6PnHofUV5d480OTTQTAq/YzI0gbnjp8oFehaFc3E8HlSIAYjlZF4BHY1rXttDqsEttdwhkcEk9MHsfrXk4fESwda/TqOceZWPnCRw65lCr8uV7gnI9On41NFJbPGu7crDgOCFwMdxz7ZrovGHhW60O6ymTEzYikjB6Y6N71zSM6RncSVZiCAdmPX86+up1YVoKcHocTi4vUdBYrdwtKJEjZWIYFuAvQYNUJo2Rjn5scZzkGtJ7uRHUO53KQFZeCAeoz6VBcStLHtBUKvBJbJPP61rByvrsRKMWvMoBMfQ0gU9gT9akbavzAkkcjtTVbkNk5B/KtznsthBgHkc0mOORz0p5IJByMfSkQGRto3EnjA60BY0NCi+03UUOwkls/Uelet6fqC28MhlCiYnawPTAGB/KsPwD4YktI1vb0BXcDEbdQO341L4mkiRQY+ZlGDsGSOa+dxtWGKreyjsj1KEHCGpR1K+82d8Z2Keg5BPtXNzKrll3gZJYk9Pp+gp0120UflMAM84LZI/wAKo3Mu1EXaTu5z713UKPIrIU5p7kEhy+0ncwHGOx/yKqvsyPlwKe43A+/PHaomx8uT1Pcdq9CKOObFJyuW45qjeMTJtznHNWXk2cnn+laHgzwfr3jjVptO8MWP269jhNy8fnRxYjDKpOXYDqyjGc81tTWtzhxVTTlOz/Zc/wCS7eGf+3r/ANJZa+p/Fj7Pinqh5/5Ath0/673teHfBH4W+MfBHxh8Kal4n0f7DZSzXFukn2qGXMhtJ2Awjk9FbnGOK9m8fTGL4n6iOzaNY5/7/AN5WxwFr7YWHyk5965XxF4bS8El1aRnOMyIhx+I/wrStps9cA54FaySFYMjg9KAPHZ42sJSs7cN918fl/OtfStfvLVhHuJtz/wAsye39K2vFOkC7ha4gVfOj+cjGc++KqWmj2+r6al7ZN5c33ZIz0D9xQB1Wma1YXFssbyCB+vPQ/jVwxqxLIwde20153Pp97aE+ZC+M9cHFVo7+7gI8qaQbeykj8KAPRBEwmGSSo61aVQAcKwwK4ay8T3sAxJskx2cda2rbxhbSHEsDITwSpz+hoA07kHcy44rkfCpa98S+ItRYfJ9oWwhJ67Yl+b/x93/KtrWPEmm22nXV4ZQBBC0hB4J2jNZHgVEtPC2mxzTobxo/NnG4Z8xyXf8A8eY0AdJr321dAvjpEPn6k0LC3TzFTMhGFJLEAAE55I6VymlfCTwbY6Tp9tqmg21/qaW8f2y4a9uPnmKgvjy5QuASQMDnFd3bgzwAoeOpwetJ5RVmIB4oA5TwFol94c0fUtPngWPTre/kOmMZ0cm3f5wu0MWG1t2SwGd3etO4fOVBxjtmtSePahPA4xWPIBhicbuT6kCgDifiLYi/vfB9n9pubY3PiC0i8+2kKSxbiw3I38LDOQccEVB4p0NPCOnDxXoms6/JqelN5kP9sXkd5GQTtYAGJdrEHAYHIPTnmuh13Q7LXxYpf3GoW0dpci6jlsLhYZlkUEKwcq2ME5yBnjtUFt4N8PRXsNzet4i1wQHfFb6zqnnwB/7xjWNN2PQtg9wRQB0qIBkzZG6NZACOm4BsfXms28uoow808ixxR5LNIcKB3JJ4rRuJpL2aae4l3yyNuY46knP4d64nxVaQ6n4r8JaJf5fTL28aS7jDEeckSb/LJHY4oAhPxC8KvcfZ11aDzc43FHVM/wC9t2/jmtd5hNiSNgyMoZGByGHYg9/WtzVLqW+tDY3CQjTFyBYJEot1X0Ef3ccntXO+LLtdO8P3M8UKQ/Z7RYIEj4HyoI41/RRQBZtb2J7XzYnWSIj5WU5BHPcdf/rVOlyqwqFUlsc98VjaZZLpWi2tkuGEESR59wME/jU9xfLZWjhhmYtwD6UAWDKjOVZgMnnPYZ71ly3kFuXjklDKvCkHqKw7qa71CX90+Zc5HGRj6CpFsLiRiXQqQQD2GaAFutRLk+Q2OeT3qrHbzzkuScetXBp7QMNwAA49aujG0jbtwOQOtAGNPaugyGJweuf1rvv2d2J+KTA5wNGusDOcfv7WuPuMKx7Eda7b4AKB8VSV76Ndf+j7WgD6VooooA8A/bW/5JZpX/Yai/8ARE9fIvhnxPqnhmS8fSJbZPtcJt51ntIblZIyQSpWVWGCQO1fXX7a3/JLNK/7DUX/AKInr4qoAv3uoy6hqMt1crbJJNjctvbxwRjAA4jjVVXp2A7mlHP4dMVQFWoHyvYEcVE11OmhP7LJT14pe4wO3agHLdefSmZycj8qzOpuw4gsOfX9Kev3uTg+1MHIwScUoPAJoHFlk4yuDx9e9dJouou0Wxsb1+8VHUVygOfvEZParEMojYHow7561z1qSqRszqpVLO56roupPIVMcgMqgcbjlgOSPw69a63SNXjvGZZDmZCQMnk89vXH9K8dtb5kaKWGTa4O7APTmup0/V2bMySlXf5XB9cdev8ASvncXgeqPQjNSPSryyg1Cze3vIlmhkHKsuSv0xj868x8SfDaaBZJdFZp4sbvKc8j6EdcV2OkeIYg2ydwQMFWIyQfqPeui8+K4Qm1mVjnlR97pyMep9q86jiMRgpe7t+ApwUtz5vvdLvbFtk9tMmegZCBms8hlBLBvTPTNfS9xbJOCk0aCMLhwcEn6g/SsO68O6LdnmGAjt+6x+tezSz2L/iQ+455YS/ws8DI4POM8+9IOGxyT3xXt03g3QUkDNBHgZIAzj8+KWw0nQ7cP5dpDvz1KAnvXR/bdK14xbI+pS7nkuj6DqGqyqLaBwh43sMKK9D8NeDrbTcT3pWWdTlSScKa3p9QRIgkMSxxj7xxx+XrWTd6g2HIYsSc+hA5rjrY6vifdj7qOilhoU9d2aV5qpigeNGaIkY6Bj+FcjqNx50xyUQjpgj19B1zxTZrl5JvMzxjOP6VnzzE7vl2qTwFHbI5qsPhlTNJSM++VFyEYyA5+du5rLlOVwck9fStG6DBmcY3Z6E5wKz5iVJ5GD+tezS2OWoQgAgt0A5wKiJJx7+vWhyM8Hg9qjlcL8xI+UcCulI45SsiK7faojA9z61UpzsXYseppldEVZHl1Z88rnqv7Ln/ACXbwz/29f8ApLLX0v8AEPH/AAtK+z/0BrHt/wBN7yvmj9lz/ku3hn/t6/8ASWWvpL4kkr8U709v7Fssj/tveUzMoWrDIIHX36VqRSiSLgr71ztrdFySrbRnP+RWnbzYXOeT/h/9agCxMjBiQR9OxFcvDI2gayQWIsLs/N6Kex9q61XVkA5I9TWPrtqs9o8Mo+U5KsOqH/8AXQBsLcRsnzEEfnms+5tLWebfLArDuR8p/SsDw9qbbfsl222ZeFY/xDNb6SLuGck/z/KgCC78MWMoDQyvEW6hjuFZV/4UurbBhkSVSQeuDmumR8knjaDkCpxIHHze3NAHjvjnSr5LO0snjcG+uEgHcFR87/8AjqtTovPicgjnv3rurpBffEKAB18jSbBpWxyPNmbavHrtjf8A76rQmFncZWSCNz0wV60Achpur3dr80Urp3xniuksfFXyj7UintkcGpv7LsXP/Ht5Y6EoT7+v0pj+HLE4YSyJ6hsGgCafxFaTBhHvT13D/wCvWY94JpAQw2egp83h3zDvWcAdeRWTPpM8cpEUynB7HFAG3HtJUEgA85NOmlVX+Vdw6nHSuWnt7uIg8k+gNRvdTxPmQHA5wRQB1cZ3JxgY6dcfnWD4o0efVIrSfT7lLTV7Gdbm0uGBKKw6hh/dI69fx6VWi1tI2wXK/wC9UsmtAJw6dc44NAEcR8dX0CxJoehW7Nn/AE6fV4vK+vlA+b6cYzx0pfGFqDP4f0ZrpLySSWKW4nVdqyGGMPIQCB8pkCgcdCKt22sRYUMMehzWZDd2934yvLsyqFsLRLde43yHe/5KIx+NAGjqCjY4GBjBx3rl9UnN3ehl+70wO1a2ralE8bRQEtnjcaw7NGNwGZSUBJORQB1uj20dpbqFGJGGWP8ASpJgHJLdT7UxLtLkgRrzU6RFl5zzz04oAz7mMZYZGDWazMmQw5XjNbktuWX5iQe4qldWhI3qoJAwfcUAYs7HPQgjqPT0rufgCpHxUJ52nRrrHPH+vta4+4iBxt64z0/nXZfAMEfFTDAgjRbrr/13taAPpOiiigDxX9qzRv8AhIPBOg6Z/aWm6Z5+sp/pepT+Rbx7ba4b53wcZxgcckgV8W+LND/4R3W5tN/tTS9V8tVb7Vpdx58DZAOFfAyRnB4619e/trf8ks0r/sNRf+iJ6+KqACnxtsYEUyigadtUXldWXI498U4jI6YYVTikKH1B6irQYMBgnk1k42O2nUU1qO+UHOKTp0HHqKGGCOeMdBSjB2nocVJoKr4PSnBsEc5z6Uxhzz0PakyCeeM8c0WK5mi5DMVOFUE45rYsrwQTK0T8YA6Vz4JHK9uvPWrcMoXHp6HmsKtNSR1Uqljr4LxowphKusg6ls4+vNan9ozR+SwyiKA2zJ5+n+NcLBdFJgoZtp9TV6S9kWYiAnYew6Z7151TCXZ2Rq6HpNjrckcQckTQY4V8Pg9OoORU8mtRzBXaIx5Od4fj9TxXnUOqPCqqSp57pkH6/wCFXI9beVk4RSON+zbj+defPL9bpGiqI75r2CWNDgKmMcnk+mMCqL3duhZZGYe3f+R4rjZNduUldhK4IwoPc+61Xnv1nbP7xuOSxySaIZe1vsP2iOmu9QtyW25A5IPTn2rGutSV3YbQMjuOo96wXuRG7BG69zzUU1yWyuCwPXPGPxrvp4NRM5VS/eXskfyggL1AHOKgZwAG3tg9T3z71RFwAxCjK8fh/n6UGcIxKjdgcCupUraJGTncW5YKCVxvHvVIMSW/hHQinPNubnr1JPaomfsOneumEbI55zTGMAAcc/hVGeTecD7op9xPklU+70J9ar11QjbVnl4iqpPliJRRRVnKfQH7Pfg3+xviZ4H1v/hI/Dd/9t83/QLG+827g32Uz/vY9o27cbW5OGIFex/FDJ+KF4o6nRrL/wBH3lfOP7Ln/JdvDP8A29f+kstfR/xN5+KV4CR/yBrL/wBH3lAHMSRtFJuXqOuO31FX7WXIPY+npVUkmQjJ6kZGeOD/AIVKiYPyjHcAf596ANSCbOMYH65qW4w8DZOTtOB6n0qjHKFb5sKR1FSm9Tpnd+FAGHfWHnxJJCAJwoIx3/wNQ6Vq7lzBcjbMh2/P3/8Ar4q5ceb5jSQAKDzsJx+VZl9ZRXqgz5SYDIbpj/EUAdFHqKYABLYH8I6UqXryDhsEeprlLOW+tuJFFxEvG4n5vzrWt76CVciTaf7rUAUPB0xuG1fVXff9uvW8ts/8s4sRJ/6AT/wKuhjdTlSvJOQRWPH5VlaR2unwKI4xtVI+EWpLaafcCzQIT2VaANdJSsoRyF56t/nNI9yssiquQFPQNxmqUgLOWkmLZPQcUMUHXgD8KANCa5bBbOfc9qoSzEt8v0JI4p3mqFIReoxyMms2dx5pwf5UAXFiLLvLZcfw4pJIQybpY0dem3GaSE55JA9Mdv8APFXZIwY1JYYxj/P5UAYEmj210WI/ct2wM/nWTe+Gp0JaGRJB16YzXUFTE+0g4qTkgFiPpmgDz+SxurbJkQqozn/9dYnhlpZrZ51DH7bM8xPsThf/AB0Cu/8AGc72fhy+eHIklXyIvd3Oxf1YH8Kp3OiR2NnAlipKQIsZT2AAz+goApWuj3M0oD4TPPJ/wrqrDSoba3CohMh6swzmqGiXy/LFcEA9Ax7/AFrow23AIbOexoAxLvTDHIJIOHHJA71PBehIgJYyGAwcDqf8itVwDjJB98VBcWcYLS4Xn7y+hoAom6glbABUjj5ulK6IU+QhueKtNHaeRghcjk5GDWZeD7OwbOYzzweRQBTuIOHUrhS3HHt0ro/gVx8VQOeNFu//AEfa1gXflm1/dSHb1Bz610HwLIPxUGAAf7Gu8gf9d7WgD6NooooA8A/bW/5JZpX/AGGov/RE9fFVfdX7Vmjf8JB4J0HTP7S03TPP1pP9L1KfybePbbXDfO+DjOMDjkkCvmzw/wDDPTrfxilprXifwxqtjBFFcNHpmsxKLpnkZRAskhQBvlLNjJCkYyWAoA8oorpviZo8GgfEPxJpVmkUdpaahPHBHHMJgkQc7F3AnkLgEE7gQQ2CCK5mgAp8b7T6j0plFA07O6LqYcEg8U7npj8apo5Q5FWI5VbqdprNxsdcKqlo9yU8ZB59xSgj3JpuADkinLkEY5qDdAcjHI54qRcjB4Bx1FRkjnGD9aA3HOcmluUnZk6Ocq2eR0p/nPgfePOeOKrq4x0B/ClUrt7D3IqXE0U+xdS6bYd5JUnkD6UqXJXAOAM5Oev4VVMmB0NIeMEjcT39KjkRr7RmjJMfLGNp5696ZJcJ95FOR0PvVJm5GB2/Ck35OMEMPQUlTQ3VLDTFt2OCe/FRMy424HTk96jfGBt/MUiccMfxxVqKRm5tkuRjPODxSGTd8pPfuc1F3GDx6+tRyOqAlyPw6mqUbkyqWWpNI4AK5wfXPaqU8+4bU4X19ajlmaTg8KO1RVrGFtzgrYhy0jsFLSVY0+N5r62iiUvI8iqqjqSSMCtoR5pJdzkehXor1HxP8P7K308JYagsutwQSXV3GARE6K5RhGSBkoUbdnrzjOK5Lwh4VbxJrM+nPrOiaK0UJm8/WLv7PC2GUbVbByx3ZA9AfSt6+FnQ1e3cUZqR2P7Ln/JdvDP/AG9f+kstfRvxQIHxSu8nH/Emsv8A0feV5P8ABHwB/wAIr8YfCl9/wlnhLWfMmuIfs+j6l9omXNnOd5XaML8uM+pHrXp/xbZh8VLhVOAdGs//AEfd1zFGQXjUEtyajN0w/wBWNo9frVUE54J7ckf54pcHhu/pj6UAWJDnLM5JPXn3qIXID7CvOPWkZmwSR+nSqckbPIHGPUjvQBrxOT0BGexNOliWSE4OGHGcVVtZMDDdRVoSAAckjpgLxQBkwlkmljkbbzkZ9ParZt45NpYckcFeKfdwhgJQQCAcj1FQQTL5WYuUI5z0H0oAQM6Aw4GOT6nFPjdwQWx6+tQXO5sMrDzEP3SOo71JHJu+ZRkDnBPSgC4ZMqFQjPr349qjDLnvn69aYzkt8wPT096i3KGO3PHvQBO7YXnOPWqTxjIIyp7ZOfWrQBdCzEnA465qIkE5OfoKALFmWTZwM9eK0GdduSfmPGKoQsGAwMn3PAqwi5GSSQB7ZNADHb5gfU5yen+eKar4bag5OeRUmFaMqcEdMGm7AQy5YnoOf8+lAHPeI2W81zQdO5IErXsmf7sS4XP/AAN1/KuhSVU4Y8/THH+f5VUXSwmsS6k8hLtbLbIu37gDFmOe+SV/75p7H97znA4oAp3OmiRvNt1UMeq9iappqNxp03kycZGNrdcexrVaSfBEG3zBwMjj9KfJafaLci7j8ybtjjb9PagCoutQTHak3zg8qeo/HpWtEZZbclPvDGDXKTaPI1wDC7Lg/dYZ/CpTDq2nIWhMhXHJXlaAOokBZALjax78dTisu7REQrHGvnSHYvGO9c3B43uLe5aHUoQ6DOdq7WFX18RWc0xnEcsmB8owOP19qAHMklrN/puBCwyjJ0BPrXW/BGRJPiojRj5f7Fu/mxwf39p0rj77WFvrdozakx45FdD+z7I7fFLYwwiaNdbRn/pva0AfS9FFFAHgH7a3/JLNK/7DUX/oievi2OR4pEkidkkQhlZTggjoQa+0v21v+SWaV/2Gov8A0RPXyv4H1nTtF0vxNNdQWE2qPZxppq3til0ol+0RFyFdWUHy/M5bjt3xQBzF3cz3l1NdXk0s9zO7SSyysWeR2OSzE8kkkkk1DXt83izwLd680lxZaHHYW2twy2qw6OI1azNvL5ocLHl183yvlfJGflAA4yJvF/h7UPDlvbX1loMd3Po12LtrfRYoXW+Er/Z9rpGNvyCP7hC8ndzmgDyeiiigApaSigCVJWXjqKsxzoxGcA/7VUaWpcUzWFaUDQxzx09QaQBl69KpJIy/dJFSi4b+IA/pUuDOhV4vfQspk9ePTJpc7jhufSoFuFP3lwfUU8TRnvz7ipcWaqrF9STJzkcEds0vIPPJ74rrvhr4Z07xSPFn22e4j/srQLvVYfIYDdLFs2hsqcr8xyBg+4rivOTIO/8ASlysPaxT3LI3bA2cL6Dimqx3YyNvvUP2mPqVOfpU7W9+dMOqLY3A00z/AGb7WYmMPm7d3l78Y37educ45oUWEq8FrcQkdAM015FjPztgkZwKpvPI45bj24qOrVPuYyxX8qJ5Lgk/Lx71CSSck5rtPFXhSx0j4a+BfENtLcte679u+0pIymNPImCJsAAIyDzknnpiuJq0ktjmlOU9wooq3qGm32nfZv7Qs7m1+0wrcwefEyebE2dsi5HzKcHDDg4pkFSp7KZre9gmRyjRyK4YdVIOc1BRVRlytMGdprfj/VL2K5t7Vo7a3uNxlEa53FjlypbJQMeSqkKfQdK41mLEliSTySa7T4zeFLHwR8SdY8PaVLczWVn5PlvcsrSHfCjnJUAdWPYcYria0rV51nebJjFR2PVf2XP+S7eGf+3r/wBJZa+g/i9/yVK45x/xJrP/ANH3dfPn7Ln/ACXbwz/29f8ApLLX0F8X/wDkqs3T/kDWf/o+7rEo5tScEjAOD1HPSncMCB1xxxxTC3Qrx65NIZEB5bp+lADnYKOTknoMUxGz1xj9MVGW3nvilzyDQBOSQ2e/f/P41NFPuPzHnriqu4AdgO2fWmbim1gR+B/z60AaeSFxjj1PpWfEqxKVXhc8HGB/n/GniY7SGJII9PemA5IxkDmgCRmUgEHnHXPaqzKC25mwc+vSrBUHPGO30pjBQSTk/WgCB3nQqUIkHdTjJqWKZWJZ22sD909f0pgbP3MEE5+tSCOOThgp+vagCcOfLICsP89KgzvxjI6jJ9KV41xiMsvsCaiYlCSshHP6UAaNsgfA+Un/ABqdmIIyQO/HHesiC6mEgBkUg9COKuLccjeuG9T2/GgC5uU9AxzxkE0kUYyw/HOM1HDKshzuUgdxVqScRjO0nP8AdoACAEyADnGOMZqB06bgwyR3qYF2UME9+euP84pQC4+Z+R2A4FAFVnZWVgBkdRmrdtMpKggYx061XljIYAk4Hc84FNVNuCS35mgC3cRhXJHQngUqy4YHAII6YoI3Qqc57k1WjchT/doAh1PS7DUVH2q2SYr0JGCPx61HZ6Rp1sqiCzjznPPzfzNXVfLHceh71LyMcDceMDigCtcRRC3cKgC4q/8ABgj/AIWrGAMY0a8/9H2lVLwZt5MZBKng/hVr4MLt+K6DGP8AiTXf/o+0oA+hKKKKAOA+Nfw6/wCFm+FbXRv7U/szyL1Lzzvs/nbtqSJt27lx9/Oc9uleKf8ADI3/AFO3/lJ/+3V9VUUAfKv/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V9VUUAfKv/DI3/U7f+Un/wC3Uf8ADI3/AFO3/lJ/+3V9VUUAfKv/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V9VUUAfKv/DI3/U7f+Un/wC3Uf8ADI3/AFO3/lJ/+3V9VUUAfKv/AAyN/wBTt/5Sf/t1H/DI3/U7f+Un/wC3V9VUUAfKv/DI3/U7f+Un/wC3Uf8ADI3/AFO3/lJ/+3V9VUUAfOvhD9nG+8K/21/Z/jG2k/tbTJ9Kn8/R2O2KXbuZcXAww2jBOR7Guf8A+GRv+p2/8pP/ANur6qooA+Vf+GRv+p2/8pP/ANuroP8AhnG+/wCEA/4RD/hMbb+zf7T/ALV83+x287zfK8rbn7Rjbt5xjOe/avoqigD5V/4ZG/6nb/yk/wD26j/hkb/qdv8Ayk//AG6vqqigD511r9nG+1fwn4c8PXPjG2Wy0L7T9mePR2Ej+fIHfeTcEHBHGAOOua5//hkb/qdv/KT/APbq+qqKAPlX/hkb/qdv/KT/APbq6Dxf+zjfeKv7E/tDxjbR/wBk6ZBpUHkaOw3RRbtrNm4OW+Y5IwPYV9FUUAfKv/DI3/U7f+Un/wC3Uf8ADI3/AFO3/lJ/+3V9VUUAfOvj39nG+8b+LL7xDqvjG2hvbzy/MS20dljGyNUGA1wT0Qd+ua5//hkb/qdv/KT/APbq+qqKAPAPhb+zr/wgnjvTPEn/AAlP2/7F5v8Ao/8AZ/lb98Tx/e81sY356HpXbePvhvfeJfFX9tWGuW1husorN4Z9Pa4z5byuGDCZMf60jGD0616TRQB4v/wp7XcEf8JZpuP+wLJ/8k1G/wAGtcbr4t04fTRn/wDkmvbKKAPE/wDhTOt5z/wlem/+CV//AJJpR8G9c/6GzTTx/wBAV/8A5Jr2uigDxcfB/XM/8jXph+uiyf8AyTR/wp7XDn/iq9M/8Esn/wAk17RRQB4sPg5rmc/8JXpp/wC4LJ/8k04fCDXef+Kr0z/wSv8A/JNez0UAeMf8Kg10Y/4qzTf/AASyf/JNMf4Oa43XxZpv/glf/wCSa9qooA8V/wCFN63/ANDZpvp/yBX/APkmnj4Qa6CP+Ks038dGk/8AkqvZ6KAPGD8H9dJ58V6Z/wCCWT/5JpjfBvW2znxZpnPporj/ANua9qooA8V/4U5ref8Aka9M/wDBK/8A8k1Kvwi10Y/4qrS+P+oJJ/8AJNey0UAePL8KPEC/8zXpX/gkk/8Akql/4VV4hPXxVpX/AIJJP/kqvYKKAPIB8K/EIA/4qrSuPXRJP/kqgfCvxCOnivSvX/kCSf8AyVXr9FAHkH/CqvEOQf8AhKtJyP8AqCSc/wDk1TX+E/iBlC/8JXpYA9NFk/8AkqvYaKAPIU+FfiFU2jxXpWP+wLJ/8lVH/wAKn8QH/ma9L/8ABLJ/8lV7FRQB48nwo8QJjHirSjj10WQ/+3VPHwr8Qg5HirSh/wBwWT/5Kr16igDyB/hV4heMo3irSsH/AKgkn/yVWp4A+Gt74Y8WNrd/rltfn7HLaLDDYNb43vExYsZXzjygMYHXrXpdFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracoronary OCT (A-C) and coronary angiogram (D) of the right coronary artery in a patient presenting with acute coronary syndrome with sudden onset of chest pain and transient ST elevations in the inferior ECG leads. The coronary angiogram shows a mild, non flow limiting lesion in the right coronary artery (D). Intracoronary OCT reveals atherosclerosis with concentric, mild intimal thickening (A) and focal thrombosis (B, C). A mural thrombus is protruding into the lumen in 3 o'clock position (asterisk) and is casting a shadow on the arterial wall. Thus OCT is able to reveal the pathophysiologic culprit of the patients clinical symptoms, that is missed by angiography.",
"    <div class=\"footnotes\">",
"     OCT: St. Jude/Lightlab Imaging C7XR.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1831=[""].join("\n");
var outline_f1_50_1831=null;
var title_f1_50_1832="Diffuse pontine glioma";
var content_f1_50_1832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diffuse pontine glioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Mark W Kieran, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Karen J Marcus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1832/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/50/1832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brainstem gliomas are characterized by heterogeneous biologic behavior, ranging from low-grade tumors needing little treatment to those that are rapidly fatal despite aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Prognosis and treatment depend upon both the clinical symptoms and their duration as well as its location within the brainstem.",
"   </p>",
"   <p>",
"    Approximately 80 percent of pediatric brainstem gliomas arise within the pons, while the remaining 20 percent arise in the medulla, midbrain, or cervicomedullary junction (",
"    <a class=\"graphic graphic_figure graphicRef53866 \" href=\"UTD.htm?20/62/21479\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The majority of pontine tumors are diffuse intrinsic brainstem gliomas, which are usually high-grade, locally infiltrative, and have a uniformly poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/9\">",
"     9",
"    </a>",
"    ]. Histologically, these tumors are usually anaplastic astrocytomas (World Health Organization [WHO] grade III) or glioblastoma multiforme (WHO grade IV) (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"UTD.htm?14/49/15134\">",
"     table 1",
"    </a>",
"    ). However, patients with WHO grade II tumors identified by biopsy do not have an improved prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, most nonpontine tumors involving the cervicomedullary junction and tectum, as well as focal, cystic and dorsal exophytic lesions, are low-grade astrocytomas, mostly grade I pilocytic astrocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/6\">",
"     6",
"    </a>",
"    ]. These are discrete, well-circumscribed tumors without evidence of locally invasive growth or edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately 10 to 20 percent of non-pontine gliomas will be high-grade and are treated similar to diffuse intrinsic pontine gliomas.",
"   </p>",
"   <p>",
"    Diffuse pontine gliomas will be reviewed here. Gliomas arising from other sites within the brainstem are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link\">",
"     \"Focal brainstem glioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gliomas arising in the brainstem (midbrain, pons, and medulla oblongata) account for 10 to 20 percent of all central nervous system (CNS) tumors in children. Brainstem gliomas are more common in children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/3,4,11,12\">",
"     3,4,11,12",
"    </a>",
"    ]. In the United States, for example, there are approximately 300 pediatric cases and 100 adult cases reported each year. In children, the median age at diagnosis is five to nine years of age, and the incidence is approximately equal between males and females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used classification system for central nervous system tumors is that of the World Health Organization (WHO) (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"UTD.htm?14/49/15134\">",
"     table 1",
"    </a>",
"    ). Gliomas are tumors believed to be derived from glial cells (ie, astrocytes, oligodendrocytes, and ependymal cells). Astrocytomas account for greater than 95 percent of all brainstem lesions. Most centers classify these tumors based on the modified WHO criteria, which combines histology and biology (",
"    <a class=\"graphic graphic_table graphicRef55058 \" href=\"UTD.htm?14/32/14861\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diffuse pontine gliomas are usually high-grade astrocytomas, and nearly all tumors progress rapidly. On postmortem examination, these tumors are typically anaplastic astrocytomas or glioblastoma multiforme, even if the original histology based upon a biopsy was of a lower histologic grade. This observation suggests that either the tumor transformed to a higher grade or that the low-grade features initially observed were the result of sampling error associated with a small biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even low-grade diffuse pontine lesions can behave aggressively. Glial tumors of the pons rarely metastasize to distant sites. Instead they tend to progress along established fiber tracts, especially into the thalamus and cerebellum. Spinal seeding is rare but can be observed in the end stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. With an average life expectancy of less than a year, the absence of metastatic disease may be the result of the rapidly fatal course of the primary tumor, rather than a lack of the metastatic potential of these tumors.",
"   </p>",
"   <p>",
"    Tumors of the cervicomedullary junction, as well as focal and dorsal exophytic lesions, tend to be low-grade based upon the WHO classification. When a high-grade component of one of these lesions is observed, the tumor tends to behave similar to high-grade glial lesions in other parts of the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tumor biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant insights have been gained into the molecular biology of diffuse pontine gliomas using tissue obtained by biopsy from newly diagnosed patients and autopsy material [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Amplification and over expression of the PDGFR A and c-Met seem to be important molecular events in the transformation of cells to a malignant phenotype. More recently, activating mutations in PI3K [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/19\">",
"     19",
"    </a>",
"    ] histone",
"    <em>",
"     H3F3A",
"    </em>",
"    encoding histone H3.3 and mutations in",
"    <em>",
"     HIST3BHI",
"    </em>",
"    encoding histone H3.1 have been shown to be caused by a pLsy27Met amino acid substitution in each protein [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/20\">",
"     20",
"    </a>",
"    ]. This rapidly emerging molecular data will significantly aid the development of relevant mouse models and targeted therapies for DIPG. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse pontine gliomas can present with varied symptoms depending on the location of the lesion. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial nerve palsies, long tract signs (eg, hemiparesis) and ataxia in over 50 percent of patients. Cranial nerves VI and VII are most commonly affected but III, IV, IX and X may also be involved.",
"     </li>",
"     <li>",
"      Hydrocephalus with elevated intracranial pressure (ICP) is observed in fewer than 10 percent of patients at presentation.",
"     </li>",
"     <li>",
"      Intratumoral hemorrhage can be present in about 6 percent of patients at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/21\">",
"       21",
"      </a>",
"      ]. Symptomatic hemorrhage may eventually occur in up to 20 percent of children, usually in necrotic areas of tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these symptoms is pathognomonic of diffuse pontine gliomas. Other brainstem tumors can present with similar symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link\">",
"     \"Focal brainstem glioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervicomedullary tumors typically present with lower cranial nerve dysfunction and ataxia.",
"     </li>",
"     <li>",
"      Focal tumors tend to interfere with the cranial nerves adjacent to the site of origin.",
"     </li>",
"     <li>",
"      Unlike other brainstem tumors, tectal plate lesions present with hydrocephalus in over 90 percent of cases. Although these tumors are rarely biopsied, those that have been studied are almost always low-grade astrocytomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to focal brainstem gliomas, diffuse pontine gliomas usually present with a short duration of symptoms (typically less than three months). The duration of symptoms is an important predictor of prognosis in brainstem tumors. Patients with symptoms of greater than six months' duration at the time of diagnosis tend to do much better than patients with a shorter duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link&amp;anchor=H5#H5\">",
"     \"Focal brainstem glioma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diffuse pontine gliomas have been reported in the neonate. Unlike supratentorial glioblastoma, which in infants has a significant proportion of long-term survivors, diffuse pontine gliomas in this age group appear to do as poorly as in those over the age of three [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/22\">",
"     22",
"    </a>",
"    ]. However, spontaneous remissions have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     MRI and CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies, particularly computed tomography (CT) and magnetic resonance imaging (MRI), are the standard method of diagnosis and classification for brainstem tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/6\">",
"     6",
"    </a>",
"    ]. The brainstem is one of the most eloquent areas of the brain, making biopsy difficult in centers without expertise in this area. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Diffuse pontine gliomas have a typical appearance on CT scans with hypodense to isodense appearance, and variable contrast enhancement. Calcium is rarely identified within the tumor. MRI signal characteristics are superior to CT for defining the borders of these lesions. On MRI, diffuse pontine lesions are typically hypointense on T1 and hyperintense on T2 weighted images (",
"    <a class=\"graphic graphic_algorithm graphicRef71275 \" href=\"UTD.htm?0/11/181\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    High-grade tumors typically invade adjacent areas including the medulla or midbrain. Axial growth is commonly observed through the cerebellar peduncles and into the cerebellum, and the tumors expand the pons, instead of displacing it. They frequently have exophytic components into the pontine cistern and often encircle the basilar artery. On sagittal images, the tumors appear to respect the medullary boundary. &nbsp;",
"   </p>",
"   <p>",
"    Contrast enhancement within the tumors can be variable and may be ring-enhancing. The apparent well-circumscribed appearance of ring enhancing lesions on MRI is often not confirmed at the time of surgery or autopsy and does not indicate a lower-grade lesion or more benign clinical course. Many diffuse pontine tumors have no contrast enhancement. Tumors that demonstrate diffuse uniform enhancement are more likely low-grade, are usually associated with prolonged symptoms, and may have a better outcome.",
"   </p>",
"   <p>",
"    Magnetic resonance spectroscopy (MRS) with estimation of choline to N-acetylaspartate (NAA) (Cho:NAA) ratios is another noninvasive method that can be used to support the diagnosis and may provide prognostic information [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In one series, children with a maximum Cho:NAA ratio greater than 4.5 had a median survival of 22 weeks, and all 13 patients died by 63 weeks. In contrast, the projected survival of patients with a Cho:NAA ratio less than or equal to 4.5 was significantly better, 50 percent at 63 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other new imaging techniques that are beginning to further affect non-tissue-based diagnoses for brainstem tumors include rapid diffusion MRI, thallium single photon emission computed tomography (SPECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/27\">",
"     27",
"    </a>",
"    ], and positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/28\">",
"     28",
"    </a>",
"    ]. As an example, 111In-pentreotide binds the somatostatin receptor, which is frequently expressed in gliomas. Scanning with this agent can both help confirm the diagnosis and, if labeled, potentially target radiation therapy to these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/29\">",
"     29",
"    </a>",
"    ]. While these methods continue to undergo further development and refinement, they are being used more frequently to assist MRI-based diagnosis, particularly in difficult or unclear cases.",
"   </p>",
"   <p>",
"    While MRI has become the standard method of evaluation of diffuse intrinsic pontine gliomas, the heterogeneous signal characteristics of these lesions and interobserver variability make serial assessment difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/30\">",
"     30",
"    </a>",
"    ]. Evaluation of new therapies should therefore be based upon overall survival rather than MRI changes whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in imaging techniques and the difficulty in obtaining an adequate biopsy sample make the interpretation of the imaging studies critical in the differential diagnosis. If imaging findings are typical, biopsy is not usually necessary to confirm the diagnosis and should only be performed in the context of a formal clinical trial.",
"   </p>",
"   <p>",
"    A long duration of symptoms and atypical clinical or imaging findings suggest the possible presence of a lesion other than diffuse pontine glioma. Such patients should be considered for biopsy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Vascular malformations, encephalitis, rare parasitic cysts, demyelinating disorders (eg, multiple sclerosis), and hamartomas in patients with neurofibromatosis are the most common causes of nontumorous lesions in the brainstem. Rare examples of metastases from extracranial carcinomas in adults have also been reported in the pons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient with a diffuse pontine glioma includes control of peritumoral edema, as well as specific measures directed at the tumor (surgery, radiation therapy, and chemotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) is an important initial step in the treatment of patients with high grade brainstem tumors. Peritumoral edema often contributes prominently to symptoms, which can improve rapidly after steroid therapy. Although steroids do not treat the underlying problem, improved clinical performance can be an important matter for quality of life in patients with a limited life span.",
"   </p>",
"   <p>",
"    Unfortunately, many patients require prolonged administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , resulting in significant steroid-related complications. A number of clinical trials in adult and pediatric patients evaluating newer compounds (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and Xerecept) that can modulate peritumoral edema without the complications of steroids are now underway [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Novel treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the clinical or imaging picture is atypical, surgery is usually not recommended in children with a clinical diagnosis of diffuse brainstem glioma outside of formal clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/34\">",
"     34",
"    </a>",
"    ]. The morbidity associated with surgery in this eloquent region of the brain and the sampling error associated with routine biopsies preclude routine biopsy to identify patients with lesions that are not high-grade astrocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/10,35,36\">",
"     10,35,36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adults are more likely to benefit from a stereotactic biopsy. In this setting, determining the final histologic grade (low-grade versus high-grade) may permit a more precise estimation of prognosis. In addition, up to 30 percent of biopsied patients had a diagnosis other than astrocytoma (eg, lymphoma, ependymoma, or infection) in studies that were completed both before and after availability of MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the hazards of the surgical approach and rarity of brainstem lesions, referral to a highly specialized and dedicated neurosurgical team should be made before treatment is initiated, particularly for lesions that lack some of the classic clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging features [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in neurosurgical techniques have permitted biopsy of diffuse pontine gliomas to be performed safely. In one series of 24 patients, diagnostic material was obtained in all. Two patients had transient neurologic deficits as a result of the biopsy but no permanent deficits resulted. In two patients, low-grade glial tumors were identified, which required modification of the treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/40\">",
"     40",
"    </a>",
"    ]. Based on this study, pretherapy biopsy is being performed in the context of formal clinical trials to identify molecular pathways aberrant in these tumors and to use this information to guide treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is the only treatment that appears to alter the clinical course of diffuse intrinsic pontine gliomas. Despite multiple trials of dose-escalation, altered fractionation, and radiosensitization, none of these modulations has been proven more effective than the conventionally delivered radiation therapy. These are reviewed below. &nbsp;Investigations with targeted therapies together with radiotherapy are ongoing. RT treatment fields are typically restricted to the tumor volume plus 1 to 2 cm of adjacent brainstem tissue. The standard treatment dose is 1.8 Gy daily given five days per week, to a total dose of between 54 and 59 Gy. Patients with severe symptoms may require urgent initiation of RT.",
"   </p>",
"   <p>",
"    Although the degree of tumor shrinkage induced by radiation therapy can be dramatic, the response is generally transient and patients are not cured by this approach. The median survival is about 10 months and the two-year overall survival rate is less than 10 percent.",
"   </p>",
"   <p>",
"    In older studies, the duration of response was correlated with the tumor grade, as well as the bulk of disease, although this has not been demonstrated in more recent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/41\">",
"     41",
"    </a>",
"    ]. The time to progression may be prolonged in patients with neurofibromatosis 1 and in children as compared to elderly adults. Treatment failures are usually local and occur within the RT field. Although up to one-third of patients have evidence of central nervous system dissemination at the time of progression, most symptoms are referred to the primary site [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the poor prognosis in these patients, hypofractionated radiation therapy has been evaluated to minimize the time spent in treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In a pilot study, regimens of thirteen 3.0 Gy fractions or six 5.5 Gy fractions were well tolerated, and time to progression and overall survival approached those for radiation therapy given over six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alternative RT techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of alternative approaches have been used to try to improve the effectiveness of RT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose escalation, using multiple daily treatments with smaller than conventional fraction sizes appeared to increase the radiographic response (",
"      <a class=\"graphic graphic_table graphicRef59706 \" href=\"UTD.htm?10/26/10669\">",
"       table 3",
"      </a>",
"      ). However, no overall survival advantage was observed, and many patients experienced significant toxicity with prolonged steroid dependence [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/46-48\">",
"       46-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The addition of radiation sensitizers or concomitant or preradiation chemotherapy generally has failed to improve the time to disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/49-52\">",
"       49-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brachytherapy has been used to increase the delivery of radiation to the tumor after conventional dose RT. In one report, there was minimal morbidity related to placement of 125-I in nine patients with diffuse pontine glioma; however, this approach did not improve the response rate or survival outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stereotactic radiosurgery has been used in brainstem lesions although great care is required because of the potential for radionecrosis in vital areas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/54\">",
"       54",
"      </a>",
"      ]. There is no data that this technique improves the outcome in this disease.",
"     </li>",
"     <li>",
"      Reirradiation of pontine gliomas at the time of progression is being considered to temporarily extend palliation although increased toxicities may result from this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy has been ineffective in diffuse pontine gliomas. Numerous treatment protocols, including single chemotherapy agents, multidrug combination regimens, and high-dose therapy with stem cell rescue, have all been tested in both adults and children without clear evidence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    has become part of standard therapy for most adult patients with high-grade gliomas, testing in combination with radiation for newly diagnosed diffuse pontine glioma has demonstrated no improvement in activity compared to radiation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer regimens have combined chemotherapy and biologic modifiers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/60\">",
"     60",
"    </a>",
"    ], but no regimen has demonstrated better activity than radiation therapy alone. Most of these efforts have been based upon results of studies in patients with high-grade gliomas arising elsewhere in brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for the lack of responsiveness to chemotherapy remains unclear. Research efforts using novel approaches for patients with high-grade gliomas are discussed separately. The application of therapeutic agents directly into the pons using convection-enhanced delivery with concurrent administration of the MRI agent DTPA to verify drug distribution may become an important modality in assuring that novel drugs reach their target [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of novel molecular pathways in diffuse intrinsic pontine gliomas offers the opportunity for their inhibition. The identification of the PI3K and sonic hedgehog pathway as a possible activating event in xenograft tumors can now be targeted with molecular therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. A variety of other pathways have also been identified that may lead to the development of targeted clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of diffuse pontine glioma is typically poor.",
"   </p>",
"   <p>",
"    The results of treatment are illustrated by a series of 62 children treated at a single institution between 1987 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/58\">",
"     58",
"    </a>",
"    ]. Although 77 percent had a transient response to treatment, the median progression-free survival was seven months and the median overall survival was 11 months. Another series of 10 children all less than three years old suggested that younger patients may have a somewhat better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/62\">",
"     62",
"    </a>",
"    ]. Neuraxis dissemination frequently is present at the time of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While both high- and low-grade diffuse pontine lesions do poorly in children, adults with low-grade histology may have a somewhat longer time to progression, although most eventually succumb to their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1832/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse pontine gliomas are rare tumors that are more frequent in young children than in adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of their location in an eloquent area of the brain, diagnosis is usually based upon imaging studies. Surgery or surgical biopsy is not routinely indicated, unless atypical features are present or patients are part of a formal clinical study. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corticosteroids are used to control tumor-associated edema in symptomatic patients with a diffuse pontine glioma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend external beam radiation therapy as the primary approach to antitumor therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Our typical approach is to give a total dose of 54 to 59 Gy, in fractions of 1.8 Gy five times per week.",
"     </li>",
"     <li>",
"      Alternative radiation therapy techniques (hyperfractionation, radiation sensitizers, brachytherapy) have not been demonstrated to improve outcomes.",
"     </li>",
"     <li>",
"      Despite aggressive therapy, the prognosis remains poor, with an average survival of less than one year. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy does not have an established role in the management of patients with diffuse pontine glioma. Currently, chemotherapy in conjunction with radiation therapy is considered investigational and should be provided in the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/1\">",
"      Guillamo JS, Doz F, Delattre JY. Brain stem gliomas. Curr Opin Neurol 2001; 14:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/2\">",
"      Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A 2011; 108:4453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/3\">",
"      Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 1998; 40:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/4\">",
"      Rubin G, Michowitz S, Horev G, et al. Pediatric brain stem gliomas: an update. Childs Nerv Syst 1998; 14:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/5\">",
"      Epstein FJ, Farmer JP. Brain-stem glioma growth patterns. J Neurosurg 1993; 78:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/6\">",
"      Epstein F, Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 1996; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/7\">",
"      Robertson PL, Allen JC, Abbott IR, et al. Cervicomedullary tumors in children: a distinct subset of brainstem gliomas. Neurology 1994; 44:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/8\">",
"      Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg 1993; 78:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/9\">",
"      Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 2000; 89:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/10\">",
"      Albright AL. Diffuse brainstem tumors: when is a biopsy necessary? Pediatr Neurosurg 1996; 24:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/11\">",
"      Packer RJ. Brain tumors in children. Arch Neurol 1999; 56:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/12\">",
"      Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: prognostic factors and classification. Brain 2001; 124:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/13\">",
"      Yachnis AT. Neuropathology of pediatric brain tumors. Semin Pediatr Neurol 1997; 4:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/14\">",
"      Yoshimura J, Onda K, Tanaka R, Takahashi H. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) 2003; 43:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/15\">",
"      Singh S, Bhutani R, Jalali R. Leptomeninges as a site of relapse in locally controlled, diffuse pontine glioma with review of literature. Childs Nerv Syst 2007; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/16\">",
"      Gururangan S, McLaughlin CA, Brashears J, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol 2006; 77:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/17\">",
"      Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010; 28:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/18\">",
"      Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011; 29:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/19\">",
"      Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 2012; 58:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/20\">",
"      Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/21\">",
"      Broniscer A, Laningham FH, Kocak M, et al. Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer 2006; 106:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/22\">",
"      Shah NC, Ray A, Bartels U, et al. Diffuse intrinsic brainstem tumors in neonates. Report of two cases. J Neurosurg Pediatr 2008; 1:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/23\">",
"      Schomerus L, Merkenschlager A, Kahn T, Hirsch W. Spontaneous remission of a diffuse brainstem lesion in a neonate. Pediatr Radiol 2007; 37:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/24\">",
"      Krieger MD, Bl&uuml;ml S, McComb JG. Magnetic resonance spectroscopy of atypical diffuse pontine masses. Neurosurg Focus 2003; 15:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/25\">",
"      Hipp SJ, Steffen-Smith E, Hammoud D, et al. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol 2011; 13:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/26\">",
"      Warren KE, Frank JA, Black JL, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/27\">",
"      Nadvi SS, Ebrahim FS, Corr P. The value of 201thallium-SPECT imaging in childhood brainstem gliomas. Pediatr Radiol 1998; 28:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/28\">",
"      Kwon JW, Kim IO, Cheon JE, et al. Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. Pediatr Radiol 2006; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/29\">",
"      Pichler R, Pichler J, Mustafa H, et al. Somatostatin-receptor positive brain stem glioma visualized by octreoscan. Neuro Endocrinol Lett 2007; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/30\">",
"      Hayward RM, Patronas N, Baker EH, et al. Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol 2008; 90:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/31\">",
"      Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 2008; 86:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/32\">",
"      Salvati M, Cervoni L. Carcinoma of the prostate: brain stem metastasis as the only site of spread. Tumori 1997; 83:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/33\">",
"      Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009; 75:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/34\">",
"      Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 1993; 33:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/35\">",
"      Pincus DW, Richter EO, Yachnis AT, et al. Brainstem stereotactic biopsy sampling in children. J Neurosurg 2006; 104:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/36\">",
"      Chitnavis B, Phipps K, Harkness W, Hayward R. Intrinsic brainstem tumours in childhood: a report of 35 children followed for a minimum of 5 years. Br J Neurosurg 1997; 11:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/37\">",
"      Franzini A, Allegranza A, Melcarne A, et al. Serial stereotactic biopsy of brain stem expanding lesions. Considerations on 45 consecutive cases. Acta Neurochir Suppl (Wien) 1988; 42:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/38\">",
"      Dellaretti M, Reyns N, Touzet G, et al. Diffuse brainstem glioma: prognostic factors. J Neurosurg 2012; 117:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/39\">",
"      Rajshekhar V, Chandy MJ. Computerized tomography-guided stereotactic surgery for brainstem masses: a risk-benefit analysis in 71 patients. J Neurosurg 1995; 82:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/40\">",
"      Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 2007; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/41\">",
"      Schild SE, Stafford SL, Brown PD, et al. The results of radiotherapy for brainstem tumors. J Neurooncol 1998; 40:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/42\">",
"      Donahue B, Allen J, Siffert J, et al. Patterns of recurrence in brain stem gliomas: evidence for craniospinal dissemination. Int J Radiat Oncol Biol Phys 1998; 40:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/43\">",
"      Sethi R, Allen J, Donahue B, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol 2011; 102:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/44\">",
"      Janssens GO, Gidding CE, Van Lindert EJ, et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys 2009; 73:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/45\">",
"      Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neurooncol 2011; 104:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/46\">",
"      Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/47\">",
"      Fisher PG, Donaldson SS. Hyperfractionated radiotherapy in the management of diffuse intrinsic brainstem tumors: when is enough enough? Int J Radiat Oncol Biol Phys 1999; 43:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/48\">",
"      Freeman CR, Kepner J, Kun LE, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 2000; 47:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/49\">",
"      Marcus KJ, Dutton SC, Barnes P, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 2003; 55:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/50\">",
"      Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol 1998; 30:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/51\">",
"      Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol 2002; 20:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/52\">",
"      Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 2005; 103:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/53\">",
"      Chuba PJ, Zamarano L, Hamre M, et al. Permanent I-125 brain stem implants in children. Childs Nerv Syst 1998; 14:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/54\">",
"      Fuchs I, Kreil W, Sutter B, et al. Gamma Knife radiosurgery of brainstem gliomas. Acta Neurochir Suppl 2002; 84:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/55\">",
"      Fontanilla HP, Pinnix CC, Ketonen LM, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 2012; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/56\">",
"      Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006; 7:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/57\">",
"      Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer 2008; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/58\">",
"      Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 2008; 87:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/59\">",
"      Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011; 13:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/60\">",
"      Sirachainan N, Pakakasama S, Visudithbhan A, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 2008; 10:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/61\">",
"      Lonser RR, Warren KE, Butman JA, et al. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 2007; 107:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/62\">",
"      Broniscer A, Laningham FH, Sanders RP, et al. Young age may predict a better outcome for children with diffuse pontine glioma. Cancer 2008; 113:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/63\">",
"      Selvapandian S, Rajshekhar V, Chandy MJ. Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 1999; 141:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1832/abstract/64\">",
"      Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology 1998; 51:1136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5229 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1832=[""].join("\n");
var outline_f1_50_1832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY AND PATHOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tumor biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MRI and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alternative RT techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5229|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/11/181\" title=\"algorithm 1\">",
"      Diffuse pontine glioma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5229|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/62/21479\" title=\"figure 1\">",
"      Anatomy of brainstem",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/49/15134\" title=\"table 1\">",
"      WHO nervous system tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14861\" title=\"table 2\">",
"      WHO brain tumor classification by histology and grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/26/10669\" title=\"table 3\">",
"      Hyperfract RT Diff pont glioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=related_link\">",
"      Focal brainstem glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1833="Growth hormone deficiency in adults";
var content_f1_50_1833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone deficiency in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1833/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1833/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/50/1833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/50/1833/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/50/1833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone deficiency in adults is important for two reasons: the evidence that growth hormone deficiency can have adverse effects and the availability of growth hormone preparations for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The clinical manifestations, diagnosis, and treatment of growth hormone deficiency in adults are discussed here. The decline in growth hormone secretion that occurs as a normal consequence of aging and growth hormone deficiency in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=see_link\">",
"     \"Endocrine changes with aging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of growth hormone deficiency are the same as the causes of deficiencies of other pituitary hormones (",
"    <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .) A study of 172 adults with hypopituitarism found the following distribution of etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A pituitary tumor or the consequences of treatment of the tumor, including surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy &mdash; 76 percent",
"     </li>",
"     <li>",
"      An extrapituitary tumor (eg, craniopharyngioma) &mdash; 13 percent",
"     </li>",
"     <li>",
"      Cause unknown &mdash; 8 percent",
"     </li>",
"     <li>",
"      Sarcoidosis &mdash; 1 percent",
"     </li>",
"     <li>",
"      Sheehan's syndrome &mdash; 0.5 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, the secretion of growth hormone and gonadotropins is more likely to be affected by organic pituitary disease than that of corticotropin (ACTH) and thyrotropin (TSH). The likelihood of growth hormone deficiency in such patients has been estimated to range from approximately 45 percent in patients with no other pituitary hormone deficits to virtually 100 percent in patients with multiple deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When growth hormone deficiency occurs in childhood due to any of the organic causes above, the deficiency will almost certainly persist into adulthood. In contrast, idiopathic growth hormone deficiency in childhood may not persist. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=see_link\">",
"     \"Growth hormone treatment during the transition period\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND BENEFITS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone deficiency in children typically presents as short stature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .) Two lines of evidence suggest that growth hormone deficiency has deleterious effects in patients who acquire the deficiency in adulthood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a greater frequency of certain abnormalities in adults who have growth hormone deficiency than in the general population. These include differences in body composition, lipid profile, cardiovascular disease, bone mineral density, psychologic function, and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Interpretation of this evidence is confounded by the deficiencies in other pituitary hormones that are often present. At least some of these abnormalities appear to be worse in adults with growth hormone deficiency of childhood onset than those with adult onset, perhaps because the growth hormone deficiency or comorbidities are more severe in the former [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is improvement when these patients are treated with exogenous growth hormone. However, interpretation of the available evidence is made difficult by the lack of a placebo group in most of the studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in body composition is probably the best-documented effect of growth hormone treatment in adults with hypopituitarism. Studies using different techniques indicate that lean body mass is decreased and fat mass is increased in untreated adults who are deficient in growth hormone compared with those who have normal growth hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. As an example, CT measurements of the cross-sectional area of arm and thigh muscle show that muscle mass is decreased in patients with growth hormone deficiency when compared to normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In growth hormone deficient adults, exogenous growth hormone administration increases muscle mass as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 10 patients with growth hormone deficiency using a placebo-controlled, double-blind, crossover design (placebo and growth hormone each were given for six months), subcutaneous adipose tissue mass, as measured by CT, decreased by 13 percent, visceral adipose tissue mass decreased by 30 percent, and muscle mass increased by 5 percent during the period of growth hormone administration [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were noted in a randomized, placebo-controlled trial in which body fat, measured by dual-energy x-ray absorptiometry, decreased from 32 to 28 percent during the administration of growth hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Eighteen months after discontinuing growth hormone treatment, mean body fat had returned to its baseline value [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized, placebo-controlled study in 43 women with growth hormone deficiency, growth hormone replacement decreased total body fat by DXA and visceral fat, but not subcutaneous fat, measured by computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, growth hormone deficiency in adulthood is associated with a decrease in lean body mass and an increase in fat mass, both of which improve with exogenous growth hormone therapy.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1294035\">",
"    <span class=\"h2\">",
"     Exercise capacity and muscle strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because replacement of growth hormone increases lean body mass, one might expect it to improve muscle function, as well. One meta-analysis of 11 randomized, placebo-controlled studies demonstrated that growth hormone improved parameters of exercise capacity, such as maximal power and maximal oxygen uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/14\">",
"     14",
"    </a>",
"    ]. However, another meta-analysis of eight randomized, placebo-controlled studies showed that growth hormone replacement did not improve muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lipid profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the effect of growth hormone replacement on serum lipids. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with growth hormone deficiency have higher serum low-density-lipoprotein (LDL) cholesterol concentrations than do normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/16\">",
"       16",
"      </a>",
"      ]. The results of measurements of serum high-density-lipoprotein (HDL) cholesterol have varied.",
"     </li>",
"     <li>",
"      There are conflicting data on the effects of growth hormone replacement on serum total and LDL cholesterol concentrations; some studies have reported no change [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/17,18\">",
"       17,18",
"      </a>",
"      ], while in others the concentrations decreased [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]. In one trial, serum total and LDL cholesterol concentrations fell during the first three months of therapy, but this effect was not maintained at 6 to 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are also conflicting data on the effect of growth hormone therapy on serum lipoprotein(a) concentrations (a lipoprotein associated with an increased risk of coronary heart disease). In two studies, the concentrations increased [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/23,24\">",
"       23,24",
"      </a>",
"      ], while a third found no change [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"       \"Lipoprotein(a) and cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a placebo-controlled study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/13\">",
"       13",
"      </a>",
"      ], serum HDL fell in the placebo-treated women but not in the growth hormone-treated women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiovascular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone deficiency may impair cardiovascular function, although data are inconsistent. In one retrospective study, patients with hypopituitarism taking usual hormonal replacement therapy but not growth hormone had a mortality rate twice that of age- and sex-matched normal subjects, a difference due to an increased number of cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/26\">",
"     26",
"    </a>",
"    ]. A later report by the same authors and another series also found an increase in overall mortality in patients with hypopituitarism but did not confirm that the increased mortality was due to cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth hormone therapy appears to improve a number of cardiovascular factors, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 30 to 40 percent increase in cardiac output with a parallel reduction in peripheral resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/28\">",
"       28",
"      </a>",
"      ]. Myocardial contractility was not reported.",
"     </li>",
"     <li>",
"      A decrease in carotid arterial intima-media thickness after one year of growth hormone in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/29\">",
"       29",
"      </a>",
"      ] and after five years of treatment in another [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decrease in fasting serum homocysteine concentration in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/31\">",
"       31",
"      </a>",
"      ], but not another [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decrease in C-reactive protein [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/13,23\">",
"       13,23",
"      </a>",
"      ] and interleukin-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/23\">",
"       23",
"      </a>",
"      ] concentrations, markers of inflammation (acute phase proteins) that play a role in atherosclerosis.",
"     </li>",
"     <li>",
"      Duration of growth hormone treatment appears to be important for modifying cardiovascular risk factors. In a 12-month prospective controlled cohort study of 20 growth hormone-deficient men and women, serum lipid profiles, plasma fibrinogen concentrations, and systolic function improved, but were still abnormal compared with normal subjects, suggesting that more than 12 months of growth hormone therapy may be required to normalize cardiovascular risk factors and performance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 16 studies (nine placebo-controlled, randomized trials, and seven open studies) involving 468 adults with growth hormone deficiency, growth hormone treatment was found to be associated with significant increases in left ventricular mass, wall thickness, end-diastolic diameter, and stroke volume [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/34-36\">",
"     34-36",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/37\">",
"     37",
"    </a>",
"    ] studies, bone mineral density of the lumbar spine was somewhat lower in untreated patients with adult-onset growth hormone deficiency compared with normal subjects. The degree of osteopenia appears to correlate directly with the degree of growth hormone deficiency; however, the number and severity of other hormonal deficiencies are also more pronounced in patients with more severe growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/38\">",
"     38",
"    </a>",
"    ]. As a result, it is not possible to determine from available data which factors are most important in the development of osteopenia.",
"   </p>",
"   <p>",
"    Many reports have demonstrated an increase in bone mineral density when growth hormone is administered to patients with growth hormone deficiency, but most did not have a placebo control group and virtually all used GH doses that resulted in supraphysiologic serum GH concentrations. The results from placebo-controlled trials show an increase in BMD in men but not women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/11,39\">",
"     11,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one placebo-controlled trial, growth hormone treatment of men with growth hormone deficiency increased bone mineral density by 5 percent in the spine and 2 percent in the femoral neck [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/11\">",
"     11",
"    </a>",
"    ]. In another two-year placebo-controlled trial of physiologic GH repletion in 67 men and women with acquired GH deficiency, GH therapy improved spine BMD in men but not in women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/39\">",
"     39",
"    </a>",
"    ]. A randomized, non placebo-controlled study also showed no effect of GH on BMD in women, even though the serum IGH-1 concentration achieved was supraphysiologic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/40\">",
"     40",
"    </a>",
"    ], suggesting a gender-specific effect of GH. The reason for this difference is unknown.",
"   </p>",
"   <p>",
"    There are no data on the effect of GH treatment on fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop growth hormone deficiency in adulthood often perceive themselves as less healthy and less energetic than normal subjects of the same age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In the few placebo-controlled studies, the effects of GH treatment are conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, growth hormone treatment was evaluated in 36 patients with hypopituitarism who were treated with growth hormone and placebo for nine months in a crossover design [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/41\">",
"       41",
"      </a>",
"      ]. Growth hormone caused a significant decrease in the sense of mental distress, as determined by the Hopkins Symptom Check List, and an improvement of borderline statistical significance in the sense of well-being, as determined by the Nottingham Health Profile.",
"     </li>",
"     <li>",
"      In contrast, two other placebo-controlled, double-blinded studies showed no effect on quality of life with growth hormone compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/11,19\">",
"       11,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop hypopituitarism in adult life have reduced life expectancy (no single cause) as compared with age- and sex-matched normal subjects, in spite of replacement of adrenal, thyroid, and gonadal hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/3,26,27\">",
"     3,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cardiovascular function'",
"    </a>",
"    above.) However, to date there are no studies of the effect of GH treatment on mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the manifestations of growth hormone deficiency are subtle and nonspecific, evaluation for this disorder is usually performed primarily in adults with known pituitary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation may also be performed in adults who had been diagnosed as having growth hormone deficiency in childhood because many of them have been found to have normal growth hormone secretion in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=see_link&amp;anchor=H8327080#H8327080\">",
"     \"Growth hormone treatment during the transition period\", section on 'Testing for continuing growth hormone deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of growth hormone deficiency in adults is likely if the patient has documented panhypopituitarism, that is, documented deficiencies of TSH, ACTH, and gonadotropins. In a retrospective analysis of 817 adults who were evaluated for consideration of growth hormone therapy, multiple deficiencies of other pituitary hormones correlated highly with a subnormal growth hormone response to a stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of growth hormone deficiency in an adult should therefore be based on the combination of documented pituitary or hypothalamic disease, panhypopituitarism, and either a subnormal serum IGF-1 concentration or a subnormal serum growth hormone response to a potent stimulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum IGF-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum IGF-1 concentration lower than the age-specific lower limit of normal in a patient who has organic pituitary disease confirms the diagnosis of growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Provocative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either insulin-induced hypoglycemia or the combination of arginine and growth hormone-releasing hormone is a potent stimulus of growth hormone release. A subnormal increase in the serum growth hormone concentration in a patient who has organic pituitary disease confirms the diagnosis of growth hormone deficiency (",
"    <a class=\"graphic graphic_figure graphicRef58987 \" href=\"UTD.htm?22/44/23247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other stimuli, such as arginine alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , L-DOPA, and the combination of arginine and L-DOPA are much weaker and therefore more likely to give false positive results. All tests of growth hormone secretion are more likely to give false positive results in obesity. All are performed in the morning after an overnight fast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Insulin-induced hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test is performed by administering 0.1 unit of insulin per kg of body weight and measuring serum (or blood) glucose and growth hormone before and 15, 30, 60, 90 and 120 minutes after the injection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/46\">",
"     46",
"    </a>",
"    ]. As noted, a subnormal increase in serum growth hormone (&lt;5.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;5.1",
"    <span class=\"nowrap\">",
"     mcg/L])",
"    </span>",
"    confirms the diagnosis of growth hormone deficiency. This test requires constant supervision by a clinician because it is very unpleasant for the patient, and if severe hypoglycemia occurs, may be dangerous in patients with coronary or cerebrovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=see_link\">",
"     \"Insulin-induced hypoglycemia test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Arginine-GHRH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bolus dose of growth hormone-releasing hormone, 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight, is given intravenously at time 0, followed immediately by an intravenous infusion of arginine HCl, 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    body weight (to a maximum of 30 g) over 30 minutes. Serum growth hormone is measured at -30, 0, 30, 60, 90, and 120 minutes (",
"    <a class=\"graphic graphic_figure graphicRef58987 \" href=\"UTD.htm?22/44/23247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/47\">",
"     47",
"    </a>",
"    ]. The cutoff value in one study was &lt;4.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&lt;4.1",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"     45",
"    </a>",
"    ] and in another study &lt;3.7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&lt;3.7",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/48\">",
"     48",
"    </a>",
"    ]. Yet another study demonstrated that the cutoff value varies by waist circumference, BMI, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/49\">",
"     49",
"    </a>",
"    ]. Transient facial flushing often occurs immediately after administration of GHRH, but otherwise there are no side effects of this test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Arginine-L-dopa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined arginine plus L-Dopa stimulation test is a third option. The dose of L-dopa recommended for the arginine-L-Dopa stimulation test is 500 mg, given at the start of the arginine infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"     45",
"    </a>",
"    ]. The dose of arginine HCl is 30 g in a 10 percent solution, which is given as an infusion over 30 minutes. Blood is sampled at times 0 (just before the infusion begins and the L-DOPA is given), 30, 60, 90, and 120 minutes. A cutoff point for serum GH of 1.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    provides 95 percent sensitivity and 79 percent specificity for the diagnosis of GH deficiency. A much lower cut point of 0.25",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    improves specificity to 95 percent, but lowers sensitivity to 75 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719165\">",
"    <span class=\"h3\">",
"     Glucagon stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test has been used for many years and lately has been recommended for use in countries where GHRH is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/50\">",
"     50",
"    </a>",
"    ]. It is performed by administering 1 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (or 1.5 mg for patients who weigh &gt;90 kg) and measuring growth hormone every 30 minutes for four hours. The cutoff is considered to be &lt;3",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&lt;3",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    Side effects, including nausea, vomiting, diaphoresis, and headaches, occur in 10 to 30 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Choice of test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries where GHRH is available, we recommend the arginine-GHRH test over insulin-induced hypoglycemia. In countries where GHRH is not available, we recommend either insulin-induced hypoglycemia (but not in patients at increased risk for coronary or cerebrovascular disease or seizures) or a combination of two stimuli, eg, arginine and L-DOPA. Another option, as noted above and recommended by the Endocrine Society 2011 clinical guidelines, is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H719165\">",
"     'Glucagon stimulation test'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, there is substantial evidence that growth hormone treatment in adults who acquired growth hormone deficiency in adulthood results in an increase in muscle mass and a decrease in body fat. The evidence for improvement in bone mineral density is less convincing and the evidence concerning improvements in the sense of well-being, muscle strength, and serum lipids is conflicting. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations and benefits of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Who to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant differences in opinion about when to administer growth hormone to adults with growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/52\">",
"     52",
"    </a>",
"    ]. For the majority of adult patients with growth hormone deficiency, we suggest not administering growth hormone. However, for patients with severe clinical manifestations and unequivocal evidence of growth hormone deficiency due to organic disease of childhood-onset or adult-onset, growth hormone replacement can be considered. Childhood onset of growth hormone deficiency due to organic diseases (eg, craniopharyngioma) is often more severe than adult-onset and therefore more likely to benefit from growth hormone treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=see_link\">",
"     \"Growth hormone treatment during the transition period\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The criteria for therapy are different in children in whom growth hormone is required for normal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    have been approved in many countries for treating adults with growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    is administered by subcutaneous injection once a day, usually in the evening. The initial goal is to start with a lower than maintenance dose and to gradually increase the dose (to minimize side effects). The eventual goal is to find the GH dose that maintains the serum IGF-1 concentration within the middle of the age-adjusted normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients over age 60 years, the serum IGF-1 concentration can be maintained within the reference range when the dose is about 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight; a few need only one-half this dose [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/53\">",
"     53",
"    </a>",
"    ]. Women who are taking estrogen orally will usually need higher doses than women taking estrogen transdermally or men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following protocol to minimize side effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The starting dose should be 2 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight once daily toward the lower end of the range for men, women taking estrogen transdermally, and those over age 60, and the upper end for women taking estrogen orally. This weight-based recommendation is for the starting dose only. The goal should be to start with low doses and increase gradually until the serum IGF-1 concentration is normal.",
"     </li>",
"     <li>",
"      If the serum IGF-1 concentration has not increased to within the normal range after two months, the daily dose should be increased in stepwise increments at two-month intervals until it is normal. A dose of greater than 10 to 12",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      is not likely to be needed.",
"     </li>",
"     <li>",
"      If side effects occur or the serum IGF-1 concentration increases to above normal at any dose, the dose should be decreased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Monitoring treatment efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum IGF-1 is probably the best single test of the adequacy of growth hormone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/55\">",
"     55",
"    </a>",
"    ]. Growth hormone treatment should increase the serum IGF-1 concentration to within, but not higher than, the age-specific range of normal to avoid over-replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of growth hormone treatment in adults with hypopituitarism are peripheral edema, arthralgias, carpal tunnel syndrome, paresthesias, and worsening of glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exogenous growth hormone therapy does not appear to be associated with hypothalamic-pituitary tumor growth or recurrence. This was illustrated in a study of 100 patients whose hypopituitarism was secondary to a hypothalamic-pituitary tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its treatment. When they were subsequently treated with growth hormone, recurrence was rare during three years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/57\">",
"     57",
"    </a>",
"    ]. Although most of these patients had been treated by radiation to the tumor, the lack of evidence that GH treatment stimulates any kind of tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/58\">",
"     58",
"    </a>",
"    ] suggests that the presence of residual adenoma should not be a major factor in the decision to treat with GH.",
"   </p>",
"   <p>",
"    Benign intracranial hypertension (pseudotumor cerebri) has also been reported, mostly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/59\">",
"     59",
"    </a>",
"    ]. Macular edema or proliferative retinopathy in the absence of diabetes mellitus has been described in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/60\">",
"     60",
"    </a>",
"    ]. However, this complication is rare; fundoscopic examination of 61 growth hormone-deficient adults receiving long-term growth hormone therapy revealed no retinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active malignancy is considered to be a contraindication to growth hormone treatment because of the theoretical possibility that the treatment could stimulate tumor growth, but available evidence to date does not support this concern [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects appear to be more common in patients who are older and heavier, and are over treated, as judged by a high serum IGF-1 concentration during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/56\">",
"     56",
"    </a>",
"    ]. An open-label study over three years suggested that the adverse effects might persist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=see_link\">",
"       \"Patient information: Growth hormone treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    The causes of growth hormone deficiency are the same as the causes of deficiencies of other pituitary hormones (",
"    <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Likely clinical manifestations of growth hormone deficiency in adults are changes in body composition (increased fat mass with a decrease in lean body mass) and decreased bone mineral density in men. Also possible, but not yet confirmed, are decreased bone mineral density in women, dyslipidemia, cardiovascular disease, impaired psychological function, and an increase in mortality. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations and benefits of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum IGF-1 concentration lower than the age-specific lower limit of normal in a patient who has organic pituitary disease confirms the diagnosis of growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"     45",
"    </a>",
"    ]. If the IGF-1 is not subnormal, a subnormal GH response to insulin-induced hypoglycemia (&lt;5.1",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    or arginine-GHRH (&lt;4.1",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    is necessary to make the diagnosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evaluation may also be performed in adults who had been diagnosed as having growth hormone deficiency in childhood because many of them have been found to have normal growth hormone secretion in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=see_link\">",
"     \"Growth hormone treatment during the transition period\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence suggests that growth hormone treatment in adults who acquired growth hormone deficiency in adulthood results in an increase in muscle mass and a decrease in body fat, improvement in exercise capacity though not in muscle strength, and improvement in bone mineral density in men but not women. The evidence concerning improvements in the sense of well-being and serum lipids is conflicting. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations and benefits of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adult patients with severe clinical manifestations and unequivocal biochemical evidence of growth hormone deficiency, we suggest growth hormone replacement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and benefits of treatment'",
"      </a>",
"      above.) Childhood onset of growth hormone deficiency due to organic diseases (eg, craniopharyngioma) is often more severe than adult-onset and therefore more likely to benefit from growth hormone treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=see_link\">",
"       \"Growth hormone treatment during the transition period\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For other adult patients with growth hormone deficiency, we suggest not starting growth hormone therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and benefits of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize side effects, we typically start with low doses of growth hormone (2 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight once daily). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the serum IGF-1 concentration has not increased to within the normal range after two months of therapy, the daily dose should be increased in stepwise increments at two-month intervals until it is normal. If side effects occur or the serum IGF-1 concentration increases to above normal at any dose, the dose should be decreased. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment protocol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/1\">",
"      de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/2\">",
"      Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/3\">",
"      Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/4\">",
"      Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/5\">",
"      Koranyi J, Svensson J, G&ouml;therstr&ouml;m G, et al. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J Clin Endocrinol Metab 2001; 86:4693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/6\">",
"      De Boer H, Blok GJ, Voerman HJ, et al. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 1992; 75:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/7\">",
"      Binnerts A, Deurenberg P, Swart GR, et al. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/8\">",
"      Ros&eacute;n T, Bosaeus I, T&ouml;lli J, et al. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1993; 38:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/9\">",
"      Cuneo RC, Salomon F, Wiles CM, S&ouml;nksen PH. Skeletal muscle performance in adults with growth hormone deficiency. Horm Res 1990; 33 Suppl 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/10\">",
"      Bengtsson BA, Ed&eacute;n S, L&ouml;nn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/11\">",
"      Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/12\">",
"      Biller BM, Sesmilo G, Baum HB, et al. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000; 85:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/13\">",
"      Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/14\">",
"      Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab 2008; 93:4413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/15\">",
"      Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf) 2010; 72:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/16\">",
"      de Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormone-deficient men. Metabolism 1994; 43:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/17\">",
"      Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995; 80:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/18\">",
"      Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/19\">",
"      Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/20\">",
"      al-Shoumer KA, Gray R, Anyaoku V, et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 1998; 48:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/21\">",
"      Christ ER, Cummings MH, Albany E, et al. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab 1999; 84:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/22\">",
"      G&ouml;therstr&ouml;m G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001; 86:4657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/23\">",
"      Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/24\">",
"      O'Halloran DJ, Wieringa G, Tsatsoulis A, Shalet SM. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency. Ann Clin Biochem 1996; 33 ( Pt 4):330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/25\">",
"      Leese GP, Wallymahmed M, VanHeyningen C, et al. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol (Oxf) 1998; 49:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/26\">",
"      Ros&eacute;n T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/27\">",
"      Svensson J, Bengtsson BA, Ros&eacute;n T, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/28\">",
"      B&ouml;ger RH, Skamira C, Bode-B&ouml;ger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996; 98:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/29\">",
"      Borson-Chazot F, Serusclat A, Kalfallah Y, et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/30\">",
"      Colao A, Di Somma C, Spiezia S, et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2008; 93:3416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/31\">",
"      Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab 2001; 86:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/32\">",
"      Colao A, di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/33\">",
"      Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003; 108:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/34\">",
"      Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/35\">",
"      Johansson AG, Burman P, Westermark K, Ljunghall S. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 1992; 232:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/36\">",
"      W&uuml;ster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . J Bone Miner Res 2001; 16:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/37\">",
"      Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004; 89:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/38\">",
"      Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/39\">",
"      Snyder PJ, Biller BM, Zagar A, et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res 2007; 22:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/40\">",
"      Bex M, Abs R, Maiter D, et al. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002; 17:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/41\">",
"      McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989; 356:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/42\">",
"      Bj&ouml;rk S, J&ouml;nsson B, Westphal O, Levin JE. Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 1989; 356:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/43\">",
"      Ros&eacute;n T, Wir&eacute;n L, Wilhelmsen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 1994; 40:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/44\">",
"      Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002; 87:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/45\">",
"      Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/46\">",
"      Landon J, Greenwood FC, Stamp TC, Wynn V. The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin, and the comparison of this procedure with other tests of pituitary and adrenal function. II. In patients with hypothalamic or pituitary dysfunction or anorexia nervosa. J Clin Invest 1966; 45:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/47\">",
"      Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998; 83:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/48\">",
"      Chanson P, Cailleux-Bounacer A, Kuhn JM, et al. Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations. J Clin Endocrinol Metab 2010; 95:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/49\">",
"      Colao A, Di Somma C, Savastano S, et al. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab 2009; 94:4414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/50\">",
"      Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab 2009; 94:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/51\">",
"      Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/52\">",
"      Frohman LA. Controversy about treatment of growth hormone-deficient adults: a commentary. Ann Intern Med 2002; 137:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/53\">",
"      Toogood AA, Shalet SM. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. J Clin Endocrinol Metab 1999; 84:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/54\">",
"      Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 1999; 84:3956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/55\">",
"      de Boer H, Blok GJ, Popp-Snijders C, et al. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996; 81:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/56\">",
"      Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endocrinol (Oxf) 1995; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/57\">",
"      Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001; 86:5172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/58\">",
"      Sheppard MC. Growth hormone therapy does not induce cancer. Nat Clin Pract Endocrinol Metab 2006; 2:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/59\">",
"      Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med 1993; 329:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/60\">",
"      Koller EA, Green L, Gertner JM, et al. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab 1998; 83:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/61\">",
"      Blank D, Riedl M, Reitner A, et al. Growth hormone replacement therapy is not associated with retinal changes. J Clin Endocrinol Metab 2000; 85:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/50/1833/abstract/62\">",
"      Chipman JJ, Attanasio AF, Birkett MA, et al. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997; 46:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6641 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1833=[""].join("\n");
var outline_f1_50_1833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND BENEFITS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Body composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1294035\">",
"      Exercise capacity and muscle strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lipid profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiovascular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum IGF-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Provocative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Insulin-induced hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Arginine-GHRH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Arginine-L-dopa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H719165\">",
"      - Glucagon stimulation test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Choice of test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Who to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Monitoring treatment efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6641|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/44/23247\" title=\"figure 1\">",
"      GH peaks adult stim tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/8/18571\" title=\"table 1\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=related_link\">",
"      Endocrine changes with aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23463?source=related_link\">",
"      Growth hormone treatment during the transition period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=related_link\">",
"      Insulin-induced hypoglycemia test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=related_link\">",
"      Patient information: Growth hormone treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_50_1834="Seborrheic dermatitis axilla";
var content_f1_50_1834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53407%7EDERM%2F68137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53407%7EDERM%2F68137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intertriginous seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intertriginous seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhrF7chJt/nBNsSfPx0Gfbr1+lbOn26tchwdyMihowOS27nj+vpXMxxP5cUaqo3yjeIxjB/uj09wK7nRoJIZiroSxIYYOM/wCye/rXhUnqfURi2jcNi7keRgFgcMvQkjGOOoq7ZIyzoVJjVGWPGfTg9Pxqxbks0X8KDcv3sBmPQ/gKu2wgtsI4wFHDZ+9x/PNd8bPVHRTm1GzRpBIbiPIcBlXaMrz1/lWRfad50rugIjBBABwM9s+9WrIxwy5Z3X5TklemP4hViJxNIrZdk4PynP8A+ritE+4Rbg7oqmwmS1xnsAWyBjrnJogEsj71fKn5Vc4CKMdBTzF+/ZQWMTHBiPAbvn86uWEJSMG48shQAsbDhfqO5qJK4py01M57Y7icyFWGCwGC2M9zyT9Kz7i1ihi2u5TDfIAfm3H1PTPTrzXSOHldfOkb5gcIflJ9zgcAc+lQz2C3KTKZ5IZ5iEt51UF12ANlQflPOT69axcDBvucdc2U21kfzSASxUytgn6cA1npp13azmWxlaAtzlMqT/wE8fjXYDzmujpk8CQalK26J1JWO6iI4kUk5GDnIBJXA7GqV6sKy3ggmiguoMQzR3GCBxkEDHK9cMO/UVm4NFRqaFKz8SahYsVvIkuAvVo2Cuv1B/8ArVvaf4usLglRcJGehjl+Qkn0JrmLjR7+RY4pQbpNmVljXyJkcjIAwSWHocEdjWDM8W77NexO8y52tsMDspPBZT1/DNHPJbktRZ68mqxyKsqMGQdDnBHrVp7uO7i4cl1PmBh2PXNeJ2UrwTolrPdRlwVUFtpDg/MhH3TxyO5Fa/8AbWp2cjLcW7zbekkZw2PQjp+tUqpCgrnoup6gILtXYqY5EPzYz83fn6VmLqlqstxcxbZJJRtK9ckcD6YGfwrJ0nxrYzMY3ljjlB53Lgj6j+taM4s7mXNqrTSOQSsIBDnPQgdvrxW0ZX1RvBJLVEWtXKQWRlQxhHUnlcblU8t75Y4GPSuas9N2BFcBvs8bbs5JyVO7/wAffH4V181jMkUMtyAJUAMVtnzAjdQc9CQTwo4B9TU1nZeRaSK6h3cr5xTnpkhB+Oc056mU5aHmPjTw2txatBIBuWJUYFQSONw+uM4/Cm+D5bObSLo3bG0t7Vimo2MLIskhIAVVJBdoiAWwoAHIJ716BqVq7K80yg3EhPC9/TA7V5J4x0JodRXUobS2uZoGEn2edN0cqryUfGDg+xrJNRfkzz8TQc1zLdGhL4k8OavZSyXmq2z3UzLAlvMrhLWEHaxBHy5IwSFJ7cmqGt6dpMWtxPavb6haxxvNaMZgVkjQY3OQSpywODwSQMrk1dfx/c+LbdrOZYNI04Md1vbjzT5ZGAmEUv8AeIwoI4HOOtcL4ggTSNSs3lLJbCXZLJHCERiPnR12sQQM9iD8xHvWjSbseffTQ6vT/ADP4Yn8Q6rKtvYNG9xEjhRIuMHlmyyrgfdwc5Hrxnay9k2jXDWUmn2LajskNpawOytsGFQyMAowTlnB27ieprPvNXvvEkduNWutszRDc80hWJYIxtjhRF6FmByT64G0Zzztub+7mhgsW81CgBSEvnPcuFwV25HXjI9+TlMnO5sWnh2fVfDt9qU8qWlhpzobibJdmWSTbhFABZRnbuLHJHB6VgzQ29vrrRRQ28lhG3lSrdwyIqKeA0qxMWBBIOEOeMHPIqEwh7QTQCKGQSxoiRuTIxyWZ8k/NkqDnBUccjvsXHgS7tY1mmjaS3eMXEkqKH8uIOQx6gnGOTwOcZGK10j1IV5GFIbryhHGiNbyOJTBHFsJI4OeMgckAkirVs9rprSlYluLffhY5GKTsn3WQkHAwWzwDynpnOwdYNmkkdraLHojMQBNEPM2HGVGeFBOcDPfPJFUtJt4725a3uTb6ezl2gM7NsfnhNzdicAu3THPSjmfYkr+GbtE1KI/v4bmN3dWV9qyBcn5g2FzkDOcDGcgniuttdQgvJY3nsnlundrh3jWMDaSDnJ+Xdk9lycABR0rn7B5Zp/s04t0tLSUBktn3kJuwyqCTvjzycHnPFenahcx6fqKrewWdsLaKRLO0cRg5lG6MHKuqjIO1cqFz2rOpJXGos4mTUoo7DUrJw8UoOWLXDRB13D5WQBcHk7mz83A296rSWktpqEccqXSQtHusVeRnjCh8srbh8wGORjJ44rv7i803+z9UsZtIv8AULOZY7YPKsMU1tdMuQYwDvKk9cAjIFZiaVGbC2Or3tnbvbSkiIsYmXdnkMqkyOpwxBwRgriou0Vy3Ks+sWt54U+wNp9lEZGAL/aXZTGuVGxcEhiJGxuIGQx4NU/s1tpkjO8cU8rDy1lt381VEuUfBwA7fdYBOB3PUVP9lWzS1huYbcQkyh/OmzvWUJGbiNwoIQkHAbODnGcnOvY3rWj2drDZRxtAX+ySYZ3l+dJBHvwAq5U/KoUENSchqNi/pkT3Gmt/ZWlalb3qwIYlFs5jJQndKCFKqqqsZYAZz0OWye8skWye1W1lv1sZLX7OqmJi904CuJGeNfu+rBucnp386aK90pFgubu4+zv5riOC4SKJzIpLRqxfJXcqqe2FzzWnbrq97bCwtgbJViV3jhaQJEinPykkAFhghF5JBLYBxSuaOC2izftrlNTt4LKMCeMSSTNHHB5cSR7yVG7JyDk9ecDsabJBdSWs8Fk0FzcJcyxR2MTxRhF3ZHzemO2eAPWqemQ6il5HpnlTmEH7RO0u5Hm6hS2Fz2HHAA46V3GnA2kEKuiw5jSNFKAgqV3EhlGNwPOO1StWaVKPs9zmdRaa4Z4pLa2tCVKXM1tEStsoGfKVscsecn34HesTwhfzQaPZyx3EAaOCX7Q7xfdQSYxGNw5OB35I/Cu31m5gtdCubuDE1vCpaNYk3b5TwEQHOcnqx7Zx61xNha3/ANquLKIQ20toRFI8nyrbo48wynOdhJOEwD06VezOeTdrLY53XRPf+ITFdytHatGtzIoYNI8IA2lmAwu5gcKMYA57102nPCiSajctaJcB8NdSSbgqqvyKinqQCeecDnqTWVd2VzaarNDaWt1LrN5EZFJXB6AMS2OBgkljwACRyQKueGIdTkWNbSOxmmifyrdWtd0arg5facjYOTubgehJoiyGmy/pl5aQx/b9Q8iJJJHlFsSARsH+scDpjgKD1JwMkmmaTfLFqt8IhDcB7WIpDDKpEQ3MSj4B54XCYIAIAxWkugNp1vENMuiJkBMt3eyFwMDoinO0jJAIyQW7DirsI8q9tbm0so7cGxxEDmW4Z5N4xuPBYHkk8cZ56VRahYks7i7hmOm2tnBAAxVZJJjJKy9VwAPQ8Z7DnmrtrANOa4IDXGpSsIwdy5jVsYHJ+Vcjn1xTbTStRhubC4uZ7WN3LeYqbpGRWAGVY4yx4yxGeeMAYq7fRQWrMZS8ogG+WHOBJlTw2OgHXmquWl1IBqNlp0SWttHJLqDZCW6qd0kn95uMAE/xn8M1C+nzkrd6gIJJQMx2EbtJHFIT/wCPmpNN0/7NbxalcteLI23cmS6RBuMe3YYznvxUkly00ktlY3EiCNSJ7mFcNGO6wgdXPTceF69aLlFLUJoby8iDFbqeBhIIY5cpC2MZfnAxnCg9+3GatKBDOll9pl82D52CRnadw/1aKBnAA69Qcc9auWVpDZ2n2e2hitLGJSsMKHJZ/wCJ3bqz/wC0eetU4ry5lV3tfsn9n3E23zfMZZCDxjA7nHJz3xjNNPuOxQuLBEklu77Q0ZJU/wBJuZEE08YAwHDE/dwPqMZ4rOa4mvknGmwSXmlSR/Z4v3YjEcORuOM/MTgqOmAB9481162txJKJNTLJbF/3dsSBnA4JAJ5x0H581XtBc2j3az3tt5abY3Fx8p3kZZiVHJIYD/gPalYfLfc8S060mmnh2BiTIQD/ALRGevpgc4r0bT7cEKzovmr8m7Ge3DA+ntXM+Go3nMrmQIxZXx1GT0H5fpXe20YlgBVjGx6AdeO1cVOOh7zk09SKKzIVZEALRnG3b0Hv7VLFloh13t79DV1FVZvKJbDjcRycADGKkFrwQ3HTaQcbua3Ssaxq9yrCQ52THy8cFUXH/wCup2Bt/kjUL/Fu3Y+pNTp5bTMJHDOo5BP3c8du9VAu3yiMFSxUluWGPWquVz3J/MZpAySru2jaynJ+h9KsySEHbKCzOSAoH65qpFA6LKyZEi5yrdce1JKGEaiNSz7mJ3H6f/Xouybps1bd8onylZQCSCc9KcIo5hDHIPlV9wX3wcHP4mq4RnjkYB1bPQnkdvx4qSQHy1E6gKXQDI64YGnzGT12KF5Db3thBJcQLLAocos5IdSM52nqGGCeKlurJ57OFIXgm8yHajTYTc3b5hyCR6AjNW7uxeWJ0hZFm8zz4Sw3BXwQQR3U5Ofqaq2kErOYBOLN94mjtlQSI6qFB2s3TkHjrTRm1dXTOetdFtbWSVdTtdRIjkLefNcMC+cMQrg7dw6KeD04pmoXvlK8Opwm5id/kkvFXfAh/wCWjLnKN2PQE8iu3t445NLaHcoEwJlSY/OSD79PWubvo4WVb6OZpzNIUEsOGZIl7MDw4Jx8vX0pSilsVfnbbMC/0qyjtvPs9SvorsAtveNXcq3G4gjnHY575FVI0lvbpYN6SJbfLO6Ls8wgfKuB27n3qxqov3gur6UWks9ujLE1tNhFY8AIrc4GclfyrpvDGnHTNHiScwyzMpeWULy5PJqIQ5pGySjG71ZzGoeFo7yRJivmRR5DxYAKkgdD6Vjtd6n4ZufKWeWbTpF+YtkMoHVWA6gV6f5EZMfljaNxAz1Ixn/P0rG1y1jnWOOQLuCGSTIB/gbp+YraVK2qM3JrYtaLqS3cEUjPGq4IWRSORjoD2z69fQVtJJGQpRVCZwAnGM9gOw9Sea8kNpqXh6RbnTlaSzYgy2/bkHO09mwp+ua67w94jt71BsmJx95GG1kPuPaoUr6E6SOjuogUMkiYcEg4HXmuO12xMspOAQzbR7nqceoFdlJcrdxlYmIQctJxwPQD19B71latEIDFJMu8hSkUXXLHgKPXPc+xocbhyninjTQobSGfWdFZFktl2SMGKM/zA5VhyCO/qCRmvMtc1e5vpxeJELQLK/7qFSIUdhztHQZH417Z4uvBp8eo6XDF59rgKZyMfeGXwPTOcfSvGJ7iGxWFbm18yFoWQruZAx5CtgYw6ZBzk579a1o8t+U8jMKXLJTitw1K5kh063ExMM1sBFEEUgkrzuJ6cenXn6U/SNfWy069t2i/4+SGWfOZU25ygPTa2QGGDnANZUkazQBjDNFbALgRksA2MFiD6nH8q6FdFkm0i081kNjatEyyIBvJmjMrBlHJACEbsYBBBrflSPNcklqT2F9G89rNqId5lgEMSNmOOLflmZwvUckbBgYYE9Np2tQ8SX+twSj7FGsAto3XCBkKKWVQQMYV5MEl+yjrWC9r9nmne5S7gMkwjktC+4hidrOcfdIweOuWQcjNWYtaa206481kn+0TxTSoceX5casUTpnaCSADkHg9RUNK5nzN7GVq+kyRSXEci5vbNkEsCr8nI4x7Dp79sA1iWgkyPLR5IhIu4gAxgE8Kc8Dr610eoaPLb3DX2rolnNcN9pjsEmLTIjHIdiSWz8wxu+Y9TUM1lIsSJpixzNdKr+UhbEWBkNtzg/U96bko6M1p3Z1eiWGsefI8lvbvFZO1vK8VxGrqMgbvOIIYZwN3PpXReHU1FNU1KFNN0qTW3UfaLm/KzJZxKdqsqqpUs2eDtOfauX8NXV4llcacI7zaH8ydsicDfw+1fu4IA5PPFdl4O06xe+1FtKtXN6sqyw293eNA0kRGC4UEFlAH3S3UiuN7nXBaFmbw7FFPDDDZaULy1jErPcy+W9ySflIjOApyMbSBjIwMGu90jS7DWtILWV7AqFts0JsUhEEinBZlzleABjjnn1qxHpNoNSkbRi8PmRqI5JoFeHcoydwVdxOePwqG7ll1y7hvtT0+GCKUExXMJKGUpwoctgjqcZz0oUUtzbluro57UtKtLHS57+wGk31vbStFJb3iHargqoVXIw65w2wjkgemK0D4L1K4ktbUQTWSwK3yW8gj2t6gyM3y4HPU/N+FdNrcNzNpNzZW8TRvPGcCeVZCXABRlx0bK4GcdfXFWPDmpf2xLd38moMsKSKrCSIRs5CrkOx6LuJ4AyafKr2MnE5G3sJoNe1WY6hZSNZzLbRzakD9pncKNqg7SGjLHjA+9ng4plrC8W5dQk+2XDN5UsqvuUZZQSM4HAVhjHRBnOa3ta1220W5iijlhnv/AJ5l80oy2cbAlpQOo3EfXnjqRXNpY2l4ipPfyXFmkiyvMH8tbhl75PLZGQAOOalnVQwynqzRggSfVJ9QU3sNr5YDztcEiVVJJG0DGBkgNjnHFZKRzXdpara3F6iSXi+XcKgZLhDkqgViAuAcD15Oa6priKWE2tgIWlY+ZIpf5VQ8EMewA49OOKy9bmuruxmhhCWdnGghTf8AK0kQHzSKO27GPp9adjonSXbUy5ZZ9SufNv44pLfzi1u8ET5uyg+7g87cjG4cEjg4FSwz3n2iR2tHt43lV9kbF2mm24VWblnYewwoB5q7oq27aa7vGkivb7ri6+ZtkI+7Gi5B/LH51K18yaVNNbB9OdYlhtHmUholYckqM9uePYU9VqefOg7vmMnxa8sdtFZOZo/tEyWQhjfymuTnfJI78kIoDYI/EcCtOMSWUkQltvItXheOMbyuWyrKioOSRkZHoDzliarxyWemeKre5W4j+w6ZYCOVrgb2Eskg8wAdiQqjHcgj1qrYzT6nqdlqcyyyg5AhZ8SFmYsxVc/LnABz/dxSuRyrax0Wnw3W+T7RbJHfXDZnlt3VhBH2Qdw2B09ST2FWbJLuG7uLxo5J5JVSILvLIseT8yFsdznHVhx6VaXzbjT7yfyWsNOhjLpuwJHO3dkjtycY6sfaraedBbLNcwsLyQrIywnPplVH+yvyj8T3q0PlKTy39z5ZjtJYkDNGjBgJXP8AdVWGAo/vdeOgxVITRBDc3EEkGnREM8k/Jl2k468kbhwP4utS6veXUWlX8reVZCMtHA8jB2hQ/wAQC9SecfgKNH0htWFrf3ryJGP3kVtIA20jAzIOgx1CjuaOo1EnuLS68TlpbuEQaW6CSBJFxK7d3YHocdPzqciAOkFhEiabBHtXbwHfuq464HU1dkh867n868lkhgwroQAgPXAA5P0ziq01irussxkllVt0MOdieYwwOB1wB9KZSiPu9vmQIqeTZxRsJHTJYZ7KByzEDt0FC20KQxtCkNmXfc0KoGBHUlsDO8jHI9e9XzG8MAJk+c/uy6LyznsPRQasv5cxSCKRs7w0jqOUI9T0z14qrBYziDK0c1xbtBJGrNb+Y2/DZIyfTjgjrg1Ws7kWDOb9lAkYhbnrG0gGOTj5d3v349K2QGbyAg/eYMiSg8AjoCD2OahSVTLJF9lYbRvcOA0eSx79xx+tA0jxbQsWkkxZPlikdtq87uABj3wMV1Ok3LSYZljQqoxn+Dvknv1H5Vg6TaKsCZBd5Dt64AC9/bt+VdBpu1JIkI8yEZZT/C5z94/SuSB9DyqxfS6dpUDTyRs33nZMJtPdfc+9acNuZWUxKYowBlnzvf3/ANkfrSfZvtYLhT5mABubhyOpx/KhPPtpS1wm+3XqS2Afr7V0JXIaT23LJhSNyqqjF+eOSfXmo44ucudmQRtPX/AVpG4hbDxL9OOAOwHrUM24q0p8uWQfeyvyj2Pv7CpaMVJ7MpNMI4nQSKXXHLDJ/OsO6vrq0kkeJN4J3bB1z6gfQdK6eGb94I2j2oTnc4AOP9n+6PrVlPIKqt1bRE9c47//AKqflcfNy9LnH6f4ss7liokBI+VoicMPwqaTW5/tKAeS8e75s9lx1X3rW8U+FtH1a2O6zgWcqcOg8twccEMOa8b1GPXdGurgaYZbyC3G6SC5TfJGMZ6jkjsDUNTiXTq0t2rep7dFdRzKjfiMGr0ggfMZyyH5sEA4J614Ho/xItTKI73zLSVSQytyoPoccg59RXoui+LorqBNsqyqedysGB/EUubuKVNPWDudwun2kmBGzK+ehbP0znt7VnvZ2djDNdxW0XnRRmOM45yTwQOmaZp2rQyyqqP86jJJHbpV2VftaSBNrspD4z/D7Vd7mavF+9sYWp6cn9isG2SPvQvkDJwev1zWneEvahSOSPLVemc/4VE7k3M68Ln5lGf1/pSPuEkHnMMgMxb0PY4+lawsjpTva/qOEaCXDucKuxO+Ogz+WcVmSWpuGYkOjlRGnPOCQAD/AOPVotLHvmVTl5DtGB+GPbPT86juDHJvits+SgMO5DyXIIJHqVUk/VgK0lqjKRh6pMifZYix8u5kJVQMjIDMM+ny561zmsaF5hS7tGMMmxSrqcHOP1Fd5NYxq26FBh8Jsz8u7AG36BQF/Op720hVBD5YCBUwSORgCsJxTJvHSx5zpPiF7CZbfU4hFPuwk/8ACxzjJ9D9eK6ua5Ekst2XPmqmyMkZ2AjlhnqTnjsKpa3osN/KT5QIY8k9Px/CuQvdNvrCFPs5kmtQB+5kYnA9FbsKUJ8ujK5n1MbxZia8uZpCyxxg5291A4B9zWDqvhy6bw/LFqdo4uJgktsQv8bYwjDscYAI6g8813vgnRoPEOtPDfhk06xVZ7lNwBlkJyi47oMckdeBXf8AivTLbVra6SVQocqyt/d2ng+3StadJ2czzsXarLkXQ+PpfLht40fG51dsBCzdtqMc9ipHqKqrNdQwo8fyLIhfqPmQNjA74yDx9a19atodP8T3kcnmMplMilcbguct143DB/Ee9VdVskEUL6dI89m4dQZVAeJQ+QX2k4GCDn3I7V0xaaueJJcr5WSx3jxG6vIp2jLBTsZ8lSRkZHVlzjB6ggUtjcTTBY44ofPmI8svgLGASCSOgAGP51kQo0dyYisDgEpublT34P4cfWtW3gCR28NwZoyzASIBtKbT824nkngnbxjNRKyGoFvS5ESCSKO5a5u5ZfOncqPJjGD8zseX6njgZ9Tit+LTpbpLuPy5ggjSIpIvLE42KSMYZl5CL0UdeDVvQdLs/titp0VpLbRvhLXUjtDZxtZxnH8XrxnNdXa250rUruXUYotVnE58gRM32aEtnDuQM5XKkDPQkZ5rmnU5tEbU6etyPwzoGsaVqk8dpeQx2qaeZrnzB+52jGUGeXwSv3c/WutMmnWml2c2s3OlXMyf6NcSfZjMhR+VlDryo6AgjjFVfsqzXcTatftaX1lC8N8GjCQg7QNkYbgYAA44OQe9bGjp9rvG1TTG1h7aZn2i1dJIxGTk7k6MD3rHdno04Jalrw2bVY0XTNfvLGeF/tIFtOBC5JIICtnKgjnPJ61q+J7O6vvC99aXVympefM/2dchPMmIztUDgMBubA4wCRTE0mGSeC8jsRGDEW86C03o4B43x9mHrXN3Ojy/2jNdSaijQyL51j9muRaxeainDMnIDEZXHHG4d6vZWLsrXj0O4gvZbUS2UkUotGVhDeiEYQhcmORc5L+hHBHXBrJlvbPVltTPatbXEwyZ5+GXGOIVHVW2kBiOOe9Z011bxv5sq2r2MseXk2F/Jyvbnrjd+oqDxNr1neahCthIYr0w4V5R/qkJBDFRznG7A9aJPuXRw7qSV+pF4g0vSGiYBjbwvIYnmujvaViScdAQFPcdPzrKgF5NYQyW2+SSLJYSQhVUgYLLnrgYxj61qGztrmWBIo5YbSNQDc3b7iepKheuTwxJ5PpV3TzDBrreQ9xci0hU+ZM25WLDnaP4iFI/l2pKJ6ih7NFWDT7iGyt7Z7y5Fldv58t2oCmcdMN346Y6fnXQ3lrF5dukEBmgVC+bxyXY9snvnNU9QvlZ5VLRtBuEEjJ90lhnYD2PY46ZFFnJJKkZgkDXqZz5udqsoAYt9BwPUmqSsclVuWpsafp6LqJvL9wxjhRViiTbFEx7YHX05qhql3aWhge8naMW8omdy2WeZ/ljfpgKM9OnIrQsJLh7pt0oCH95Mwxl2PQfT0qxeRW/22eS5jiuRK6wqH+6i4zgj1Jx+lHoedONnqciuhzbLa2tra3tLSOeSTZJIXkIXCl37MxJIXPTrXVWVhh7h2UW98JTtVwAIkMaknA6jBx+NFlaLax3cztJd3LTvNuAGGD8BVH+yoyAO/XrWjPcQ3cs727CQSxqqyKMbIyg3tk9+VUD1+lCRg25O4+9j+0aeFgUNv27RKMiQghhn265qhqVxqCH7RaralreEKpDncxlwAB6HKgc+9a6qJNRhji4jhiICA5HOBk/QKR+JrH1C3+0WsrRX13C8jLGr22AVTzBknjG7jAPXmmyoxuVZLBIbF4Ck/2sI8MLrHuS3A4LgDqzHOCeT1rUM25YJoSLWVgqyFh+7IUfd9yPX3FSWabLq4thKRaRH5pkU5ZmGdpPqByT/tCo7qS2luEVYyZNjPFGAcNjk/TgCjbYqxLCm3VJkARLNo0mXd183O0hj/4970hkW9v45rHe+FZEboq54Ln9ceppLoNJBNDAim9lkWSfzBgKMY2r/ePB/WtOzW2/drEymIAMWyMs3QZ9MelUuwW6kN6qQ2wQcW6AR57/AHhx9SameDzGbMe4o/zgEgsAORj8c1Be+VLC7yqfsCS+cTtJ3bevHXr0NN0pknie8iWRluiJELNlY07D3J6/jT2HymgHhEgVSJMDbsQdDjIGO3HrUUkqRZS7kVWkBlMK84UYHOOwyPrUUmyD7aWRZUZtzHGWRioIHHUk9uxNQHzd1u7QL9quFyYFbLFBycnsc7efrTTGonm+m2qCNvtDCSdgGUjpjJ4xWqbKMQFo8pyQNnAUZycj+orN06bNrHG7swGCkg64H9e1a0E0cqHySCuCA2SME8VypHtpsuWTsmEWTKZxub5dvoAa1AWkQq+xmA5OD/npWFlowVQb4UX5gQT+megq9bz7Y1jZ1KEgqxyqke1Wm0KS6ov20XlwbBk4HBY469s0qmUZbHMYZl9GHsPpTDKCP9Zkt8wKnpj2q3BIH3Mp2qwK8/hRe5lJ31HSANgYjV1wzc8c9d3r24qBXCsRuUCRs5Ixz/jU3y+dsXaYnG6EYPIB5+uM1QLC3WRproSjzthaZSdpK5wCPbpTkjOOmhdY+ZuDDdgbcnggVzusaIbqQT2s7RXMXzJIpKtkYx+HtWwk0j+Tt3GNkLhl+YAc459Se3bv1oSaKTT1uonyhOxlwSyPnG0gcg5pqTQ3FNWPmT4h/DXXbXV7rVYWmvhcStNMRxJuJycdj1rzzT7vWNPuZGs5Lq3mj4cDKkexH9K+0n23Mah+VcA4dccYz/LmuG8Y/D+z1ld8DmC4U7o5FbBVh0IraNVPSSucVTBzj71F2Z4zoPxY1exZU1ONLuPj5h8jj8v616j4c+L2i3kqCS5+yS4wBcLgfQnpXl3iHwprOlanC2shPsMSeWl55StEgBzhlA479etZSaNpOpp5qy/ZrmeQlY04jjjA646j1OfXjNS403qjKOMrw92or+p9RWmvabfiH7XPGByY5UcMue+GH8qs5sJAEfUTIgPGGHzf59K+XNM0K7jktn0DWZbeCWQQSPKGVd/G5gFzuTJ4yNx7Ka2IdV8WeH3SWYRX9ozEJNGmC4B5IGA3HfjI70ODjs7nXQx0Z7po+lI5oJEKrIU8w48zHz49F7kn1q5Y28cTKsSmFIwQig58rk557uc8+nWvH/CnxKguU8y4VlY4BYrvxx03jkduCBXpdl4itbtI5BKpOBgKuR+dTza6nVJtr3djovJIAdwFCrtjVT8v1PoMZ/n3pk0aysCGOCeSR1/zzUcOoCSL5YgQwOWPXNDXC7SdxYnqf8KdzNXRRvljVTlcoMnA79qzjBHL9ojkG4RpjAHfqat6lOW3YwxjAIyOAf4V/Pn86jhtjY6eBNKu8/vJd55J6nnHHP48Uox5mdEIXV2cNrVjJYPBdae4tr+CQi3lXt3CsB1U9CK2V8VWeu+GZJIg1tdICl3CCA1u+MsB32nqD/WoPEEySxokZDFjgHA++eT+XFcOtrGL26SGdbe9lUpHcEYaKQJleegGeTu9RWik4u3Q5sXT5ffW55p4rmtx4pkiiJiuYZEIdQCdxALAk91bGPxqhYm40m4E/wBoa3vYpkkMUiFRtYBtzIeGjIIBH9DWzr2kSafOyatp13pt1aCMlY0zHKhH+vO7nnK57HPUZrUsrS1aC2e68uZntzEVaQxSW0isSjRyA4wdxwWyCOOg4vnUVY+bcW3qZ9lpPnOl/pVrZ6fOYI96XEgMe8JkyRMx2BmZSdjHI425HA6+y8MvNfxy6YuofazDHdqHiE7SpuKybiPl+65IPG7pgHFSf8I3qreG11LQVjkt42SDUNOgicS2s4UIwdOPmYHfuHDc+grufA82lKj31jcm5KBULX10wd94B2vuQNGTwQclW45FYzfMzelB21KENt4c1iL7RY2skOoJETNbxMpjYnIk2B+AQMkJ6rjtWroOiJ4ltpQmuXMMUS/ZjHJlJLqFSWQSIoAyOQdvOFXPatTUL+2aF4rsXdpfSSRnfJGrjzN3DSumVYYHUHOV6UzRiLrxBfWMV0wmkQXLwyxoD5g4LEHjJBHKkZ74NZJa2O+nBMs2/gvT2tLN4NPgkv0CgXEk/mBSox8+4EAduQTgU0Qtpt2NPvpLaKeMeZbXNu5AU9SCF4XjOFx8wNb0WnXVrPdzQ2NvNdOqvFL5jIX7GORDlWweh/PHWnRtp3lSJdk2M/V1YbAT2YEEjrnr9KbijaEVqMt2ht7m23X9tf2NwhW3mdvnRvvbQyDP5025utNnjlgl06O8WVj+58pSfUcNgtznpzjtSalBYNBA6PbIMEO6QFSsgxgkgcc4PPXmomvob63FnqVoj200bKygYMh7hc9OvOD9KG76GtOjezRxGs2PhmDRp5rO2nSQSrJ9nYvGzfOCV2nAz1HB60tvcrFPFb6NbraqAE3XK42nJOWz/Fzwc4yKt6s0YMQtzPHbI67SBnyx3DI33hgc981HYXSzr51xbxxxnAWdgWHXlSQMgdOx9OKIw1Pbp0XGN5amk8U0IW4IR/sxO+Xd8qAcsT1AJ6+tZjQySWd+Z3kQvIkiLG2wEv8AKQT1+/jgdM+9bk1lDd6esbLEjvlXjDHChj8zEdjtUD1Ge2ar6nYxPq9irJ+6klEIkJyAgUvgL025Vfm9vfNbct2QpL+vI53VHFxa3MVoizQxE/ZpUGFRVGWlI/vZJ4/+vWlprtptubWymS5llbzAsjESBiB80nrgdfoKinsy19rbvGsVlMpII4fK5HHPRiT05q9p0EejOnnJtkc+WxVhv2gAAO38PJ59qjlsrnPUilE3tOnFrPFbQwfvIY/MkfeSxdhx8oHPrjtU0huvt88NqbYtIpe58wEuGfCqOOAAuSBjPNYthPNc6fPKqTLMs265KHaZZA3MaHrtwB8w4xW9oapDb3k8zZkmuiwCKdpwcAYHOBx15NZ7nmVYJ3Y83X9n3McMiMIbJWMYZCV6Bd5cZ4HPBGetR2TXCyOYCxe6uTMznC+arKCiIMepyT25rRtHD2VkYU2CRERVBB3ZZiQex4H61TbTHl1I6pDcpaykMquqFoyoxgbDxzj7wwe1HU51BX1NGK0iRUlmmJl35fnaODgAjvjBFV7REkGlMZArS3DNLF91wFWRlUj6nJ9altI5I1kaUvLJO43YVQIjySqjueT9OtWpbWGSQDawEbEDcejHGSDn04p7it3I7M77WZBLCIPtDKZCNq4BAAz3wO9Q3Enn39pJBGyx7/3s3TAIwpGeuWGPpmnzeRaSI8rJslJwcAkSBvl5PADAYHTkYzmp3Ecl6jMxQo7D94CNp6ZJPbGT6VQ7EttGJrm4lkdSkZ2hccDAxk/mantoYiQ6R+W4c5ePAOP/AK9ZukmO5s5okFx5cckikFyC5ByD7Ag5FbEG154yvGAzBB0AOBzVJ31E1bQdaxLLcOpYsbdvLOegyM5/I0xbeKCyDxBo1QFgsfQ4PAx7/wBakmDJHI0BTz5ptg3kgMD1H1wDirMrrFC0qqcRggKBySOmKrcXUzIX8lbULBm7nbcrOcpk8k5H6etFtZQ2h87cXuZXQSSHqwGWI9hz/KpIl+zyyGRT5BO7eBna208Y9Aen5VTtLmPyJL2eaIsw3IqOGCHaAxPrgj9cUi7djy7RvLIKOzC4DE/7QRsY5P6VttAnHkBQSArswJUkk9COSa52C3M4UwhGQhgh6qQDy7epzyBWxpU5iZmmUsxz+8YdVx/CO2PbArGKtoe44vdFuIlX2Oj7iA+VBGOevHXvkHFSklXkFv0B3IpO35sZK454P86Y0LzltsbEJ1U9/XPv7VFcQQyQptuXQdUe3xlDn+Hqce3am1YlpGtBMsojlif5GXcOvP8ASpUlKZSMqhJ3ZbnHPI9M1x88uq6aZp44jf2J5Zo4hFKh7kITtcH0XBzVrS/EFlfljbXCs65LLzuRvQqQCM/SpbMZU5JXWx2YJOXjbdKRwS3U9ar29wwgJhU5W4LIhXJkjGQygHjJJ4/Ks+y1AShTllZfvfwlvTHpS3V4bC+scBBDPJtLBuVY88emDjrxyauMkYO+zQ60may0zT2UZFpdNJDJJJsSVNrFeSM5AI4PQj8asavDB595PYny74ypDJ5MgiMhJG7cCCOc4HfIBrA06QMtxZTlAh1CSNmBLtHI20Iw99h2lT79QasIX1D7Xpt20r6iJI2CA7QXQqySAEZ2jaDjnvz1p3Bb3NGSWWa1uhaIZruDP2e7h/dwsgPzbkOT94N14PGMbgKns3/tPT47m2EeyQ8chlBIHy9fvDv6YrHh1d59OgvLItNdRStNHawfLugLAOqr1whJxn+Icdqd4c1OwtNH8+0sYJZpn8q2gjUFppOQTxwQQoZm9yfap0b3NUmlZIh1zR7t5FiSQFpfuKzAAj6Efz4ryzWvB8bmeTT0gguGJ32pGws3cqD8ob/dIHtXukNiluj3Opy7r64GZDGRHtGPuJnooH+JqklhaS6fLK1o0dpjAkYknPcj1+tHI1swlGnUVpq58/2E72csETQIi2gUC2aLJc45YhuCQe+cjqPWus1fV2uru3tPtdpJEzs0lxjKid8E5V/vHA65DDB+Y12Vz4UttTske4RWLlirbcMB2+v1rir/AMI3+nW8kWnyyKiusiwFsKpBzuAxyTzyc+lOM3HRi+rpfBrYqX3gzUJdTubyy1SGW+UKVls4lUJuDkRyR7sMhcBAeQNwOcCrEOoXmiDHiTTZLJAoY39p++typOAzAZKcjHIPPfpVaz1C20fzLmSO40yTzCyxBh5m4AD5QOHGSGz0Gcd66bT9WN4WtIoHiv8Ay2gvommWNmxHiVAvONpIQpy2G9VBrRWkZKLjJ8rJbPX5o4ll0+4ju7Z+hjP8j0J/GtCy8VQSt5MzLE3QKxwa4a58GxW13JLZLcacC7bbizlDKynJTeB8uABjkclTzzVW6stYtYVe7WHV4g2M2ybbgKT8rhMndk5GF5HHBDCs+WXQ3c4x+NfM9hhv4nKSgrtDFhk98deO+Ko6zqsgg3fNGXGF4PGehx3J7fnXmWiXcjxCbTLrMTHhSQRn0wehH4VufbrmVvN1CUuyjb3BNCqWVjppxSd90XTJsnDXY3RRKZZMnoo5JY/UfXiuo0fQor3w5plxc2qw3NwjXDhV5Yuep75xjjoOwFcfarLql79hij32zhZ7kR4+SFSMjBPJJIHrXrUVxHNEkytHJGVwrIwK8cYGP88VvQXNds5Ma+aUYr1PHviF4fltDPd2ckSEnbP9ojDx+SSdpbIyNrHOR0weCK4uLTpWkvYrO3i0u4yGudGZWRCwGHMBfdzlQcE8FxjAFew+OpGe2l8hVMzRmJUZsKxdgqhuOh3Yzg4/OqWh2Wl63NHBeWkttfxJ9lZZJF85o0A2B1yS23PDL8y4XOR0iS3R41elapocToOuTK8MFtLJFrkcfkW85Owyxgqqw3C4AfjIVjnazEk7Tx65pS2+oytqUMflNHt3WylUYyEDcp2gBCcrgHHzcHpk8ZfaVPa6nOdSSdZ7l3iu54mdIp0Xa8by5KncOeUbPyj5QSKg0GLXNG09J2a42iNXiu4VMp8oYDLJjKlPvbsrnvletT6hGDieowW1q8TpJAs9rIrBoJFG+M8HcBgHjnIHIycZrmvEWkxQGz1WwmnBs2AngndkLw/dJSQj5SOPUdDjBrS0+e5kEOqWkqXUSlQyI3zAjgNwNyYJIIwcdweQdOfVGvLOT9zNNEXaQS2yGZ7Yk8JLFj7pA57EE4oaOuMuiMy01DULeSeKFnuIBxHeRoBLE/8AzzmjB2Fv9tcA+lTwXjokyXUyK5IbzkyVjJHUhvmCnuCDisSC/CRedDa3IYM5Hkq6nyc42SDADhQBtfqRxzg1rILbU9JtTJJ9tWFiFBYtvUfwknnPOCrAEVF77HVGCSLUlw1xIyj9wzRjOVQAgHgg55X0bt0OK58w3NnJcQxy2ojVtzRyRkhd3QpjpzngCrWrWYhsX+yn90BvgbBzAf7rH0PTBrJur8XsNrfWvlm/iPlSxv0UHjBHpu6E+vpVRR3Yai90UruW9+0p/ad2khR9ojEILN0z909ecZNXLUP5tw8c3lo/7xliILcnGCfUgZ4xS6bHmeXejtNOfM3Ef+Ok9M5z09avRW7R6/BukjVG/eZUg5KqApOfq3P41so2O6rJRjym/DbRIqxILe2JxgMflWME8fjwCe5P5Y17OrXUErxkG2um3pjl5HVgg65+5jPYdO1ajTR3d7fw2g+eIi3hZPuRnAyWI5PzEe+7AA6msHxBbCO7VZHkh8thHEkSiLZEqkFwf73UZPBJ4qktDgpWbsytK73MUbndJJJOjFAw+6CAAoHb3P51FY2by6pNb6k7SfaHkYg8ZQYx8x69/UUsbR2rafLbAgRhsunJBIyCN3U+/wCNXrKH7T5kgVYwp3tKzlm65CMw6L6+uaznG45q130HQWbaZdXM9jOGtHt/KVpfmMWMhe+cdj+dT6bbXYuF0+5urmBJIwyMmXBB5wxbkkEcHuKmSNZ8i3R0VcLM5U8A/wAIODnjvW5ZwxyaqSASUhEGCAOuD/k1jscVWXKtiJRbrqLW8gYyMAyhDjcQOVYj8auRxlzHDLCzshCjc2Q2ckE+mAOnWqFhJMLjUDcLm13CSOX7xLZI49TgDmtWzR3unaZd0jMW2luIgMLt9zxmg5Zw5RJYmRHkbzJMFJV+bA4IDAfhzU0iK5BiC/IGG5TgK2eB9euQalkZVtnIIJwfvHHOTVa2UMhYq0e7JyF6cAdc+3+e6ISHKyvC4uEAi3ZBIxkHrj1OeCO1V9K02zBlC2ylHRWJkJcFWLEKAewp9rZ/ZVXywRMTkyuzbSTgY6EflimafLJPcu8WbVvmUqeQrqdpX3B65HtVbvUb62NSdH3P8xO8FdjHjGMcY71HZSFZLaMqI5EUx4zkEAdc/wBKrxxzPqKTz3Cl0iYKI1xjJAPWrpjR1iClsj51cHknt9apakWHoJfNmkbLQwONmO/HzGrCFpY1k29iyr1455NZFky26fP5jDzjHGpwVJJ+9wP51cQu1uwtXRIjgMQckgnHy4zjr1/SqTBoklkW3tUiiJEsnzKx/hA5LE9sD+dV7lobfSmEiIolCRsQclgzADA5PerLJ+8CFFigUKpYNv3jsOnT+dVpEhXckIjR95xGyckqeTkdsmhjR5DZyNDDAHcYjxHgDC4Axk/lnit5N5EshkVVkG5mYrgLjGBnG0YzXMQNFPF8z4wARxgH2+ua17edpXK3rAwxDzCrqOT257n26VEZo99tbjhNMxR5PMCHHlD+8B6jv9emK1QsTTxRkgzcE7Wxx2C9snuainMfltLGFd5Bvzg/uk/DoAfzpY40CgPJFtTPzM3Y/wAR+vp+FTJ33FKaeqNezIcjCcAFV3cD8PaquveHtO15VF7AslwPuzRfu5U9w45/Dp7VYt5FeVY4jiTYD0z+P09q1YcIGI6nAJPBJ+lKya1OZzad0eZ3ul6/4cmEkTHWLFORtG25RfoOJPwwfarVrrGn+IbJTbyiVMgMveNucgg8qfrXo8kQmBUjcQOuOlcR4q8D2uq3BvYHOn6pjAvLcgMfZ16OOnB59xScbApKe+5h6z9q0yaPU7KVQqqhZsY5XjGDxgjoc9ePStG8J8T6MrWu6DUoA8QdiVMWPmVh/Fk8YxkEE5zXNXes6z4XVrfxfZrJp7nYup2iF4GzxiReqHnvx6VZ0GO0vbW3vdCmieNlWRrVn/dkgjJVxkoTnp0qbtadCeVXut1/X9dDS0XVlludPls3jt47qF45pwhjSHgkxkHpyrAgdG6Vq/DqBGtp9bETIJy0dqETy9sAY4O3naXOScdeOnSuT1i0vHeaOxMloNXn8uWKKdSCTxv6cZUdc8nrmu6ivJ7XSbeGO0laRisIjQooznHrxWlLV+g3F2t3NU2qzXKj7PgyOQz4zhR1wTz6CtO/jN3bwW7IfOk+RsjGUHf69qFuYrSHy4IirbB8rkE/L05/Gq0uoNGVaIfvpCI4UJzubvz6D+ldTioowbk7MCiyXJby9sccjKuO+Fxim3dgrpESi5Qddv6VZsYY1tV8wsQDsiVushz8zfTNakMQkyOSo5Oe4PX+lYuNwdSx57rnhKzv4WjuYEkXOPnQHH0/SuCv9O1Tw/KGim8+3ERgSSYH92CxYs7DDFtxDF85GB2wK98lthLtIyvYg9xWHe6akqMAgw3GD0NRyuOxrCpGb97c8uXW0ZIZLOMoPLbdcGaNy7DoylTncT/ARjnv2bJMl1aQTQhLe3P79Xj5OWbkoAOAGOGTtjjHFXPFHgdJGlm05RE5xngsoYEHcBnAbtnB4rnNLttW0gi31C2lltFlM0TWxOYyScgL3Xnoc/0p86ejNbPtdGXr9lF58+o6ept7ud90dwkf7uY4Aw4JwQT/ABcMM5+bkVkr4hmglEWqxSwsSUVkQtGxH3gDjqO4OCK9G0K9huITbX1wSSrPtUKsblnIyY/4WxgEZGcgn2hu/DelXuoCGOY2kt4ojQ28e4bvvAlAemR95SCPfkUOKauzCXPTd6T+XT/gFLwtc2l/PFPZXEAuYmDjLDJ7YI6ivRP7WtEtz9uuINOijXeTK6pFj2Ynbj26+ory/UfD8tpdwWfirR4byOWZltrqzcpKOM5Ury+fQYI7DqKbb2PhjzEuLOIzb/8AU3EkTXIjI6h0m3KG46rtP+7VwfKc9TEym9FZnY289j47vXit7maCytsSwRsrQT3UuDtuELdI0BO1WHzFiTjIrUg0yaaRfKkB8RWgCzOq4mJAypGVywYZwSSV+ZeRXI2mr2qo9rql3cTiNUAmikBZHJJVlmX5ge3z7h/CSRxXaWd++rQ20kdxuubR22TrIBI4OTjaPvZHBTI5GQc4NJ67GEYqWr3LEOrz3mm+fcSpPdQ7ftEMsQCSJjDEcduhOF+6DztObGsaLZ2cl3e2SNCtxGsgT5v3mG5QjOcnJx3BPB6iobmykvJ1m82G2vMq0N5EDH8+PnBDfKykHBXPPXA61btbmSaWexvbd449ixBYSZImdAQQS3KthcjB/hVs8sKfruO1nYqT2dtaMtsElCXzbrK6t5THLBK3ylQ3Q5XLAHOcH0Fa1h9rsb8qLhpLlcxO06bEJH3S+3jkY55POeg4iNh9o0uazZo7m2aeRHi2FuAquCyHv8wOVI65xnNUoNLTVbWJbe7lSSCMwPE2cxsp+62ThkwcDIB2sPm61Oxaj1NWWwt5LfYsjWVxGzupR84JOTxj5gSTxj3rmtUSe02XjDzLhQpukVSCQP8AlooXBDAdCMg8gitFLC90uB3spPN8rAeEkMYx/EqBuqnryR7U5NVt7+SJAwe5XEmYSQ8f+/GcHH0z+FFrs7KO+upT/tCR5iRPBcwzgSQyx7hvXrlh0JzwD9elYWpWkTXkghnhjnkJwWUYfGDg91OfwpZofLvpIyrQ2+5jNFH83lPnh1x/e79j35q3E1vI6QyiEqG2hlIKtzzx1BOK0iro9iklTV0Rae0rSObN3mk67ZQAEwRkE+1aM89xGDLHL5l4r4VkUAl2AVR379h2z0psMMdvczP9o8mI8oZBldwyOc856fWrel77i5geOV9qsGRZCFIyQCx/Pg/T3qktLGdZp3YugZt76aJFWMbVZdz7ioVQS3Oc/KS2T0BI5yMZc0Uax3c8sY8wzMzPIwZgu47cfgf0rpbl4k3XExd/MgITfHkMFOCCQMqMkAEEZ6elcvdWs7LFE5iYRBmZSAd8mOSfUjp6ZJ61Xoc9HWTexV021hljF1iSS5nUlWMpCx8cgc9AByT1Na2mQCWVY4og6QjaNz5Jbru9OnT/AOtWbbOscshaNjHLKZIiXJZQTwp45b8K2IFYXcjRxZmHzblz+OP8KhqyNaqdrGnZzTNbLmMKgmy6MQQfUnB4x6VpPOltdh2YbJWJUgYHTAx+P86xIpHtmLwwmVJkwW4AJ7vg9PTBq9HBDq1oba5SYwyx4MCbsKgPCljj68VhI8mtHW/QvQo0ssMcSboI8LnPDPnO0+w5P4VILxLWzuboyMwiMkrserkk4GPrgD6U2CX7LOluJMLapjy87yvvkdsetMhRJoFmk4X55Y1TGAGJ+bjqTyMnp+NT6HPu9di1ZTwTQRKJFcKQrbeRn0+tT2jEqrCRsOoc4IK53H+n8qpx+VZFgwbICmHIJPOVxgehI59DVixM3lxpHbnYiqgLkKu1R6deT/KgJ2voSXTx71jlnBdg6BSQccA4xWbFJKktyLeJgUVXRuCNhG1hjuwAz+VaoiAYu+1p2bG5Uxtx2HtUcQZADLFhmBPTKjHAAPr7fWmJNJCKbdb+ARlCssTD7pGQMEcdT/KnywSTQhLNmjRCWyepHcL3A9/ypLi12tC0BTMbFkDk4BxyPoeeKlj1JPOLiCZpgoCwDG78fT69MVQtegxC0hkSCMrAuNzq/wB48fID1HHU/hV0zLBGAi/KiGQKBxgdB/XPYCs+ytL9raNw9vZ7izzR8zZcnkjBAHv1+lWobVYLglmaR5D/ABHJP+PTp2q0J2JH89oXWMgb+s3X5j/dHT8+mOlIiCxBOA7O6B5GblyflB59jyKbPZRmeBUkeNlbcMMdueeMdOefypt5FchDF9oxbvMinIG4DOchj346YpiPmFddk03UzbatbT2GoAfvrabjd6PGR8rj3HUc12thqEV2izRMDkgkg9+30pPE/h6wvr+7TU9Iiax8lfLWKRtmdzDzFAP7sg4JxgY49a4XUvB2u+GYBf6DdG4sd5jntLv/AJYsD/ez9w9m98H35nC3wnfHESjpUXzX+R6Ajh7iQyGRC4BXYSBI3qQOvsKtxMpljgLbwm0nOOhONzE9cdc153aeOPs1z9h8T2dxpd8MbGkH7t+/Df16V0a6wYNRsNs8dyJyVjeT7jEjjPqOopO8dJI6I141F7rOy0cM99vE26ZG8uAs33lz80jfyBro7HVrYSSB9xRJDCoPzPI2cYH+NcbcboGE5+Z1haFAU5iZefmx1BBxTrnUVhmsb2JHSwt0IcxR58tzj5iPTnb+NaJkSXOeks6gB5WMeB/GfX/PSo7ryFUM7S525VV6muWk1hgIltdtzcyktHI/3Rwcso9B69+laFkkNqyS30zT3M7gKr/NJOeCdo7KPbgCqtcj2bjqx80drdhxFPtdwQyN91uOhB4NeQeKfA13o80l/wCCZotOv0kaSS2RiI5xgfLtJ2rjBwAP4jz0r2VzBfDbPZRKwTAdSQI2zz9cAYAqtcxQy3L2rxRl1TeHUYONwAP17UODWqNUoy0kv816M8Xs/G+la9aPpXi0NoevxFVBdSke4HIYN/Ce/PHPBrsLDxMIXt01KCW5vYxiF7WMyxzEj7wI46U7xx4BsfE1sUuoo47yEssVyqjcgxkBv7w68GvKJ/Dc3h68iWzuNT0q6VT5zRzgW8rAj54yeMHnKNzk8cU42b00Zy1ZVKG65o9+q9T2Ww8QvfuRPp8pY/KsWMg89WPQf0roNPKttluECykFGZXJITP3F9D6kda8TuvEviXw/MsVwU1m3OfLljUwTYB+Xch4ORg4Ge/pXQ+GPi1o95MkN4TZzrkHzhsKn0Ham+dfEEcRCovddvI9st5Vlcb1UZAUqpwEX0+tXjfqC0cI3MDlhjjHoK5DTdctL2ESWk6MhHY1NFemO7Kyvt81X2ljwDnt74xTjMPZ33OtjkjZSWO1iQFHrUF2VdUOQAeAPasG11DM7JMP3yY257ggEke3+FWY9RTLyEjGdqA9/U1TaYKm07lvyEKk7lHLA8cH3/nWDqdokigsmXAOFAHIxWuZBJA5SQFIuW3H7zHsPp1/Ksi7vI57ldm8uhwvHUlTj6//AF6bgrHTSTOc1HQ7W4Uu0YJK9OhP0NZemW95pt2ZdOKzBSCsc2DjHOA2OB7frXYTsJEMSRs007bIoxz1zgfXitBPD11bwmFP+PlWXDyH90oB5XA5P19aUKeo5uFrVDlrnWrG+iudL1myMJmIaWK4g+Ulv7j5x07jkdc5rgr7Sb/SryxmtrqZEdiw3S7ZJFOflZjhWcY7jnAA5r2TUtC+2AJfWMUdyG3Q3ETJLGrD1Vxxn6Vx8UIhubjQdasopYEXzRC4ba6MTkjOdvPXHTGRinKK2OOdOL1Wpyk2gxWlyJpba5tlDbob/S51AjOR8zxuuRk9Rnr3o02RbCY32rXLyTfaI1haNPs8k5IYnOBjIxghgMnGCa7S2gXTTLBZxpJaS/uZLO+f5mTncI3PcdMHrWJqcdndWk1rNa3USkt5TYPZhxJGB8jAkcrxz3qWuUynQcleOjOq8PanBbmRxN9pV12OHbAdlIXIVh8r8ruTPcEcCr84tpYVvNLuTFb+Z5ZELYALHgYYfKAzH5e2TjuK800zVZ9FklsJit3bSRK64xL5mDgo69eeenJ4HAwK9F0TUrKS53B4ZbbUF8+3lC5AD8NE49O4PY5BpWMozu7S3L9rbNdRQ/ZJ7uCVJpQ0Ik81Y8EjkfeUcAqAehAHFUJ7xY7g3L3P2i2ADKcFtmePMbGCuCMEEcjnORVGaaLw7rb3MXlx2rhXuYkLHbGmFEkefvkAqSOpGeeK0tQv/s9zNd6YH8mZ98iw/vBcf3l2nnJOSCPcHOaFqjohdOxdj1Rywkj8hWxt2ZPK+2cD6c85rAn0eFb65v7dGMjyCYszbX3EYO0/wNjqBwfSkjtYwst3biOeEjJt8feXPYdQy88U64v3gvXgi8rexw0bN1XHBU9+v4U7HoUabXwmbI6CQsV3qcqZHyPMB6ZHVSOh7d6rQ3FwDHGJnj+0uDEJSCCePl3Dndn86uXEiyXD70uLeYcZdNyt77h+VLZxQ3LSQgxPHJ8pTA3H19iB+dWl2PUSSjdomiWKOd21CJ1dI9wJ+cM27gZHPPIwa2lmZfKiDr9muNu4KNuQQSB7d8/lWZGZbO0ijT/WrhPMnyQUBz165z3rf0/T4LxwGAKqBtU844wfY9TTSOOtNLWWxY1mRZ7GGH732h1M7ovymNMsFx/dzgAe5PauUkKs9xc/Nh3Kr/ugnkfU812HiS5WJ4rVc5aLKruGACSNuPpg/nXIZD2Bt/nDt+7V+mcn0PXAyKrqY4V+7cz7Qv50kIJCRtk89O+PwJ/WthHeCFUVNwkBZpP4nPtnpz3rOWOG3mzJIiqNplLse2MEd/QYq3pjtIxhWNlRsqyOc/L1znvnPas5nRWaeqJJ5JJbCGQx5kZfMOwk+VGOrceuO/WtTT7mKSxEjXpRFlG7OBvHuRVTymUwoTKqo7buf9YccA49ulPs7q3jjktTbNCskgtypi+VgeQQe3TrWLOKcbrRHRZV9PdBGGMgJRQMdRj+eKimtE8iFIZ3jKAKoRhyD161CGdiscgeMwAO8/TIzgMPfGQaWaEw3TLA6EuDyeu5vRe2Bk/jWbtfQ4bal+5s4poXld2Zl+4ScbWGTn+dWoTOgYfu2Ac/P0znkcVXmOxEtosNKfl+XoqjGT/9bvV2Ta29QwO5gufw5H86paGTGbfKk+Yl36k+mT0qUFkTGQYy3TupPp+NQ3geKNGXbuYhc57bh096bdSeUrPlhnjHoev5iqEtSd8ySBCm6I5Useh9gKbLAkczTxrslKKG2AbiucY/+tUyARtD1UE5xnpnoKrvdNIzNDtYlzsVl5OOuPb3NUBO0rQiQ+WWiUYIjGWUn/Z6kH2otpVaYNggKhI3LjbzyeaHiIYXBYyyKp2jOAAf7vvUUTNPKBOzSfL8kfAL4PVvQZpi6FiJJJ2lmZhHkhowR0UDGT9efzpHXzLuAIgKp858xtxUjODjt1qVTIGZ2dWmAIVB91aICwQSHBmfBIHIz9enFUScfqCQzl7kxtFd28bE4x+9jK/PGfXjBA9QDWd9ngtLO5iwYCzFcvGCG3IAQR0z2I9c1si0F1MxupGnCL50SuNvPTJA9/yzmo5FjFh8qsjA7WG4NlSO/tjg/SszdXPOG0eOysbvw/q9qupaR5S3EEcq728ts7mTuJFY5O09K8y1zwjfaFFd3vhXUGutJtioazvMhxv6BB/Fn2wR3r2O80C5tLi2hsr9gIBLKibQVhyACVfrknHB471W1LTGkA1SxjlXUFjyGncDawPzIM8DIzyeooW1mjb2cZO60fc818M/Ej99Da6k9xBdxgo8cnB3dOc9eMj1rqbXW5X0xLfzM2012YvMHVAxzhz6bai8ZfCy11LToru2MS3d2d8k4Ulo3PJGM9B/SvK5F8QeDCY9VtGu9KZiqXSAlTg9UfsfY+tHs39n7iIVpU2udad1/kfROnwppcPncz2ixCGKMnLJEo42N3PfB9a2dEs5Id97euWv7hAuS3+pQfdjX8s/XNeY/Dzx1ZaxELC5uhLNGB5e8BWkH07MPbNepW1yssH2fIDEfvCBnBzxt989q2p2Z2c6nG8Xua0cql0RoYlIb5dpznHGBTbNUm1S/vpxsjULDvHcISxI/E4/4CaxW1SZYdtqitLt2ZI+VD/eJ649uuat6Xdi5VLRTi2h+aZ+577fqeSf/r0TaIlFxRstaI8c5RPmYBxk9uAPxzmsbW/DsF8rx3MKOpGCGXORXSW+APMwc580r3AH3R+f9auBFaLa2ARjcX5wTyeazcFIyVVwZ4P4i8B3cPOhapNZ7fmRHTevTHOa8717wlrf2CC21KzTULa1labzrfHmNvbMhb+JjwD7Y4r6jvdOilVWDs2/LYI6D6VzuoaVJE29FJ9BjBPoaS547FywuHxS97R+Wn/APnXQ/D+o6fJfDSvE9rFLBCl3HbylzHJEz7CN2Mqyn7wx057V1SeLPEujWq3PiHR2lsElCm7t2E0RPTHB4z716bLoNjqqobq3G/osgAUg4IPv3P1zXK33h+50uO5TTEiu4zg/ZrobujA8HvgqDg+lOSUtWiI4TE0bqlPmXZ/1/kVtL+JGn6iB5Uql+hTdhh+HWuos9ftbiRdzZcvggnGBjt6VyC6J4W1K1f8AtjT0tbyWRCEMX3STyVZcEj73HvWA3ha4sI86fqYRlZRHDdsZhJnB6jBUDIJx2NZ3cdUbU8RZ2qRs/wCujPTzqotlMSsMO2WBPT6n9KdHc+WqEM7bN46HcucEk4/IV5aPEc2jXyx6paX8ETFwhg2zhSDgqeh4ORnuMHvXU6D4ksNVGyx1Rbh2AwhIVvXlTgk1pzPqjpWJpVHaO56b4KkW51u51CYFVgj2wqRwGPGfyz+ddk0olPOck5+lcH4bsrlllNvNHv37/Kk+Uk4/Titu31Nw7RTRyRyK2Csq7T+HYj3FdEJJRt1OKvFTqto3bqSMQyM2Dxyp4zXkvxgvZLLXvDMtj5aTfYZTNJKhc+UJPlIA/HPtXdazd21pbrfa5e2+maQoLTPPkPJjkBAOSfYDJryqPxEniXxnqGq3lvLb28iJFZWzJ+8igQ/Lz/CzH5sD1qKrVkgjSv8ACbPhnXxNBKJrW0MjPtladyUCEbUk3cjHBGfZc9a15LMBUnuZLqW36K/mjMcvQJxyIyOuc4H51zv9m2tqY7zSrtbS6jbzCp+VZlPVGQ8FT39xmtm31F7M3Q1C0RJWVRJ5KHZMOgOexGQuD9OeKlPuXKGuxkXngSK8SRolfTb1QxdkkMqsQcqcfxBcj5gRlevNc/ZX2seFiWnitprMEm5ilUSLcBSSZozwd2M5U4JXOeVzXqLRWioEtppkj2HyJYJVVkYgZ2noc5GM9eQayzpxuJZYNVjj+0MQYbhUwtyAAw+UfdfLfd6HLdsip5bbHJWpqfvGppkr31rZ2wQy2nmr5SxkOy7wQHQn+EhlyrdjWZZ3aRRagdRMi21pN5e+RNoi2/xJ39mX2B61z2nQyaNuI3xaZJKggnikO+1Ck/vFJHzpnClOqg9wK3rHXv7W1GWyvLKZL2WeSeSBU5ePOABu9WApNImhJp2kSS2lm+ohTkNNCHWWKQ7OBzlh1ODjdzx1rJV5o7x2lMklq87QQyHDPGF4GSOv1HNX2klsp1ktLdYYBcPG1mSBkYBBUj7ucnr9KybieO8u57UTywwAsluoO0AKc5LDglSe/akj2KCuyVb4R3DNHctI5BO2H5sn3/Cn2cb3EMzZEaMNw2rhvx9KzovJe2aUNDb3AOyVExy3f5e2a01+22sDPKyCLAf95kttPBA7HHOBWq8z0JSsrIusA8ePOLKu7cZHPJPt610Hhe2mIRQ4jG15ChJ3M3YZ6DG4Hj0rm4Le4RjcXKr54+VPl4VAc49z3JrufCkHmr5srJyx2kdgeDj/AGuMZ96tI4MY0qehT8RwSRT2pjg8vaPvyndhWBBOP72SPzFcxfBUaIS/6yNsfdxtB6foa7TXZQxmSVypjG1s8kluuffp+lcNLeNFq01tM2xFxvYAMRIOh9McijqZ4VtorwqEhNwUVkeXZvOSVG7qT7+vat23+aZLpSYwuY2UfNtHb6jNYlpOq2HlLHIS0u1tnIbJO7AHvnHpV3T5po5F3r5SDqwUEt7cdDWUtTWtd3ZbleRtUjUOqK0bHch3Aspztx681O8oWytZI87EnJJHfPbH14qraQZndbdxFHZuJDjBD56/449qvb2gtTEkpvZHVcBcBQRyCzevQ461lLY46jVrF576JBBLJKHQEKUKFm3Z4GPXJUfga0LeyuFlkmuXjUuuGGPm9+ex57egrG0fTfKupjJNv1Nn3NKP9WVBBUY7Z/PvXTxukqRuACGG4ZPA+v45qThk7PQoaapFs0kpyflaUouBs7FR/dwTnuTV+EcJEEDJjceR8v8AnrUUDAqissiuh2Myj7xBxge386ggW5Rp2QhGZN6iSPeOBxjHYDtQiW76lq6dpJRCkpymCzMnAH1/vVJOg81A8gMpYkE4GR9P61DbqzW8kkTm4ebmMMNq8/xn6/yxUiIsREkpWSd/mdnGCT0wo7L6CqRI9j5rPEzNux1A4A9c+oo0+Ewxr84YMpBZuGAz39fWmOJpUzj7Nls5zliMelWVcB9ku7IwMdcetNA30FOZIgduACqkk+/P9KfMfLhaUKm5RgA8cnjk/iKXMUjypgDavzEdBnvVeY/JlgSEYYPY98kVYkWUjURJEqBgi4bHB/8A11MW2gjYQAM4Az+FQQp5jhmGP4hzgD6+p9qkmVW4BUy44O48c98VRL7HNzM/kzzQRkSW5KKhPO8HOMemPzBFVpGUTXiImEEKKZH4DEZPH1zjNWdO339il48ZRy7OAHDEgcA5/vYUGkYS2cSPOouLRwXVh8pHOfmHQnk+lYnStNCK98qEb44d8XllnhVfmXkZK+uO4rmZ0hl1O/tbqRjaNEtxA0fK5HbHXPIrsAHvLdXtJ4VIyUkyGK4PB+nrWEtkjX6PCWF0D5jKr5Qg5DMR0xnv1ou09DSlUUbmVqM0UdksUYZniONiIcRN2IP9327Vm3gh1CxvLDVLiO08xP8AXSEbUGM5IPUdjnnFbelWiXSajthXzkudzKxYEEjqOTlTzyOPpWTdIuWjWcM0YSHkbwFZjtLA/wAQ+YcYrRNHQ1D4UeEa/wCCDdGe+0GE2s1vIqmKEOVde06sfuKT0B9KTSviX4m8NXTadrUbT+QdjiRdsoweu7+Lr3r2W7cIyySuzR7mguMjlY2PAI68sDjHrWRq2l2OoyX9jqNtFdSlVeEPHhjlSPvZ4yABkdGA7c1cXpqYTwrh79J2f4GboPxL0/WWVLm6aAt1jVfnZsdyTyOnSu80PU4ZYkWDIt0O8r1JPqfbNfOr+HIWvlsjE32iQbItvzeacjHT7r9FPr145roPCkfiKGOCbRr5L2CRzHHbXUgVzwGAD8juAQe4I61lKD3i7mVLHXfs6kbM+j4NTkkkZwMKAOSeCf8AD/GteHVftUaRuymNQGfH8R7ZP868F0nx+bQm11KKayu2OfLuQFDE8/K33WHIIwe4rqtL8URXbIgcRsxJaNvvY9KlTs7M7404VVePQ9PM73F0Ii4yB5sr8cL0Ax71LeSLJLulkXG7kAdvSuS0y4WKA3QKGW4+Z+eigfKucY6dvU019TcF3LL935WODj1/wxW6dkUqGunQ6CSOKbay8HnoMZ46fWsdILmSYOIpbiBM4ZYxk4J4yT1+tZ76lc3NxFblirXBQORxtUEbsD1xx+NerWt7btK0HlJKsWIwAu0j2BFXSXNqhVas8Payvc8yvdJ0nU4mtJcxGdighuYmhk3452npyMng9q52WxvrHxBDZyqWm8sPE7xgmWKLEe0Y4ysbY9xg17ZfW1tcRmN41wR0YdPpXm/xBhGlaLpt0krxPHfJbrKDuMfmLIoz7ZA/AjPaonDqZOtGt8S+8858VaK895DPLCQ53bkgyp2jqw9GGcY/iB9RWBZ6NpsttbjUYopILkgGaRcCJgzbcsvO1hjPUjGa9E1GznuI4rhCzT5WWVVASMDGCc9hhmyOucY6VgXGlK9hHJaxGV3L2hVOElZMfKM8DcDnIPcg9KxS1IqUovVGZcWWpeFfFFrDY6nrWm2bQ4niS4EwiYniRQwKsmCpweo5zzXVaXr3jG6iI/4ShZvKJVZY7CFt4PQqxXAY5GVPQ/hWTtElpbpcTSSW8Uggg3DLxRM2SGGeg7A57YrYhnje5FzDCRfj91KEBEcsgHDsv8Jde57+lO7voVTgmve1MiXTN2sG51E3V9csuzzr9zMUYddmeFyO3btVtdKiMTJOshQoXjYtnPpg9RXQpdRXdi32qBXt5iVkKDEkTDqCOu4H/GqLLBbW4eWdoyoDCYtyw7EZ45HY0jqhUcdELopcYWYk4XCOxDkjuCp5zWxbSNFdPHPtl8+N1VWUkEkDKnPT7o5Oen0qrdW5ljRpGWSEqRHuRS27HG1u/wBOODitZII540yfNicKNp79uD1UitEROUZb6XInt3t4I30Znjl35e1ZQ/3Uyw29SMbcbec4IqtPqcaxrFq9uLaO4KiN4X8yMnJbcuPQ5OOoyevFW9D0wjWvOMrOyKzt8/zOoKk8H7r8hgfY8+m9qNik0U6sY7pNuyReELgt1PXD8g5+mevFdNDiqJRdr3ON028ivY5dLu5IWmkkm8iVGBjnDE/dB5SQA5K9TyRnnFfUrGaK9to1Cfa7F3ENyzt5nzbmClj95WPGOvPtUXijwyJ7SJ9L+cRjzBDKv7ySNcZCtnhh175xxg1kx6pJqmnSxNclNShO5POkGQQ4PmRMcZxgbgeVJ7Ais23szLWMrnRafcRyyQpO/mRyYKfLtYcHIJ7lTx6kYrLuriSxuZYXhZo7iYuCP+WbkdW44yPX0qW7nt9QePVtOkUR3c4jutNbCSwXLAh1wfuEgEgnHKgjNOnu08md0kKnIUblBZgB1x3J9SeKaZ6mGmmVS1ss4dJBETjO3lmX/aOOf6VrrALu3uEnkcxAhAitw+RkFT6YPX3qjbSPvy8QhMwLDcAT06Z6571c0mzSBmnjaVPMKl03EheOMA8D8K0Sud03pcsyPM9uqvGSynaNpIAGO49feux8NahYrpTXVwkdvbmMKY1b5pGKggAHpyjcdfyrBtxG7qHIbZLyuMEgn19uua3be1h/spY7kGO4jZ5YJGXKjDgKwI74PTrz71cV1OHFuMoqO2pzt/ezSRLMIw00rkyAt91tx3Y7cDArn7jTVeZERAHKvnILLMDg7SOnHSty7mKX9y1s7eSrGIZOeSDu5+oI/Cs6S5VnhIl5R8cHG0MRgjrnHGfYmk0mrnRRTSuivHpz29xHvuJI7AsrMsXTeeM5PIPSt+zs4IWEqruSHd8+77rDqoHT0rLnLS7/ADLtw3lMzbFChOMBR3wc9fXNW5pYraOOSRGH2gIoMpwDuwc4PvWM9DKs7rUsTabDNauFSWe4mZS25iM56ggdSBVuJLUTS3llbAJEDCmU2xgr95z6n29uapWd2LjV7hHDJuGVG/OQOvfg9O1b1uQ1nEOY4o92Bs27Tj+7/XvWNjgm5R3ItEmja/mmtLhjF8jSs4/1jEcn+XNaYVV2uIhsMjHDHkEk9BWXYzpZyTt5RYSsoijAALMgB2AdsjJ9q1bRAqIJ5Q1wqeYxXgc5yRn09aDGo1zaBdTXS3CxQ2z/AL0BjKCrIhBAKEZBDEYIPIzn8bcEvmyyKD+6Cg8d85x+eCfpioQzyFl8xDvXDErwB/U4pwaC3cBGAJUEoTuOPX9en+FMxe1i1zD3JiHIPTA7g+1V1mQKstwAGLEqD3HbB+nrSuZ5pAWBiiPJzglvoOw+tK8YjcZJMjL8gK7if8n+VMSRIjCZl6sw6BeAv1bufpU8K/KWOAnJZwOW+lRFnkfySi7R8zlWzgdhjtmppMzyeX96Mfe7En0+lUhDYI9scalD5krl9nTP19qsPapvijf98ysdxJzyR1pkAWOX5FwzLwR6Zx1qVmKIAuNynOff39KpEu4jggyAsEjC7SWONo+vb61HbuZEBRGQOSwyvO3JHHb0605IslBK53s24g/d6E/4UpRTKXBAAHr0qkBj6dD5VisEY2rHnC4B+RuQDj8RTYStwsgZleOJyQpOQGXg8fr+velt1iUqqgR3AXYu0DBAGQRn+dQWyKJp1uIQwWTKs3JQ9c/gSefTisjYjFqtiWuLZWFvI5dou8frgf0FY9xJ9puojGqbnZkSVZF3FWHHHbkdO/pWzqjPby73cmFQXljwGOegdD3HPIPNZE8dtbPG1vDujWTc2OMsV5/Af/qqTWFn6mRJdQ20iXN2rRXMm6KRYGKguOCAOhPqDjsap4efUtRBS3t7b7GIyJZt24bSQz55GPT171qeMWaeFG0xZZrh5FPlMSUkbBwSoOSMZ5qo9jbyWdube3LymEyTMm19u7k5U4wD93BHGPale+h0J3Sfc5PXp9thHcM5gaRftBAT5lMPO4n73OB16g85xVyGYT3NzqCfaA00ipGjJ8qxSLlSwHK85OR7YovtLa/vVtzDsRCRMjv88gAByGH8JAwOvfNWHWe2jZrKW6ubPJWazK7VC5JCq45Xq3AGDyOOCdIu2p1K26PPPGluY9XLafHE0kISdWWMSDcApDAHg5ZiD1BwT0asHwNdzaZqrWq7PJvVW4tHkYmNdpIdJG7FVb5u42j2rt9dmt4NVsbq8RSttcKPnj8pTAFCBcdApGOf14rjNegu9Dnd9OlUROxvLPzQP3qHdsyOdr4LBkPDA7W7Yae+p5uLhyzVVb/odrrGgNcl47uzRIVk80xTgOrDAQlQxGc8Yx3OQQK5rUvCltp8t49pqU9iIpBMqMuEWHgEiJs5Ic7AcrnGcDvr+GtVXWrL7bBJJb3lvL5Udm/zeTv4aMbjuIwRgAjj0xitKbTft9pdX8U4mFxKYRuIeRYlRSMpjn5i+fm9OeCabXSwU6amlNP7jm7C48U6ZHGZ7cX1u6PJmOTY6orYOVkwN2MHAYnmtrT/ABrpjXIg1SWfT7ngql5EYTg9DydvTvurR81f7QnF3bxxm/Vlt5CzkSoAAyjGF3cKMYBwevc0bTR0lmuvNZXkluZIEQAYXYoKpyTxg85BB6e9LlS2OmM66sua/qdlZvaX4e4juo3UQsEeNlwGxkMTyOv6V1mj6hd6dFEZ7eVmGD5sP7xMkdyMkfTGa8Og8N6Z9k1G9lsFjaNt8b2ysCpJwB8rKMg8c5HNQ2set2OnW0tjrWvO87kLbJfNggMQ/LDCYx19veqhPl0RFWq3pJH0INfacEWSSXcgB5iBOPpj+deSePtY/t2XT7XShDNpVhI8kt0oLJdXZK7gh/iVAoGRwT61gXmgTu1lLf39/fW1yximWa6aSISEArIUBAxyincCDurqdPt/tlhYQxGTZbWKGAABVSRmRmjGOAQAvHsRxRUqcy5SU29LWR0kV3JNA8ElyW8yZZkPlZCsH3oBjryOp988VnvEYLjyYkQp5zTRw7sOrDrkfQjBHUNj6T2RIt47Z5HjLuXCqcsSeuCBxlv5elJBaxN5yg7mwD5sgzl920Nu5HHQYHTucis07m0FyoxNYhPkxzApsl+4sOI0CqwcHHUEMpBOf4l9MVu3sEt1cCZWciPDKzysS4zuBBX5g3UemDms7WgPtS3ZVFjuFzIFJBDMctjIAB3cHnGCPSrxuAyS2swlS3XBU5DbMjAJB5yD7/jTtcunC7Gu89jdJcWW6489C0kRyWkAPBwBjIHG45PFWykV0kNxaTtA0isiybF2sP7jIR8jDJ+tSWtzdSmPz23rM29TuVSjrxlW6jd/dbqc0psbiOffpoMlvOcSQYw6txxg8Dn/AOvRawNWE0iyijumUbROq+XKpOA4HXAHGfT+VXJLGC31GK6iQLGxAc4wjqf7w7MfXHPB69ZdJuIZ7RZRhmlBGGGN5DcK47NkYzx0rWmtF27oI2A5kKZ3kL3wTySDnj64q42aM5SdxU0y2t4ftNrG8LIABjgheThuTgrnOR7+tWY7mfzkaa0DzIxWUNIAw54YoucqfVe56Yqtbl2mMEly8T7MR8kF+fvKT+PHOOnsa2qS3un6lF5zbbZvkd2ULtkH904IAI+nIGavbY5pXb1GXUCpK6gtgtvj25O0dRg/3exB/XpXFa3bWsz3d7BIP3m0yxvwGUDae3yuuMbgOnrXX6lczi7VIh9s+QxyggAqD/F2B7decHjNclrLi1WSORVZ5W3xxlM4LD74Pfpyv0POKzk0waTRh6XP/aukrbxxJNdSJu+RgjytGzSZU/8APQckdMjOPSq7rLpl6ZJA95FKovI5VADtEw+ZcHqw7j0qhOItLMF7Gpkt2UNPvbbIjA7llU4+YjOD6VPcul4tzBZyAeTL9otJASzxqwyyqc4Izk49M1m/xN8O3F8rOih1iyuFtpkmV4ZcDco5TPHzj64B6GtdVe38tQAxeQgADOB64z9OnrXGWube782VLdZJkABh+UEgZwwPQnrjPuK67TSBDGC+UI4cnv8A0xXRB8256ql7ptWS/aLkblkWfJUlBjjGTjP+etdjeS58OobYiScRsqQQjYmDgZHcL0+bP07VzGmSNJOiBSrEkoCM46YOa3Ttt7EL5LxyxCRWaNSRIpwQQerAcegGCK1SsjhxHvSj5HN6lbWqWtofMbzxHtll27Q7Z649jgCsRURndo1YSI53sOCPf8Of5Vo6lcGS5Deav79RgBDtBGSyneOp7dj+dc/5xhwsVzJFaRZZsoM43dFPqCTgk+lSzupxkoGjpksVzeNcvJIgT91EFXczMMgkAdu3sfSny20T2sCTFnVJ8OXO7legJ5HpxVvRorc2UKFFUL0VSMrg4IP48k89akuYm+0ToqxNDcpwCxXEg/DHI7+1c89dzlqS5mOtYkNg5REhkwk0cmN3J46Dn6/XFbj6mghWETrHOOQ0ikIuDyAcfz6CuVsVSC7jASdI3G0hFA5JztJ5BPHet6B7aa4lRZYpBbSDAz9zdgYweuB3+vSosclSN9+hdsrW2RhcXODMy71wv3ADkge2DnJ5/StGZvJMc0gLQFht3nDAE/xH+QOMetVbi8E16loyK0bNgsc4b9Mc/lUrgT2rQ4lkAHlsPm2kZ68mpOSV3qyW7uJLmX7PaRfvC4EsrkbIh35B5bHAH51fgCrlQAwBBYgct9feoEgACRoscMS52hOv4dhStGuMkzE4AVE9uxpkaE6qXaXb8qBscE5wO2frU6ISAe68bs/54qGJtsRVU2tGxABOM5Oe3Wp2fAXy4w5zzg8VaEwZmR3VNrFsAqGx/P8AWmuZDujjXEknJZm+6vtj9KdGyxodyyZ5Zjs4/wDrVGZ4xvIW4fecssaHJPYcf1OKYiYsUlWJXyGTlV4wAe9SIC0oLELEvRVxyfXNQ2q+WTI8RSRu2chR6Z9as7k3fvGRVHJBYc1SJY4uyZIbg/Kq45Ix79Ka6gOrSbiRnAHb6D+tRNJ50geJC+OBn5VHqcnv7c1IokCkzKDuOQAw4x79TVIVjCkYteR3S/u/LRlk3KRg8Ag/TA59MGpbmULGkzA7twA2nqc7cA022Mis1xujLFB5gY7d7EDn04AABrH1a/AWxVw1uJrmNMyDALFl49COOTWDdjfc09S06G8ltraSWcIxOBvx0GcEDqPasae7ZryC0ljDTxSFVLOMZXoMfTtW3cXDE58qR5Ey2YSrAH1znA/H8qxorJ57ON5IZA0chnMjR/vvOzxIPcdAuKkaZlmK7jtb2eaPzJMmNdp2qVzwV9MZxVuImzhkjb/XwqrrIf44m4OR7OcEfjS3d5qBtcXFmpRm2EW8hDvj+8vbnrgmqR1O7uIFH2eRpVmaDbChJeM84Ge/Rtv+yead1sbttrY5++Mr6tFLjbHFiJSTlW3HLKc9+nJ7j1qz9vS0eaKcCSb5oQFAyw5br3x69OevFadxaWbCKyFtEYmUlyzBT6EbunLHv0OcVy1vcW1/aLC7yedbAh1frOYwTgEHJ+vJPIFNSsjrjNSj6GDqcks2oPEhWOyvYniV5VZlzkszfJwNxBOOeDnmuL1Oa6v4YLedn22jm1R4kyzjO7GG4PUYAwDnP8Wa7XVmuLvzZDOLi3tlafyidnlISQrJnB4JYjjjIBriZ2a2Ek096+wPiUxjLbcAq5AOMjp06E4qbmNa70MPw9rkeh+JLhZLfzop4nt2eKQqELqVSVN44A3Zw2ep6cGvT7HxLCrNKsTQ29vDFayyJgygxoIwFBYAjCKe+cn1ryTVpxe2zIHtd0RDktLtWXJ6Y443cgHpXdfDu5fWLY27xOLjT2Ty3xhtxHIYY2tnAOf97r1rZptJxOHDSUanI3odpJebrwzvZTYRViXfA7RxMxDEq+CVckAc7evQCrwFxYNGiwhp7i6a6Qup3ykryqhRngdccE96q6hHaqgv5t0SzNGXWGXYoccMOOWyQF6ZGa17e0SGaO/YwrO3m2rlzIywsq5Urt54zjnqeSaNT03FK39dDmZR5cdw29o0iYMsJBZlwc4z6ZxTIRs06zSdZpJi8yMjfL8oKOevGPnYgmui+xteXV9ez2TeQk6Q4lyTuZDgkrwAMDkA4yKk0e0I0hN8YWeG0luiX/1kjSu3JOMdAARnnjNTymWknqZenKwtpIJSsw3TJGOSWdSpAI9GI9fu/SrHhi1eOyiMEjrIJmVo2zlNshJwfUc474x7VZhtCZ7aRUeM20wbzM4B3ZXeQOo+bH0LetWwq21zBc2yHy2nbcFBbcwZ9q5JySPmOeuAlJKyuXLdWL1s0EM8Utuvl2luJfKLEF9xlwQ/uz7vZQMdQTViaKOa4EbvIltGpRRF1c9lx25I/CnWyx2tidgZY4gQ8ioCMFiSQB/Dli2Pf1qS1S4jUmSQvKzsQMfdIwCT6gnP4Yp2FHRGZqllBFBdSYRbZ5TcM0YznoCv4cEex9qz9ca7tLy4DQu1qrOMkHMRPQSDr36j8cV1erW6C3RJSgjDK0shUL9G79Mmor9XvLq7RmePfKJonUgBWYdT7Y496C4StJPoY1vaRR6XHs+fyRuAAGTwDjg5x3Fa9uLi3uUu4SjxXUfl7JOQQeikDqR69ap6XEbcxy5DpNIbdpAuRHKM446cjp2roNPgcXBtpkDCIEoWOPMTv8vQ46evOapasJyXUzbSCdohdxFIXZAZw4OSR8u8ZHXjr+ddHaW4W9VtzB5QpJzhdw77R0PvSReTNGtuY2k/dF1zy654b6njkU2FXtGwIkki2CMR46oAeMnqcY/L61a0OWUmy5qbGKxYsrjyfmORv79frk9O+eayNVvvO09gisJ3jQ4X96qHlgChx0wfQ44NN1rULqN1gjWOWJI5c5kIcEAFVyODwOp+lYsb/wBo6haK9q0nkxG4MZkwjOSoZ2A647Hpgj0NOTtoCjpqYVjrF9P9ot45WKBiH3beRnGAP4MdFYgr0B7YZfalO8exTLJIXZUWaHzFk7Bi5wMZByO3pW/rVtZ7Uu5bRPMgVpX3HyyykAsCy8sME4HqOlYCWTrHIkTzyW9zjyVZ+hcklVHIyeD26+9Yu6DljuZKu8loHSyYW9qv2p4ZZBk7iVVtmO2c5A/pXNadMuiXdncws/lzqYrhXIO1iSDwM9Bz2OK6HU0E+lStcSGSdYHMMiLhSR2YdeccrXNJcjUAIfLCNKVuTL9758fdB6A8HrUlXS3N1LuOK2dYMvErGMyA4WRFI2sD3GDxWvppnjJkjxNEhwAzYK5569x1rk4LgBUACeVMrtHG44jfIAx7MOceorq/DgaS+3SYh3Kdmw84A7jp3HNaxZ6UX7jOljz9rtZYZntplkCgyHcuNpz90c544rp9fW5u9G8yORMwAJKxfEmGXGHAyMglRjgY+uK5LS97WluZ9olVXRgv8IAHzH681p+Ib2axj0xLd0n/AHbCUBgFVm4CMeueMjd/d49K3vpZmFSN6kbGJehTFFC7KrsP3bqGOOM9/wCf/wCqql8sTJsVPJkIKpnHzn1z/e6nHtUdxNKZvOikSZXAVlklACyAbtp/iUqWwCOCcCkkaa/tnnklYpGpfyWQLtIPHfPGOuevSobud0Xpc2YEeJxJEqSmUyTFU5GMjp056cd+lXZJrU26tKDvbK7j8rKvfbmuaTUJrLU1D7mtmVZo/LUvgtjcpHb1GfetgveTXmLxmW4kOUSAbm9cA5+XjqfyFYykcdRNbl7TiLy8upVgk/s6SQBGLBQoVfmcDPTODWjpMcN3C8kUWFdmzkcsAeSre59Kz40E2n2qXHmJBA8kckO9WLDJbk9q0NOZoZkLnNvMgkjCrny+3lj2IOQPriskziqMs3beVLG9of8AWHa8MpxhsZBDDnIAIx39q1IcGF4cyYCh1j27VVTwQB35/Cql1bedHDGpUsXyXXjAHYewz1q6jFJT5rOyQoeMcknvnvjA/OhHLJktquzMYjKkHHzMSQD2FOgXfOSqMrIpVDnaBnA/Hp0p8ZklhxbsY1Ycnvjvj8OPxpgYBnEKFo+ijICk5yTk9R9KqxOrJ2BMQkkdcrggkbdvuKSNhslbLuAcnb8vXoAe9I8YDbmkcOBnacbR7gH+dM8n7UIpnmkdcFlUNtVseuOSaoCSGOUD9+VjT7yomXP0JPU/hViM7SNkU2euT2/Oq3lxxMCkaA4wzhjz+PWpo5MN8xkyMcCM4qkRIm+ZmHI565GTUjCJYzkhJGGc9CfrUKs7A7F+X1PBH4UsflDASJpSWJLFN2c9ee/0qkKxPHFIwB8xgAM7lINN+0Drld3UL0J/ClIjBchFRT97bxURBwNqEZ74xj3zTDcyG8ywiWGVDLbHKo6rztJyAV9s4z6YNLewxXNpPDcxpKmNojIz14A+ue9W5DGqNBJmOEAbHI+77Ux4wHDk5jH3tp6seh9+KxZZmWkZZSohDyJM2AX+bdjv2z3BqcRBiixb02JvQsxBLZwQR6ipJGADyxOuc4Zk6/QiotRZ0aOW3dUkPyLnn5z0JHp1B9qRa1ZRTzBdSTDIVmJ8oYba3Rjj0NczrN00sSNax3RaaVYxFyEcoSSRjlSMdehrsLZgsIW4kSGRDucDu3chu4rKle2SRLd9mzPyKnJBH93HuQajU2jKz2OehiS9sLhPNLSXFvkqcsVZmZSB+IU4xwc1XvLSGHQHljkWK5mi8iZUUAfLnaM/Qn0yDWnFHLNcasFQw3k8gWNiwAZFHUejk5/OmX80cOmTNJGC2xIos5Awf72Om09T7U0dFOTbS8zzXX7S4NkkcirF5kazLKGRWZSQPl56YOMe/NYFwVsFmgu9qT4zE0ZHlyoO2MfeXBBGcEHtjnu/E+nrcadHG1g7yxskgl/heMkluO2RnnvXIeI7FVs4r21ieBIXXaSucN919o75yM/hUy0dzWrFNaHH3ekfbLmRLay2mKTzfO8sFArDK7lHJU9M1R0q/m0LU7m2V9q3GESRcqEK4KnBycDnHcYrpftcrTrqGmySLJCER0VgrwEdCqHh04x7EYPUZxvE0Ntd2T3TWhW6dgWlQkYfIw2Bxnrke/FawlbRs82rSuvaQ3R6RYaddz6cfMvvPjj/AH0JkAaM7uWA7g545rasrq3m0KBb17hoWO1mwWZWHyrtbjp054wT3ryzwJqMeoeZY3MpQiQszsxIY+h5xjOcHtmvUoxDHpLxSEboZHjCO3Xb2x6c5B700rHbQqKpBHQ20FxNOYERoYNQiMcbNKWG7IHy5znIA6c4qXRrOPUNEspwY45J4lhKB9u1/mVwB3wUyM4zzWPpt5gxWM7/AD2T+dayBjmRMjofXOPyxV2yucQ3jYLwvMl7GuNpA3OjEDv8ynp3Iq0y3F27f1/wxpWsazajDDhk+0KseyTEeXxnB9DwpFJAEjeGS4dlsriLa2MkxzqZAzfpFjH901LeTPb2ZnCZmhn+0hurAFVbYR6ckY9qa8MK2cqCR8tcPNbYJURsHYOQT0DAkZ6cgihkTWqJppY4rKG2YeUgjiiVljxl2J8wEjqGO1s9i34VpTWZmhWMFYxcLvyQQSQoA47DgEd658uP7X0+1NyFhkeWRsn92Fy5ByOxIHHvWzo73UkE0N0yM8MzqqhsllB6/UAYz3xRfdmTdoqxYDGaELIqRxjJmUgb+McegGaqND9ne3hvJE/e24MWwlgCGyAc+menoSO1XJYSt6pBLlhsZB90nsT+GeaL62W7hY7RtiGVjztMo/2SehH61A1LYr2dot3HMJY3zc5juo/+mi/dZB3I4OTT4IWaExKrb4W3B3bPz4+8o/uMO3aoY7zdciJsCecITKVK52/3schh+vWrCX/ns4SSR5bclWjSPLnB5wB9498jqKq47u5dz5sCTQgx7GDgDIHXDgjqDmrE0v8AxLzIPNj6EOwCsBnAJ9cA/kKrl59gby445WbJDY2t6mo7uRbWO9lleSYMfM8phzGeMbR6ZGT9TV3JauZN5OZLD7OI7cSKqh15KrhgRtPBwdp9wTiqkj3ttdrLYzQwSAJDLEilg+5snOeV6g5+tWdXuLGykinkMhilcG4MQHCNyD6AbguPbPrUFo1qkKrfl0l3M29Ac3DlscHPbIzS1Gl5GWHnv55LfUFjtjEzYEmUZjuB27uVPQ9+ayLi8fTJJIBumlb5oICCBt4AbceoB4x16YzityQRyGeyUy2snyjJG4sq8K6huCOxFY8qSuZ38t5ILVzIBySJOhbJ6gKTx0x0rN3FO9jHuIruNJJQbPLo8ZiKkFj6Fj/F3ziuOsppLW7t44HKuTHHI2QVUsSwBPQDAP8AKum1J1ZEXz4zDMwkR0l37snbtPfJH5CuajtyGSaxY7ZWZpoGOUKoxRQPz79KjqZ1HsjYuDGoHmp5qveeewTB/hyAD3HA9MV1WgQESR3EckflKgCxqSQyk87ien4/SuTaKOGGxXYWNwi52v1iQ4xz905GB/WussJ3jWLy4DHGzhjsYOXbHUD+6vP41rBanqUdY6HcQwrLshaDYrRNMUUAMxJPB7BuOPqKr63N9strd4bhBdRJtkDxfwqwEa55y3XPPXpTLae4W3t5flLON7SH7vBx178AficVa1eOEaLpUUhkNz9kDOqtnzd5LjIHRgd49vWt7akqLjUizjNTtUs7mR4/MklKiMmSXaA568Dt1+mAKjmv4ryKSNrcGBhxKBkggYO0cZJxnJqMCS/lt5ry5mInV2VZhgAcheR6kE/gK6VbaZIy8bRxsmM7TlG544rN63sdkpW+Lcy3ayXS/LjmlFwYu4xvPrnGNo/T0qx4YmcTxreSu086breR3CLw2MDPoR0PJpY7eKTXWjnEsIIDBAhKgjOSmeo9v8K0NLto/wByzxzvbyuxEYQHIHHQ8qeM496xOOq0ovmNW5D7EkEchJnVdysGDg5DJg9M88ZzWdbzX0UstrHC8biRUTznUuq9sMDjp+IroWtEuomWSMRywusqNIcBfQ+5Hesu5VcedYQLl4wwZuI3YHoB1znnIrN9zzOa7sdHpqefCJlkDM2FKqMMg/u+39ajv42+yOjFWuHk2rgkDa2AQPTg8msbTNSadoreZUS5Cktu4dWznAH8YHrWnb/aWcC+271IxJ0Rsc4QdvfNUncyd09S+8/kK6zO0hZ9iiMcqhPf3wDzV21E/lxln8nj5UjC/Jntk55A/Kqk483ytnd90jL0YKCQM+5IBP4d6Hmu5Lp4/MiiOcEbSw6dB9P1q0HxFtxK21Y3wMffYZbJ4+hXGfxxTN7CfjzQwGFOOGqdoFKES75Tx87nHP0HSnvbj7pldl64JBp2IuRRmRsLtIHOcnJz9BSAgSlHZhgfMxbr/wDXp7IMlSxkGeFHf64qSTybcAS7IgBwM8j2pkseDtUFi3PYjk1IGfOF4GcAnr+AqkrpKpMeQDySCc/Tio2nityN7uwVN2FjYnGeapMe5dnkbcock4OcK3f3FMWfcXBGCGwW3cfgKigvYZsFGikbqBuwcds+9TTFi6LkRlRkkYbPtTArTXikbCriVuFjZTz7g+lRmJrYI0Y2pjoo79SSP8OnNWo5QwzOwQg4HOecdqhaLcoKs6up/gesmhqS2ICI3ClUzuJ4zgj2JqkI7S2L7g+5Hwrglj6lfpVhraYz5W9mKnkK2PXsaaUmRhHlHhX5WOcsCec1Ni0xSIPsfzlDCDxGxx19D6exqhesqLIYbbD4DIYdp9iCenNX/JCglYIWYseH53A+1RSzAWrRIyhTHt3MuBG3PBFLYpHNap58GoC5aMRxogimZx856ndj1Aqa00i2aG4lkHmRT4DsGONv93H0P14qxqMQuiqTecx3ASZPBIBB/n09KZDJNBNdWsnmSwgK4ntzh+RzuXjPTtzikbRbWxg6npl1ZW8VtFKskM0jJHE3/LLggEn+6oOee4ArgoNNkhnmF61wAQxLcSBEJKhgvcDb+BIr1G5kjj32k7bYJJV2SAncUYEEHP8AtYH0xXN60wg1X7TawSLHbwt5seMqw+XkjHBbOB64PtQ7HbCTbs+p57Nov9mXLSxLLJppjwJEXdtAOGOR9Bx6isu7tbO8tQ9zIHnCsrOj7VYAApIAOd2MqQR2ru3h05zcILi4s5XAy9uCRJx8ysvHPY+h/CvN/EdndxXix3ESbo0jSZ4AGzkfKWIPBx1x3qdETWVldf18jlr21Ok3cV/pbOk0bfv4mYbevQN3yK9M0DxKuoaFfTQ3cyvG3nmA4LhuAd2e+O4rz/VLaJbT7SPOiMjjaMbwT3wOgPselZ1lfNo97GimUxTKVnRk2kkHIbjP44reL54+Z5Tm6E7rZnue8NGl5bkI0MYhP8YXeCd2OwB6e9WdHvrezl069KzTAwLHIspyDngk/TII9MVzejXqNpDzxs0VzIgYNkvHPGzL8rAcA4zz0Psa2na3huEunTy4JnWQRK2VUFiGUH1HBNLqenGrGUUduPJjISQh1mCu7Hk8nsR3I6fSoY721VZ3u5S8AEsETyKR/DjkHooOTjtmqVleXKRiAGIRRlwrhQ0i4zwynGecc+vPrWBcF7uVooJjexWUswInG1pZSRuLj+6AEIx1JptinZq7ZejffGLa0CJDjfH5pCiRgmW5PTduwB0wFrofCtwZrxVt5LkhYUEzygFkJ5Mf1zu/75rCe1GmWOoLcrE0bqWUleUUkoR7bRtOfT6Vq6WGspLjd+83FclDgvhRke+7jHv9aluzsjNHZTFIbYm3mGOjK2SR71Vmm8yGbdMqW8Y/g5c/4DtxUEN8J7SXfIQgwy8YYDPr3xUrkLFKm5UhZex4z6D69ea0umtSOXlM9dOs5JWuZln3pEke7e29j13Hn349BUVxazLOsUt0BI6eZbzAbHLqOisOQeBkVrrc258gmaIOQNzbscHqCOxrntSv0uJ5cymON/njdY9yI44Dhj342ke9Q0Um3qX/ALZfNaziVfOjCbt0bAuMdeB179OuOKuRS2GoWsJt712kcbfMiOXIPGOfx4rCjc+XbvMr20iAeVMn3Vz/AHh2BI4PrWbdz6hFq812lsjwyrukkWABJD03fKc8nB3D3pqRL30NK8R7eMLILe6ldmcR4wFGfmYeowMbeueBS2GoQZhS5jeEW8zRBQf3aEruj3HqM4259eDWeXlllVWcw3EW8o2OFyCUfpz3/EYzVOaX7Xe/aWsmeGWNBNK2+NH3dnQ88Mp9uhzg07ic+xratdR30imytVuQEx50g2xjpu29zg1zd5HqUc4t9PuAtzsKvbY+6q8lo2JxjPAU+ua2WN3bvc3FralY/K27Y5wd+B8pQcj1OB2FUdSW3g02VXjtpkMaqGCmN0bJbknucZz07Um7ickzzzWPM/tKa4ZLiO9mDFUlOZIiBjggbWqDUZkaN/JYqfs8abYRtDydSfzx7GtDUnd7+2iRiyykTBhhVwDtJUn1ByM0mm3EGpz21lZTxo87CNlb5VjVCTgg9MAFie+ahLoZc15CaVbwzXNvANys5InVhvIc9OByMfliu70ewVNOiEXmIpEpLMMYTnIx6Ejr9aytDhiutQvJ7eALAspljdPkB6DzCTzt7Ae9dHdzF7ALHGBa/Z082TPyeWrEKc9Tndz/AFrVKyuevh3aKSOs1GdbuxcWsnmmKCOZnRc5IIbntg8DA/rWHe3UpgljEJkmOWLdAkePkXnv6EetWLa4gu5NPgtlkMEduXKdApTAHH13c98VB4leQ20QMwZGhYORwFccY6ZI+b9D7Vs31KppKyMnTFuJI2S5i2okbIm4DIIXKj6heM+uO9X7O4aEJA1u1wkYzuB6EdSB/EoxmoTYXMsaAjy5XUyJscRjIHzj1B47++O9a8MaQfZ5YQY/MhB2kAiHA+U+p69Rxj61EtAqVEirPHFeTbXUBVia4SQ/IwwOh9M8n8aFtntNRgkgnKjLIxY5AY8gk+p4BNXFltpSybo/tzkK6SOQZV6MSozg+h6ZI+ldBHbW8UDyQqTC64ZwpJGOMsKwluclWo07MzrGW8uVaS5jK+WWJUvuBweOnJ696vmFpo/syB1jD/3/AEHLE/3uuKlsrKDylmtNiQwZZQrHaRjLH1B+tVYNReJoCUVPP3M/mPnyywyNwxnIA4FQcbersTwWItWt/tbGTDYR5FJcnbjr3PFaa2628APkou487ySDnt+eKihn8yXYRA7HDEudxQYyM+h9qm8qSe1llkJA2HZGr7lOOQSeo+lUjObcnqLDBE0p+RJZB8vU7Ih1x7nvxVhrK3dvNdWJbhnLklvqap2SXCTtICDAo2iLI3qf85+uavyN5k7rCsSyR43l2OeRwQB26j8KvSxMlbZj/IjUA7WIB4GT1pRbo2GkCqRnG/n8aYyuJIxKTJ3wG4zjrj8ajupri3UmO3e5kxxG7bc+mT0pkoeZF+VUmjiA67T1qNAJQWMTFMA7nGFP0HU1Xe4kYfZ5IVeaQkyiPhYx/EWz+WOtWY54ZJMIfOjH3GT5tox90k96FqEkWAEKjBJGf4eP5UgthFIrAyFs5OWP6GpXV1w23DA5wX28f4VTM6hmVoncIcZTlfqT6e9URYZd6fBdK4WR4LhuFkCBW9uay5dFvLdP3WqXIhDBWO3LKGOOT7ZHP0rWN5aEFFkO9m2bVQlumTgf1qnf2Vxcxp9lkmtjkfKzEjGc89s+3SpaRabWha3oqmSbDNnl15wPf0pYphKX8nE3AY7GB3e49/WpmjEm85YsMjkYB46Yps0UUZLbYV3DOD1PuaTuXZDRKjEhygAI4fKn6c96q3EmyUJGVYMMs8ZJ2j3qy/mq8exY5IWztJPIOOlJMoQI4O0K3zIW+9nrznn6VNiSNZY2kUwyIcdOegHeqkqLdFgV3gqdzcg9fWpLl7VQJTNEQpOdp5GOvTnNRxxi5Pmtboq7NoRX+Y85LMOPbikaLQS5Maho4zC7kYZHYDK9OvYis8mIFriMoJoxhhIceapPBPoRjrzjHfpWjchIpQUiAh8sqzEDCrkYPHp/WsfW5CZBBpgaSYR5eSMcMpP3ST2OOvr+NJlwKetTWc81nFHCzySK8RVCQRgdWYZGA2Dkcj0rCvlmgRyyBpPKaV5xKZElTeAxBA6YJyDyCq9q27W/M1yYLqYwuV4hEe3GFycDn5hjnB5H0rP8T+F7e+0+aZLyIIgLDfgrJkE7cg5wSTzUO/Q6YSs7M5vULu3k865jhUwD5/NnQ5GBgKe7Y4+Ye1ZjabNcxXTuYl8zETKilcE4O3HbJx9BXTCJ0sLSUGEG2CPcG4IeMpt46Y3DHf8ACuXe4u4tReNj5rSybop5ojGpQ4G9QcfKOCBjtQnrdnXF82pyOr6UbVrqMRG3UyOYyRuAI25x7e9cdqyRfaEnngmEkjFXnxtWU45G09GHYivU9Vt3bKPe29xFF86LDHtycHkhuCc9+c56YriNQhjeC5gKxyKWJf5idjdRhR2B9MfWi/Kzlr0OfVHP6TrE2jAWV3NJ5ULn7Pk42AnJ59/xHWvRvC11DNNbTwx+bBHb4lUncMNwWx0Pr7YNeeahYSTK0V2QWEWVYfeGP4C3ORjkZqDw/qV5oN5HNbCa5swAu5Bjgn+Enkc9iMfzrfSbvfU86EpUdGtD6DF+yqZYoWxktJLE4cMVBOc9cZGM+tZOkW6POgvSAdolYtw+GyxP1BBGPQ1y2i6/aaj57wl3dEJPAXDdsg/L26d+faurjmS+0u5uI3iFxIvmARr+93A5UkdCBjnA+vWk7t3O2NTmWho6kWGnak29JBYx7YkPJ8xZAQx+q7eDnvW/C63qxOUEM0blWyMgkLkEAdiAPy9q5Vbma8ikhIjh3RqZ4SMAEDkAYyRxx+Oa0bSeWHUrZ5EeOOYY81X3LIrA7ZB+JwR15yKQOVtjT2LDqUxkDxyXBGxH+bPOOvTI5I9RW2ZUjRUkx5LscSOMMPY9sehrntRuYrYxOoAklO105dSeMEZ59T0/lSLfmG48q8dJFAYsQxyjDHOep65oV1oEpdzadXlkSRoXYq/zEjarMe+O/FLaxZilVmjjDFl+VtwC+nTg8VVfUXS5t4UDzecu7bvO+Qd8ZIwMdTRPdIbcxpCgQuqbZRtZQT0H4d8mqs2Zqa2Hpax3EkDOmXYqyIAdiqVPGPXj9aZJZyM7m1bybiToVOVnXI3LjoOBj3zVuOJ0gDQyo3lsy7CCysB05HTsKVbqMXZj/eGVUB8lcMy/T9Oe9C0BtNHM3GnXdpdw3Fv5WAxyiSlSu45z833TnHB4zzVyfW9xgk1G9XLBkEhjG+N8bgdvpgdemVYVuT2sVzaTCRFCgM4jfnAwevfIJJ/L0rl9a0lbCZS0a3YI8wxAhioXqMcZB9M5zjk03otDJ90WtQsEttJnuIHMspGySFjujJIyWRgOuDkY4HSuS1CXztTuEvy26IrlphkYCEfMejDJGD3J5rYt4riyZInlg+zXKAxL0QSFdw3qeVyByQeSOTXO69qT6XO17tWSBsRbdpKsoxtCoevrhuMc0NKwOaitTB1K3M4mRJ9u1IQ6KofaDgsDjp26dfapPD0DRpqknmFC0bxo+BlkLYfGehHTPYGsKKX7JqUoYmOMuvnPGd42swYZHrk8DP8AKrGnSFtTWFLiSKLc1rA8p3rktuO5uOp+vNT5mUJuUju9Pt4HK2elBrhQoiiY8xBwM4wM845+YgcV0kk8mpalLZyXK/Z54kSGXyhGT+7wx8se/T8azPC8zy3ZivFtd/nmIwMx2+ZjuSc89jn1q3oEYtJ3h1Q3qRSEz27rIZIzhtpU4yQF74PRhV3/ABPVjJpXNfUIUhZ5JJVWURtbQIJBvRclCPr/ABHHTcvvWlJZvqunM09u6KsKFIxxJHLt+UMvU/MTx3B9qxr+W5W+tt9zaTSQxFo4Y2RQrM/CjI5LbR79feujtLj7FDFetKLiyn2wyj5VkVgp2DsPvYGT2P1qr6CnOUUmVPEbx2tuDJGZruPkgEBplJxwO4ycDuOarabCj6bMl2yjEoiO7AZcMWyvPuR+FSarbf2vdN9nWGS4Z8T5PzR/J+5VucgDcScDOQMdKwNI1PVI1trVhIk3k5aaVgVZg5AYEEggHGSQRyc44qHK7uaQk5R06HYWT2dvfwxiKacmMSm48sMWxnardCR1OB6A1dsYpvtE1zJMYMLgrCCFJB7gjP8A+uqgVoNKRpY9weQTcINzNuHAwcduxxjGKks3uNS+1W90WeHeXAVhul4wDu6YBx05rNnLJ7sddxSXEKIjvJCXDS/MAGOclfz6/TFOtY2vnuJ7m1W4RXMc0TgBuO4A46cVqafYPBAYptjljgsF6r6dcgVVSB47y6h8pDFPumDqxDbiu0k+49aLWMuZLRFi0ggWwkeBNsMoMgjdThc+netiM5WNnUA4H75DlSfwHf3qlYzolvDbXA+6uzzOdvGMBj2NLcskWY4YohI/AOSCfcjv/nkVS0Odu5DGzWl/IhdJbQncm0HzEPQqR3X09K0FbaqtGwQAcfxOR6H2psKzctM5d3zkISAvbAFMmEaEOLWNpQScMwB+ucd8CmEpcw1ZtQuJD+6s4yDtAEpOF9+Ov0OKPs12W2yyWmC+7CxHHTA5JzTRdjDiRUR1+YIHGQfrUiyvIuxVlmIXO8OF/Hd0P4UWFtsMi06PzJNuY5eCpZt3Tr9c9xVth1863VTj/WKRjH0prLLND+8QIw+ZSuePfiqY+0scQajbpKDjY8Stu+hzmmK99ySaG3lZQyFI/vE84z2z6HvUTsTOQFmRUUESRPjB90Gc8f8A6qZ9oe3vPLuVVpnXfFub5SejAAgHOefxpVuC8bNcwGKNmJxEQSR0ycc4oFzEUt08b29y0tqylyocv5T7SOcqevQenSrceqCTEdskzE9ZWA8v3xjkke+KiRrScS/YYWd1OGePGBj3z19qZMs63kctvG8HnAl8HdvIHX0zjpT2C9yeCaAkhobh17uIyQT7GrIk2/6lzMMcqxw459f6GpHYIDvby2GerYAGOoNU/wDj9K5dUix8rAkOwPXPAxmka7k4dVYKZMvIc7SQMeo5qKW5SVXREeTkgqgAH4ntUgtLWNxtRPMB6t85PvVkbwp3/Ome3b/PtSsyXYwzBdGaPzljbZyrGQjjtuO35sfSpRcKsO+fDrG2TImS4+nFakkseY3XlvugBSTk9qz7mQZBnLRoknlgBuCf9rt+HSp5S4vm0MmSK6uClydskrgyIQ2QidxtHBJHeqqkvJqDC4a2nDq2FfaAqgYcjGAvX68jrW+mJI5RHJiRGwxj53LwckYwM/j9ahW0ijLy2sglkA+VH2tu9m4/H2/Sk4mnMrWaMe+09b4W84upnkikDiUSgMpx6DjvjPvmlvraaGMRyktG/Ek+1VJx1x2JI4zwPUVozadHdpIZ7SJJGXEsuQCw543d1HoR2rn4Zze6bIl41xHJCgSZIkEY3gcgkYY5xkHIByKTsVCTvcra9qNpcBEtrKSVp1EbzoAu1Bg7OeRwACQMY71zGragdUhMuolIY2ZBiFtjrlgQOcKQfryeOK7RxbQbbaQQn7SxKQBAuAEGAG5Oc+vGDweK5TVLNm1CO/SB45IA6q7HeqlecDGSW+bBJ4Ge9TK5105RsYLXtrHdzxLJDFIrFledinleoMZGenqPzrH1G2h1O2ijyshhBWE5yzr16DnA65OPpWrqGoSajfQadYWrRTW5y87qZJpSTwiHsfUmix0xXmY6i17YSoSknlsoMkvX95klSOnIH155qYu+jNlVSVnucdFYRR3iadOJQkTeY80WQWIwVypwetMlsZbNrm1iESrIRIUl+7nqrgDoWBUY68VtNC0Gr6Zc3UkcqykwuY2JDFTkLzjocZ56GrGr6fKYobixZriUusjQiMMigk7i4IwAo3EH9O9UZVKW67anl15DLa3u60kWGWN9jbXVUJOflyT8w4x0IPtW/YeJHDJFqDxjKAebFOBuULjlSfkOFI+XIBGCOlWL/wAN30t9cXNxCsVnJH5hT/WKqHoA/Xpzz0/Guf1HQ4Ypll3CaGVMjEe5iQMZC8AdOSfp71cZdGeXVoTovmizuI9Ysbu7hkt9Wdlhj3PKyHcDnGG2ZJ69QDnOPp0On67b3em20NyC5jxufzSpjOdo24B9SMfhXit/YR27CC3mhVmzKGkwpVT2LAYB6kqDjp3FPs59StWkELFtrCRnnzF8uCCcZHpngnP1q7dmY+3kn7yPfZ7mN4raKaVbtZ2VfMKHaFXueOv5de1CmeAi4ExFwkmDEPLxInTJXcTkDGCOR6mvIrbxP9jkT7ddKzhQAGdmSVWA6kc49jjOc10OneMwzyNc3Fkli3+qjdmaOA9AB8xYjH4D0prUJV+bQ7rS7+C31OIJEzr5J83lpWV88kHn5cc9+a6O5ETuiETJA5yWYFiSACnPcf8A6uK8hutVtoLuferRzLgqkILLdAdeOqj0zWzoPiyIbnlEdnC0I8tHU4wByQ3rUpjhUSW53+n33/Exnt5XWJiCzSPgh+2F7g8ZxjpjBrUmhTzFjnRiNuF2RfdXPTJ6DmuN03xVp8tw6NO0abQdscayM4K89ecZGa0bu+WKOOeDULeNWlEIja9Dk5z3wdo46HOOKtaovnXRmtfNc28U8sBkkV4im4HJjORgsp5PQj2+lVrzUo7iLchzCCvnOoBxnHzZ6kA87hgdPSqNzqDrH5lzqUUxZcqzF1SNe20r1b3AyPp0878Q6nELSZxO1xKQQJlG1Dnj1GSOOcHPpSvYj2ljr/FutWNgs9qLuWRp2LPGgCRxj+H5iMnOT0/PJ48o8R38jNIHklkuHBzEFCBVXndjuPYVYvdQaFYxDLb4Y7ma3tyjg85XoOc/45xWRBDDcG6xE7vE2coxDDPTPPX9e3vUt3epjKo56FOJWnj+yOxBukMjttJAUc7m4znjPQce1d3pUVwBaxXrGWFVwjqwlVx6DJ+UqvIUdfWo9A0aef7VcyYDOGVpYI2aEKy4KFl6DByTn86seHpNFlEtpbWj7niXZHub5XXhmGTgjHOCDSfY6sNTUfeZ1Ma6jY6HZavH/pFgx/10QCtGqMNrSKOOD1BOea6HSEv57i4aeSP7Ip8+CRHOGDOPmUkdPY8H9a5mHzLHR5fIt7yKSJN5kMvzqCwDKw9AP4geh7V0Gi2vl2F1JDE40udvLlthgG2ckMsiKSU2txwCOeh5xTTsekpLk1OhuWstVu47eeNzANyyw4BjR84WXjoT6jnNb0ViTYrHLOZHkl27hFsK88NwMFgeeetZWh6SYpp3muLp1kQhRhd0XJJQDoe2cH1robeKS107MkkzIqhtwIOwrzyPbjkfjnrVmVRraL2Of1LT3t9VtXsJiWKxiRCmS20sQwJ5zj35AI70y806MrILeMyW7HzUUhm8vOSw4Ix8xI3ehwQa2YrST7PGJ5VnLOyqc9RnIAIPXIGDxRNZySSwXMDb32bJlIytwnGGBI4cdx3GRUyVhSqNO1zkrK9ubIzaZ502xWKxRBfkBYZO5gMlV9AeT2rqdGMIgSCOeCKKA7o5nicPIT1PzAY5JFWYFguAMFCxyqlvu8AkZ7jg9uOfWkumkhG+eOdXkXyWlR96tu6Bsc5GMhiOR3zUpW1Mpz5ti5d6taW0fM0UZXCth+d3pn+op5dZYVkiEimPGwk5BUnnr+dRCDTWgjX920EkeGjwX3++PWoJoo00+RIFdkDAoAxJIU57dAMfjVdCPct5jjb3TxiOG4RZcPEkmP3bAHO0nrg/z5FR2U72NxcxXUiwyPJ5iLMq8JwMKw6gH8RmtGeZU2SxyQus+GUvglgcdCDyemPp60lvDFcWcZt4kk5x85PDDrz95T+OaVtTJSIp7q4Lw/ZZ8STD5HZR5Y6ZAIGWbGeOPenrDJCw8xZLiU4OfPw3ucHp29KrXGlT7mIv5LSIgFlTBZWz94MfX1xToDLZMIbiaOZsF/tJtyplX1YgnBHfjntR6g2raFaf+0XtVWa3tirHBiWIyE84+YdPy4+tSxyTpHtuJL+22n+BgVPuvAA/z1q2NQ2IsUcdxLNvb5VUNwfmDeuO3aniSeZ2jaKcAEE5XbtH1B/lVW8xc11qVluZpSSZZJYjwPOYL8w/i6AfgDU/2hWlWKWK3jlf/lkTy/uuQP1NUXe4tdRuf3Cm1nO8uGYBGHBBUZzkc+gI5x1p93aQ3unP5TG4gcbk3HzImcHgDGWH+eKBNjdSv4bRS1tcQhXlaFVA37WxgZA6cg55FZej6pOyzLJ/pUlvIySpAgjYAdCSxzgjkdevWnrHbnfDHJLDFndHtVSrHOflcg5APGBjp0qP7Q3mzwzyXC3ELAozW6uQp+8VwPmGQegGPSgll9riWeCVora5tjE58tmlLFj1IIGAOwOQQc5zTVF3f2yES/ZyFB3ZEzKOhym4YPY9/TFUYiY4555b9VQSFlywwoHTsTnH4DPGKWW4lvbC5a1YzyIWw8Tk7mAJKchSMk44Pc/WmLbU6+4sI5G8xhI7LnYjtuVDjr/k0rPKpAdd7EfeVATnvwTxUkbSEhpJdkeeNvy89O/WoTd23nmKORTKTggn5/8APuaDVSHErIyyRwSFhglw4BJ7Dn/ColMiS/LkKOTufBP0wDkU5l8xvLiTkcFwx3Y9Acd6GjWRVkKkqoKgCTPHU5zx1FIdyIlppC7GbdtyhDgBT69/zNYeoXNxBHN5TiWRXzEkMQ5z0+Y8HByTgV0COizuXjJZlXOwcY+gqOaGJbqNhFP52DhY/lG309qZpSnySu0Z9rbPFAGuIrq4lkVVlPmAg46kL6jp0rQE8Qlf7OwDBcsoXbgfiOvqKdbtKjEtG0e48lQHb6e1Nuo7SRcXUfmF+M3HX/6x9/apfkDld3ZRW6SG3Uy3PnwqzM7qPuH39h1z268VTkt0nuXuC7fZ7m3ARo5MLlTheR1JDE9ecU3UrGzaVp0kuZ7h/lymSqrxwQR+tZ0Oi6VPczS6tBDdo4M4ct8rgHk7FOA25sn221Jo0rXRcuvssjlbe7tTFHnEZQYCk8lgMDaeQO561gafpdzH9omeUzRSSyRI7ZjZVDcqQcEqO34dq6iV08tYrLT3cCQCPIESHgEMQeCB647VWh0nzbTyLiVZbhyxdipIJJ54z7/jU2uxXdjkNSsI2uWj0GFIrmJefny+V5MnmDgc5HB3HnisnSILlxbXV4txMTcBg/3YljkyG4xzyOp5rstYe9Nuun2Qs5LpFMKIoCPjHVewAH3h7e9Y+uT28lhdiHz5Iyq26SK2xWcHG47RyOp9DjFLY6o1dEluYKaPE85s5TDJ8krpNHllV2PylBjGfunPrxwaigkuptPtLRIVluZl8uRiGRfMHDMeMkdcr6g1oSSS2Vw2nRwzDyoxPDkBVlGNgcqcjrng9OtWbzSp1sbGEXhit4WDpK75IbBUg/ieDgd/amti1OTd5HL6r52nwXtvNLJOLZGaI7BxxjPBxk9OnAxXI/2Wb6SOQS3UhZQBKo5VgMbPU8d+PxzXoK6bp80IjtxcstyHRgSVDAcOWJzggHAHqazNT0dNNhkt7Tf5K4YEHBHXAJ7jGRx15zUNdWauCn7pzP8AYdnbRzPcxQu5USoB91BkAuCDncpKnGCDz04rLfwwl3HIk0Y+1TSLOJEbzMAcfKPc4OOOK7ZrM3EVg8hILJtieNRw+Bhmz2C5H1rJWya+8Qm2meW3t5QIpZtwJHy5TdjGTxyB2NUnY5J0YNvS5yGn2FvI92ssLYVD58bOTDIAQMg4LA85z2PWlawXTpYRaLbIArE7EUrIp64kGWVhjoTg9vStC5tJLWNbtYmKwuXfKbWdG6EY5x8o45z3o1+6e3sppZbKSGdgskflZ5kI3AjHGOnAxRGTOWphoqL01Ml7O6kkW3bTYrh5VMsG2zVnmz/EcdRgdQT0qa3tZIJzsupdOhRAT5Yx5Y90OMsc8YqrZ3UcKo80rr5vLZUEPJ1cbc8DmtPUklmaGaO2jj3EwxxSt90DlOMfLnkj8qptnGqa6oh0yG9sdSaONyrygkuxRSejbmymSSNvcYPU1szXOsC/mIU3QZVQyJCGBJJGGbGc8Hv9DxmoLCG9lDyWwW1IQxPLNHuAUsMheCScgfL1wfSprfQ5dTRrmSeRtrFJMna+QwzzwATnjA44HvQm2WqF1dFG+vZY41mbVbRW3ti2ikeWTA6k5yoHB4z3JwKxleOVvLjhlvWkAk8xyyBDnkKowMcjnPrXWwWFybBbNpYEuJSbWSMDayAPlixPTnYce/1rNdtQ0uUNFPGgud8FxG8hZASBk7TwSR91u/PNO4OgZr2N4G3PCi2oYAPIWVQrZ5ILHvxjvg+ldB4f0Ka5K2Ntdw2xZdrCQ4Wc4ygAzk9c+nPFU7uRpbWCeczyLvEpkUbFG0dCg6/N0I9Tx1rrtIljWwtL7UFea3luCd5ZTjcAPnHGc9AQQRihWbN6eH6mZDoH2bSJIXne4GX8+NCwjt5MhfuqTkYySMfWt9vDws9Ot4RElpd2k0UsN4GIU/7WSMnPB2nt2rEhub6z8VJIYhAt1OZAdwJh52kH+EHoSecVpajcXwnNvEu3zrl74SbS0ciZUHI44B6H8vWpbR2KNo7HTaZPba/ps4lJiuWQiQl+Y7gNg4zgbWznb0NblnoKLpV6AoCugRmEJjyN33SM7iRgEc+h5xXKgtZ3tyqKyz2rDzIZZfmlTdkiI8/MDzjuDjmu70LWbK5sbJfLknMrHdGckqOehPBGeMZ71as9yHJxVkTaY7x2YtdXldnLN5TY+dyCVOCCAcEDg4Ix3FdCsiwRyGO4jD7QmG4y3Yevpj61ylvaxW99eLuaaK4kVvKdcx3AIyVYdpFHc8kYroLRIYraOOR7qVMjZLOBICOwJPIx1z7U0zHm11G20wu7sR3NvuYqFxja2AMcjp6H8jWjCsiGe0mdjMCHRj0kBOcn37cc1JHEjI7SCIOz/NsUAkjrz+FMcBmGwec4B24U56DcvPYjFFxVJp7GdfmeC8jmt1ExIImhkAzOuM/If+eg/Xp71NcR297C7zKZowu3asnl4HoQDkkehrHvL1h4giSTzomS3aS3ilUssrc7geMjAHGOmavWuqRXsKPFIYpSFLxbwSnGcAjqPY0rmbbQltbyxSC3cokStuhCsX56kE+nvg1Nc3kdvI8bvLFOV3iA4YcnBbOMHB9KsPD5kH+uckEsFIG9M9wR/I1n3q3rTtGk3nZjUwSMMMrL2P19RwaDNu4W8qw6eZLKe0uIFOGRSkRVs87SODk4+U49qmi1OzilN7E08RcYuESBnG4dCyAcEg43Drx1qCzvrlpA6RSvMBvkjCGIKM4HznIZs96vSXE88uWtDnaAWmkDbMk8jPJOMdBimkF+hImo2jyBRGryA5+6cj8Cd3XtTJpFRytvdTRysP8AVBXAUZ68ggD2/lVYXKQyNELktbqpwHG5ARxgk9D9OPzpbDVVMq24WSO5kBeRJYvLbPpuHy+uOaLiJ4J54zmNLqaVyU4U4wDjL7hnAOT+NOuJ5JAq3BaKPcCVUZyndievJ9AOKrC5uFkKeWBO+0nuM9NoJ7gHp3xmpppJbawjYvaoTsVmnb7zdxn0pkvRk6GMrGltJnZ91EIAAx3JHSq9zYQzztcRSPDMoOGiIyWK981l3ztPJcJcxGUKQXkgiHlEYztBHLfSq1kfMiIBuYkzmKKBPLiQEZyScsxouF2bSAJCsTX8ksoAXKBAPfgDDEd/5Vy66XNNLPPMwQyzu8ZdsqqjgB4xjAyB93H4VYMcaTtC0yqgjUeX88RHOeHA9atR39nAkgmaZI88yKp2/meSPfkUtwuzM1iIWt1bR6vdRWxmwGYWZmidVx3LYXqpwfTqcVYttXWJn+23cbQ+dlZ4z5Ycjj5lXpnA6Z6+9VZonvpYo9E1drcM5YRRxxzE4GWzuyehA9B9RUGnWYguma+WGTUJGZkIVHLdDzxgHnPP9KEQ2eiWjNLI4EbzeW3MrA7Og4BPfnmlgSOEyCFIRwcYYMxxy3J46nvV2S1jki5VliHPlg9yc1UmsbaQRpLHH5hbJBO7Ge34/wCNVZnToKs3n2zIk6Rs6/M5YFhn1PTI9qZImyKNbPzGSEKkQJBXPTJz1ovQPNkW3CfKMM4wAjDAwo+h69qfBap5SxsshijTCRoOWPdj/QUWESRvOrFXWOR85DoRz+Hb6U95V84qr5nZfmGME49+w9qgEhVVSO0uFZSckBVH0OTSuJ5omb7NBBGRz5soY4/Dp9aQFlWJd8KAy4B3Hg9+1VZrqeONEikUzysBEcYGM5JP0A/Gqk89vbyQxyqZFI+YrIHRV7Zxzgn1pJ7otChnjaMvlkRVzsGR+pFK5S1Zd8lUUGSXzJm+XcOpzz+XWsu70y3+1wyLlLtEDpNx2IUggjHIIB/+tVxTdz7Hjto4VyI0eTrz1IQc8c9aranZTSfZ4hPJA6OJC8hypx2Prk9vak9Sua2lxs4t2kcxzbHQAHcM7jnPzeozz+FVBa3N5fTgTsYPLUsfL2+uSgPTvyRSS6hcTW8J8hJSwGxdpWN8nG3PocdDzVbfd3ipFq7vHCs3lNbW77Sqk/KXl6unQjGMgYNIqMnYjEdpHJO5EbQwxeU07HKNk9dw++eB/KmxvbWVnPfahAlotvEBsQZ4HPA/kPU0l9PLJPDMpWJVR4IrcRfeIbhj2UDBx+tPsrczMtzqExuCH3KjHJDZ4Dep70l2RUWzj9R0K7R7W8umdbq7ImWJzloomBxF6HGMn0zW9Fppivoi9uJHaAfIOFUMP72euB+tausLHfX8DS2wkgihlCoPl3O4wCM88c/rVHU3ntbGOxt5Y4Zvlyf4lK9SuOmelJJI6o15TioGV9luotRDgKNPZnfPJOPulgf4uuMnrUGo287akZIY4GaBSW54HuoPAGBgD6nvW0sTPaT2HlSEBHt41UFvKxsYnf3+9+ntU19oLYmiR1/fy5Axk4/vH/D2HvV2RpTqRj8W5wy6ZEo1G1WMylQwFyH/AHceeQQBxnLAe5HtVa301JJJ1st/2eT5h8/CZABcuerM3HQHt0rt4NFgXUPslv8AurdUDGENw8ydHx3PzZ56kZ6Cn3ml/YZ7d5PL8qWdUIxlA/IUn6Y+mSDU8upm6qUnfqcn4h0qaW5ihWBfMubD7NhBjaA2M7egZV3EGuA1vTbm9sHFg5lj00ZiwwVpFRgNwHcnIy3TAzwK9cvbKfUBdfZYTGgDIskhP3CNpCjrwcAe/Nc/f2kRkij021S4knWGKVSfk2qg3of9jpn8KGtRzcJRaONuNDilFmIirwIPtNrNLFugXefmSQj+EtlQ44qLWNHs2sIJbOD7JOGMcsLuzsjDBYNz06Yz1GOa6Pwlr+n6Pe3GmawrJCkxMABLhI24KEenAIHSsvxVb21vq9+Le4UaVdzxwy2/Tyn5+YDqAME8cCp0aujJLmiZGg6ReFvtEMjtFcbvuY8xQOrAZ4I6g/liug0NRbC1t3eRZCjPKWG8b9zDcCDgdBj3NZ0MYgnt2tUEUZdVkVifMt5TkKFx1UsBke/vVzUYJYytzbWhmSFVZozlADJkKzAcn5hux6c1SXUrlUVczr6Ty2kaDZ5sVwpjijBCyLwW9yG+ZgM+vtWvJpsXk6drVzbj7L5giwjB0CybsFs9CC2AexxzXP3c8Umq2kUl2xx+5muH/dkypvC7fQKAMe1dXodxFbWt7pUkaX9obYSukhX5ASMkj+EdBgdSQRVRE5Io2NpDp2qajpreXeCPDxqV5YHjjnvnkdQRVGQS6fosTW0gtQd0CjydwLbzwT26rhsd61Z7E+TZRLayNcWVzOm5ZAJvJ5YLkdSdyYbru+lZ/i52byLDT5ZnE94spjHPlkhSxB7Hjke2aJLQ1jO0Q1/URp4021j230YTfPDtHmKWXLAMffn612HhvTpJBY6tfypLZoSsqrHzHC65V89SVxwPSuB1dY5dekS2VpPLEQWCaLDkZLNuB7kDOPfArqvC3iuaPRP7OjWJ0kWRSSu0rBnI5HBdRkf7tQmru5m5Nuxr6tDJc6iXkiEiNIsMDQvtbpv5x1UjgMOh47109iywpNKR5dnM6mWaIZjZjjl16qQ2Mketcrpd1JeaZp0qnNk928UXk4BcHr8x+70yFxz1Nd9ZutksseoW9s0bfu7h0QBJB0DlexA+978irSuZTklqPmjc+dlIZXTAkVJAxAAOGwevHQ9xkdq0tOvIY4UEMkzRydEdcMh6kEeneshbQW8iGCRnhRSpZhwUH8Ld+CQQ1WFWP7kYTG/b5ZPHrwemc/pRsc0rG1JFBdI5cmKJsMAMZPvz0pHhLxn9zO4A27S+HweQ3rxUEHlqU8xPKyfldhvQcZxntVsuVMbmWNs5XhuCfT8aaQua+hzOv6UmpzS291cTwFtqoynBR8ZDq3Zsjj2z61naXLfKW0zWZ4Lhwm2OeZQpPb6HHX1wa6vUod1mxgCSKAHKAlSMc8ehrC1aOK6gSeykEd6q5VJlBR/9h8/cPo1S0K/Qvq09rHlYZWQKAr2sgl49GDdPrmov7RnZQ1zbG2CdZFcE49Tt6fTmqmn3lrKsjyCG1lxho2DRN0wSQOCR/eHFSWc96FiGWkj4G4zBxgf3ABgj+tUiGPOo3Cj7VAGuIWQiOVAWwc55HcexFMj1AwQoNQmkhnYkhnUFnUAsdxHQ4HQVed550m8l4PNYEoZP3SH6lfyzXOaml0LeSOS1vvtDqVZoIll8sd2zkZXGaHoRudHaia/ihkmaJTgM8cqYOTyF56baguo4bOaOIt9nkwyqqLuWSPBJDewIyD2PHeuf0qzuLtBI2pNfxSOxYyKYnJ7Db04AHHtUphuSVmtraG6hVnUwuzB1AOPlfPXK9+KAuzSnuHCbpxbmLHEtyrRhRkc7hwfTPBpkU7S7Gt7WC4mMmyD7RjHTkogySBn7xqulzOkkdtLpM9zKwLos0oMaKMAkg9cZ4+tTXUMESmZ4Jre4TP8AqwE3KeoHbjriglvqak/nbo03s0k3y7owAq4z+nt3qq8EKW52xStNGCJHaUqpPfdg/wAqpWepr5Euo3skzrCvmAbgAoUcAgD+LP4VKk8D20C3cpmXZ5rRxJgOxOQFHXaPXvRcamOS6gmYRWkORHhdnC7j1PU/jmsu+1aytpfs8F95koP7u3jIkkQ9+TnC/XoasmCLUbONb2PeXw5ifIXg5+Zs5P0FUdQuUtFdLdIrKMMGZlt+ApbHUAlgR+lDE5Fm48i8tkgumSMsmVZ1jDMARkKBgfXNZV/DB9pxHcGdPKkjaCGINnGDgkDA796bHdWc8qiOwt5bycku91lAm04wF9cYOPxNMla/uI2S5WORWzhWudkeCMcJxnAOM0jNu56fJcLhWub2JHHKRQKScn17mqcLXl7fTtFJFDHFxukPzOdo4A6jA7/7RrSCIrExwgysMYOAfqcdBUfmRW6RSbsyfMjtgAux4yfqRWljqTJ7K3jIR5IwuEAVW6L349c+tWZHwhZ2yX+7tByao2ktxNLMGCrGjAbg2MgDgbvx5wKn8lpEOJdnctGMn8CaaHcY0amc+SzGfYMgtkAA9x3JpZQsjsscfnt6yJtQH3PeooXBLsHmCv8AOznGGHQDjrVppt0eT+82j7oYZb8KVha3K0tizW2yN1IYYKqoXf7fSqZsrkXsJt7yVYoldNgbcrOQDj1wNv8AMValmu7p2jtY3hiX5WkQBpG4yQueAAO/5VkX7XYVbOymjWdT8yBwHjB6EkjAPU471L0LVzRYPIBLNqEqwRglkiITLnAAJ6nv+dZupQQ2t5HYMJN12pbzRJgp0AZs9OuAe5OKrWtwQ62qXUKzxo+6CIsQgzw4B5x1BPrUzW4beiWbgzuF81SpmkZWz0PAQYOOe2fSluF0h920gsJ/KCIBDkEE7gy8BQO+eOevNUo5JZtMm1GUK9u6AQqnBklOAUC+gYY/CtS4W5czvDY25kb5UTcDjHTc3QfhVWwhS3j86NDLa267GjACiM/xfL2PfryDTFzWWhVt7aeWeNrwypMztEpJDZQ/M2AOBk5A9gKku3uIZhBbKwU/NLllDxxngcdFHpmtGK633PnhhIjkrEwGEUDq3PLEnj0FZ01vA9pfpYqsaTbzPOyktKxHIX1GOPbtUNFxqaakBureE2gMubiWbPlKRmNQMfN6DH55zVG+1Fobm8kBE9/KAkcCYwoz8zD2GevciteOxSPakcBjF0ojZmTnbsGTx0OOKpy2sEd61vaCRTGiiWTZxHGvAG/+Ikceg4zRY3hKNivZaxHZojQ7pWfGACSXkx84I5x29MfNXQpcF7Yu+Dkry+AfoPQD/GsS6WN3hit8RRo4LNCNgAALZZu44z9BV/TJPtod4p5Wt2IWKTALtxk7c9RxjJprsJpWuyUW0tzJDJZ4QifmZQAWyCDjPQd/1qhe2HmW1yqPM9rbrIY2OCkZjIIbB642nrnJ57VvCF2hbzZjErM2CD/qwT0HqenSs7xMqvoklrLsSOY8Q7iCFzyzY68Z4HrTaEpN2MSS8C6JDKlrcwW90geeZn3SFFy2I+5Jycnj73HJrJmaW0hEsxCOqmSGGLiOLe33XJ9sAA8V0l8Wkgju5lRLWEhhEcDcAT5bjA+RV4IH/wBasOK1u51f7Oi+YjO2JEJiVm5xk8k4ORjpmpdyozscPr+g21ldQCaIXLM0jSpGwIVQAC4xztGeaoebJLorWs0X2ptNIDtgBigYgP6n7xB/Cty9AtdN1aG3kSN2yiPvJZ5M5LE/wc9ADzXK6Lqc1re3HkxyzuiyypubdnMY3o47nHIPXOKz2Y4T97Ur6RJBcX0dtNLcmCdltxKAA5QMOP8AeXGAe+RUeqam9h9oSV3lR4/Mt7nLLJAV3DbgfeznIJ6dKo65a29vr8DWRdrO9RGV3bG2QbTIvB7E5qxql1atIzNGYLgTotwBL8ofzAScdcHGBj+9VxbSt1CTWvkZqxPqZCQwb55ImCQl/vEDhiD1bAP1APpWp4fvlgKy+Q8N5HEqrcND5yTpjB3KeoOOn19K4zU7u4uJ3KXHnOkmICwG7dkjg8ABeTnoCxrFvNUuEnAjuTMp/eOhyVDHrn1/lWkKbeqOGpiLaWPVLTUo5gskYW4uFlYMjOyrwCF5H8K4U8+uT61dTTRPdkXby25soxJLczchwdu+VAOCOSMe1eQ6Lr82lyNuXzgWDlZW3KSBxkfTg+xrpD4r1DVbiC23RJGG81jLcZUHPCn/AGeB8vWqdNrc1hily2Zva/dzjWrq4t3VTeuLULFyWAUbn9RkYJ/3q9G1dYrTwfDbaShtrh5fJLRkKNxGGGeoO09enNcP4EspLKafUJpkhncOsf3XI3Zzgc4z/hXdS3kbpcWiW98txHB9ngd4lQLISG4UnDY/rWVtGdFN80WyW0xF4asNQ06eK3uLVhNcx4JV4f8AV8p6YABI5AzXpWmalpQt1jmUW0arkxyDeoUgdG7jnvXlXhwSQWmmCTzTewI0aoxKjy2cg9MnaGJBGCVPXg11ljNJDaxpp8z2sZ+UQvztGfuoxBwD26qPalCVjNq6Oxl02SGJZtIuEjVBhFPzxOvX8+xHpWY+qW0FzI81vLbDZmQQqzI+3oemVx/L6VVtT+83RWl55jOAxE32cp3zlSUbt2Gea0muL1f3TXDLcJhwbkbnUH6YJHGOnarZjIvafd29xh7VWcMOSsgG4HnkEVZESeUxAWMNn5ty9c+lYRmu8yKYYN7sCwgwuR/e24yp/nVdtXht7hjy7/dBfaQG9WJ9vSi5F+p0outzAv5by9pI2K5qGdY3kcx4aUrkNt5cd1PbIrNt/Elo+4LOJXGMkRM7dOMAf/qqY6slzEoW11DLtkMYNo47jnijQFIyriG6uftLaXKkak4mgliGQMdVz39+hqJbu1tEC3QuFUclraLy3Q5/uDrnuRVq/wBLW/nWQrLEnDFDhWc9vmB4+gp89hdLbskcl2sYU5i83BYY7N/9eiw5JdylLc6LEzXEd9ZeU+RJ5gcPnr6c/So4YLNkjm8uaZMAMPNdiW/vIDwBz1PGKssZLeHyw1nIhwshmQqzDH3c44b3rGOo6fZzGNrae7XcQsckLBoufu7+mOTg8nijYixpmC4gvbh4LQXNtKTIsQALBs5PORg5Oc/XrUgur5JML9nmYkCXKFMnBxjnnnAJNZU0Z8ovo8MGnSsBIjO+5mOehDYDZHFSIuo3NuSutQ3aSArsWwRcA9QxH3cYx3pkN2K+uajc28ULSLOk1vI7b5F2x4IKkAg9OnHfFZumeNLSRxbjTtQuZD9yUy5Qep+bnAOTjrir720wMkL31pOdwWRAoZkBPHfAH05xWff3bxK0klleSTE4cCRfLZjwFSMc8+o5GOaWpnJlq/1uJ0mxBcMuQROw2gc/Ng9/yPWlj1OK3gSXTrWSSWc7CVyqj056hR37muf06eBUmWayae5X94xbEAX/AGNzt16dAazpPEV3Gx22Sx+YWkyxI3H2OOB0HvSuZtncXeqtb48u5828jXDARk4B6KgPCjPVjWZqups6rHHdTpHFli0h+aRxjlR0A54J4rl5vFOo6gZLVLS3aOUHfFEGcscdzx8o7c9qzbq/nknia+lS5WJg/kqAEbtyynHbp0ouS5WOoufECRYl8+ONXBYQW6BzGMj5gx4Dcdc5/Cud1DV5fmjs5LpICvzRyoAXGTnL+55P0rG1LVhBfBViSYnGWcYCdCVUe2ccf4GqF1qb3ErQwPDtlb95g4VV6c9flHc9fTNFrkOR9d28oa0ikYhWkUHGM84zzWZDci7nK2Qju/Lb95KrgLu/uqf1NYulR/2rAgunlmikBzAm1Y0TPG9h/EQPujOK1J7PT7KeDNvbRiX91sgGQi4Jy3sADzx1rS9z0i9DMYYvIZ7aN0LDbv3tjOBwMew5qTy3uUVri4zGxxmQ7R9FXgc+vNZ4FpZ2VvHJDBETn5w3OT7/AHj9elT/ANowrKFS12N2ZiOn4A4/HFMV7GosdzJGNjukY4+ZOSB2PoPpWfqk4gRQ9tG4b7rQEu2fcYz+NIWtyrN9lZjtwWVGcfhjqaguZDbWks/2hkII3iSQr5Y4wMAgk/iKGxxqWd7GbZRXXnSMx+xwSOZfN8xmaQk5ICjpz9BVtbiGytJDC1vuQ4ckh2kcnoTzhjkcc1kXUWlT6o0do099epxJ5crnG7nbI2QoAIzjOelMvdCtgr+fHZxxBCxihkbMhBGGd+uM9McnHGc1DuaSq82rG3R83xMxne5lkFuYjbLIBJMd3mBCAOBhVJyR97B64ratDepE01/HHbyb3BSI78AgErk45xgH6YqPT4LbSA6WzCG1hQvIvlfvHkdssWfHYcY5x71JFMmE8/NvEFLBAx3cn5WY/eBIBOOvTPNOKMZSuaZkzC4j87y0OCwRYwoHbnpzntWawnJLrFFayzsqtEfnfbg4yO7AYPfrilW5LnyYkSMxNlEnIRUXs5QHcSevOBmnW7w+eggZp5H3gtEPvtjk7j+WBnFDEn3IblI7VWxMGZ9gdWG5gqg856Z9SeBVDTHWVdQnjY+X8375k3HZj/lmDwEB/wC+jUpfzPNCiGaJj5UEaDIdj94f7SqQc+pHXFUY4YBYG2WRkmM5fyw4LuOoDY+6ox93IP0FQzRO2jNu5VLWyjZi7ybRK+5xvOB3PQeuOlY9ncPNqcNtdKfKffIi7iThCMBhwB1BHXp6msbTtVhneG2tZLg2m9o5rmSIySXJTnAfoBnODkDj2regvEKPdxWUxZFCxKELkZ/hHpnrknk+oFJO47vZF42rarfQB9otgu9lQEFix2gszYySoOBj3royIoVVQFG3gRp2HYD0FZVkDbRB5HjE8z75TKfvEDtznAGADxjFXftRykcIjkYjg7SB1q0rDcmyK7KhWIuFe7yWQbchfXk8L+FZUUU7RxM5iAmGN+0sBnkgA8lSecnrVi+u41vIre5EtzO5GIIFB2d+cnC8jqalaclJ/NhRmb/WBX+VFxxuc4GfYUjZSskZU9tJstFdCIFmWRovvNcOCSiE9WIOP9lR+YiNzGLdrJkR7ksyM8RO+aXO5kUjoq5GT2A61DqGpGaNkgZ7m9bfAqQoURR3BkPQeoU5JwOOlTCzi02AM/lW8MNuTcysuCFByF44Vc5yM5Y8c0kxuXdHnXioTyXEs0E++OeaSJXkUMHEShmKjv8A16ntXI6FI8clxNCrRrLfRCMHDfMIySueufmHHvXa69BLqmoFbTfbJb2bNDEV3SzeYdz71zhN6r35Ax9K4TwbfQNqcQKPHCk1xeDgtiMoBt4xlhgjP061k/iIlU97Qu+KdJRY49Ph2HU7eZpYriMhvNkIDbSP7xA5/wAa46+vEl84yRlrqVSwiHUScDGcYADYIbPbHXkd1rc7LYzSoq+RI8UUU0nJDFDkKBznackk8ZzXCeIZ3so4GkuAZVG6CQoA0YOCW29OuSO+enUmrjuLEStqjlta024tUlF0I4WQksu7+P06cnBzgdAQSRWKJG2BMnaM4A9+tTX8vmyriTzFCjnB6nrn1Oep7mq207S2PlzjNd0Fyo8x66sdHnPyrlvTGau292Y7oOT5kbcOqoAcZyQPSqIBAyOPxqS2IEoLSeXgEg4zzjpTauLzPSfDOoQzXC7dRNm82N4khZFl64XCnGD612K+I5FjEGoBpJA0bxzkjfvXGAe4wuBnr0zXmWlCNoUt9zxyqQyyQsGRh1yGHII+h+orrdIMl68W2XM7kAlvvvjpkqCyt6EA56EVwz0dkdlGq09z1bTo43kdr2Bp7C4nWWK7UkIsp+8eP9W2eDnGfcVuWVn9ikmtLpTexfMRNBfhGdc941OBjOM8HjOK4LS706WFWaxuIbox712oHWfBxjblcHseD9B0ro7S2+2QBTYx2EKtk22AEZjyc7dr5z24Xsc81K8jV1C9JommZiGnXMqujbzHujml56qCSCeR9Kkmsby1Ta1zrU3lgsqSOVVxkcBgwOcZGBn+lFm9wtwbe5jtmy+YjLGLdm45TIBOR2Pcd+KmEUVtgxM9nLKR5KGdcEAgkoSC3brt4/GnbsQ2mZc7Xk0MSpbXkgLAxFi3mJkjI+Ybc9OG9ODWNJ4gFlNMLqEW824o0eoW/mHn3BwR/vc/zrubXXYor3y7lp0cSNEq+YoMpwcnccdfTjpn0p19Lp+8syi3D/JJIbfd82OGdwCuMZHJH6UWvrcnqcpb62L11aPSZfNTG6a2tcgDsMBslenP5Vp2uq27TCTURe2iqCyzPuCbehyVJIOexrNudGtLotdpdsfnbEihfMyf4Qo6g8cnB+tLCGsZlE8FyS3zL9tuAh4A5kAHAX15Jzximm0yGmbtrrdvJuex1G7liQb2knWRV2+5I+UVqQy29xAr+bGsb5GRMACfyyfyrn4I3lQPf6vPchH3RSbliWVz0WJMktx3IPTOaZDFBHJ5yxlrk5JzcM7qv8RJ7L+lVcaZ0TNbQBnE4aRFO0hGyvsPQfpWFfalLaOBJGjFxiSW2U5Zv4Qc9enJGRVGfVkaSWGzmtnkXKv5KtMw68E/c/Lp0zmrXmXk0aJdwwEcfNLnOODwoIGPw/GndCvqZs+py3LxYKSeSd/lvMIlXGRkKRyQOcnpximnVLiVoIWK2wUqzrA6FvlPXAQFSfQ+hqw1p5sTLO1qyRuVCyRhtgBI6FiBx9KhlttPNvLshtxHnc4O7nIwMKOnIzxQEpKWyK98xu1GbHUpoyDI/wBomCRygHjPt/Fx/Wsu2N6bOS404w28W3aUXhzub5gHY5Bx1xnvT9TsLWNXVjA0g6wnAjHfBQcgfU55pLXVbR7Eo1vaxuozGSQi++0H5uueuBSMZakU8TTWyw3MoCKQEG/erMPTnp+grL1G2FxbtsiO5fnc8kMB09DjsDjntW9eajbw7o7W6D3EjbESI+Z164ABAHryCe1ZcltJeTFmgae4lkBYy/wtjBYj27ZoZFjmZ/NlmjtijRhmDCELnK5zknP3s9AR703UIQ5IEs07PIQiCTcxA4wSAAQO+ABXUyQG2SUXTlYJ5N+EGElcDAXAHXHfGKo6jKsbiO2U2/kAgCVFURZ6gA8Ek9QB1pENHNyaZdLpsl7KsiWJcRqiuMzvnBAyc4A9PfpVf7IbiKP7XcL5BLOY4UVV7DqBk8cDn1rQ8u5eM/aSHjXI2zShSE7jjpwTwB6Vy+ua5As32Yb/ALM5Xd5WBI0YGAPQfl0I96qKbM2+iPrzTYG06dbWK4mMLp5pX5QNxxyOOOv6VXvlkurxElnm8tPlCI2xSzA5ZtuCeAQBnHJooqraHprXVklrbpBH5lsqRKMptXPbv1qje6/LYSRIYvMiKkoN5BT1HORtPpgfWiipbaG1dEaa5qGp308KPDDEm1BlC7dM9cgY9sfjWGdLn8Qnynu0t3Ek6pOsIaVBH8xAYngMQOmPrRRUp825OyOxFv8A2LocEULs0TRgqqkpgt/e5+bk8+tNvrCy0TTzcx2yyvEVlIYkK8hYIrEdPl3E/wBRRRWtiOhevGj0vS1uJUa6dED4Zyoyeen4/WspJG06yV2ZpWYgIoOxY0wCFA65AIGc9qKKbQyS3tN+6SUpJMZA7synB+XOAM8DAxg57nvUKyfbMoY4/LExhZZAW344OcEfL/sj8c0UVm9i4K5Q1bzLjU7e1mmdTe2rgmE+WqIjcqAOeRxnOB6VoSwJv0m0tI4rWG4ZpCqJwuOOB0Jx3IP0oopLcnoZ9kVgt7G0tA0S3czq7s29gEywxngH9PaujsLRGiSZ8MVXYo56k8sTnJPNFFVEruXoY1F15hGZPuKxAyByfT+WKa0R81IWkfyxyAvGcnkE9fyIoop21KvoZmkXP2qDUPIRbVLcln8vl5SBzlj6/jinXVr/AKbFE80rHakzuT8xzk7RngdOtFFShweoafbQux1OWJXlik8q2Q52wKD2Hck5JP8AKsW/YXut2izAyyyvIImmO9ICqsd6x/dL8cMRxmiipfQqLZyHiS6bTvA8t/ZqEmuJ1tyx5baScsT3fBIB6AHpXmV7biLU2hgdoQlsHDR8EN82Tk+o4x060UVi9yai/M0tcaTVL15LkouEWRkiTahYbMkLnAyCF47D3rjvFq/aJYL6VnINrJKqBsFSs3l/e78H0oorWg7y/rzMa8nax5+FyCc9KllUC2jIzkk5z9BRRXec4trGsrusm7hGIwehAJH8q07LShdaUb5ZTE6TCLAXOeM5zmiikyJOzZNb3DpYNdwu2Wceb5pDs7gFtwbAK9On55rodM1dL2MS39t5zhflcSYYFcexBGO2OP0oorCskOGjsd1pcVtcajawywuZGthLDMJm3RgtjackggdsYrrrXXNR0oRiWYXsAcKBOD5nLYyXByfxoormvpc6F0NePxNHLNJaPYkkW5uc+cAuRjAwFDd/73arcV69vJHLHDaiZio3iM5+dcdc7uM9iKKKd3c1TfLczoNea9tRA2m6cI7a7WBw0TMZCSQGzuyMfj9azdW8QahZy3Nq05nS1XIMqqeoJGFxtXGPQ9aKKmMm43FPR2NXThqGpQWswvY7d7pOHhhxInX+Ld04/wD11n3nni4nW4uXuZFJTzJep5x2P5/0ooqvs3FL4kiOaRLO3SZo/MlKMwYYG0A4wowcfXk1Vtbua6s1uGkclmYKrtuChRyPfP5D070UU38VjNa3uXJdRvVUIssaSRxhkZYV2qCfuhTkcdveq2n/AGy/0qS9kvGRUDMUC5ZyD3Yknr6YHtRRSvqPoyM26iAid3lBtvtz5Ckt8xAXJBI+bJJzyMAAYJOY7TCSys4LiWITtuLBs7eew/qefeiiqkrK5nDWVmXEsIbS0mO0SFZjbqzjJBA+8fX9PrVq306G+kuGlL/uF+bkEyHnk5H6ciiihLWwSY/7Pa2Uca2ttFGDuJxkk4Ge+ear3N5JFK3mKsywuG2tn5yR356DsKKKq1jOT0RT83Ja7KghIzsi/hGfasCO5DwG4ePO3LhQcfhRRTsZ1NDgb7VpriCSQKka+eYY0UcJnLM3uTWh4G8LW/iHVBFeTuNzDJVRzu5P86KK6qMVc468nFaH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1834=[""].join("\n");
var outline_f1_50_1834=null;
var title_f1_50_1835="CHD by nuchal thickness";
var content_f1_50_1835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of congenital heart disease in chromosomally normal fetuses according to nuchal translucency thickness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nuchal translucency thickness, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence per 1000 fetuses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.5 to 4.4",
"       </td>",
"       <td>",
"        28.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.5 to 5.4",
"       </td>",
"       <td>",
"        90.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;5.5",
"       </td>",
"       <td>",
"        195.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hyett, J, Perdu, M, Sharland, G, et al. BMJ 1999; 318:81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1835=[""].join("\n");
var outline_f1_50_1835=null;
var title_f1_50_1836="RBC changes HS splenectomy";
var content_f1_50_1836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Red blood cell abnormalities in hereditary spherocytosis: role of the spleen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        RBC property",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controls",
"       </td>",
"       <td class=\"subtitle1\">",
"        HS",
"       </td>",
"       <td class=\"subtitle1\">",
"        HS-Splenect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of subjects",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin (g/dL)",
"       </td>",
"       <td>",
"        13.9 &plusmn; 1.0*",
"       </td>",
"       <td>",
"        12.2 &plusmn;1.5",
"       </td>",
"       <td>",
"        15.2 &plusmn; 1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticulocytes (percent)",
"       </td>",
"       <td>",
"        1.0 &plusmn; 0.3",
"       </td>",
"       <td>",
"        6.7 &plusmn; 3.5",
"       </td>",
"       <td>",
"        2.1 &plusmn; 1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MCHC reticulocytes (g/dL)",
"       </td>",
"       <td>",
"        26.6 &plusmn; 1.3",
"       </td>",
"       <td>",
"        30.2 &plusmn; 2.5",
"       </td>",
"       <td>",
"        31.2 &plusmn; 1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MCHC mature RBC (g/dL)",
"       </td>",
"       <td>",
"        32.2 &plusmn; 0.7",
"       </td>",
"       <td>",
"        36.1 &plusmn; 1.6",
"       </td>",
"       <td>",
"        36.1 &plusmn; 0.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RBC: red blood cells; HS: hereditary spherocytosis; HS-Splenect: splenectomized patients with HS; MCHC: mean corpuscular hemoglobin concentration.",
"     <br>",
"      * Values are mean &plusmn; 1 standard deviation.",
"      <br>",
"       Note that splenectomy corrected the anemia and reduced the reticulocyte percentage almost to normal in patients with hereditary spherocytosis, but did not alter the spherocytic changes, as reflected by the increased values for MCHC, either in the reticulocytes or the mature red cells.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1836=[""].join("\n");
var outline_f1_50_1836=null;
var title_f1_50_1837="Cutaneous squamous cell carcinoma recurrence and metastasis";
var content_f1_50_1837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors associated with increased risk for local recurrence and metastasis of cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate of recurrence",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate of metastasis",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lip",
"       </td>",
"       <td class=\"centered\">",
"        2.3 to 22.2",
"       </td>",
"       <td class=\"centered\">",
"        3 to 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ear",
"       </td>",
"       <td class=\"centered\">",
"        5.3 to 18.7",
"       </td>",
"       <td class=\"centered\">",
"        8.8 to 11.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anogenital",
"       </td>",
"       <td class=\"centered\">",
"        14 to 15",
"       </td>",
"       <td class=\"centered\">",
"        15 to 74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic wound or scar",
"       </td>",
"       <td class=\"centered\">",
"        N/A",
"       </td>",
"       <td class=\"centered\">",
"        26.2 to 37.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irradiated skin",
"       </td>",
"       <td class=\"centered\">",
"        N/A",
"       </td>",
"       <td class=\"centered\">",
"        20 to 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2 cm",
"       </td>",
"       <td class=\"centered\">",
"        15.2",
"       </td>",
"       <td class=\"centered\">",
"        5.8 to 42.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Depth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;4 mm/Clark IV, V",
"       </td>",
"       <td class=\"centered\">",
"        17.2",
"       </td>",
"       <td class=\"centered\">",
"        30.4 to 51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;6 mm",
"       </td>",
"       <td class=\"centered\">",
"        N/A",
"       </td>",
"       <td class=\"centered\">",
"        15.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent tumor",
"       </td>",
"       <td class=\"centered\">",
"        10 to 27.5",
"       </td>",
"       <td class=\"centered\">",
"        16.3 to 30.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly differentiated histology",
"       </td>",
"       <td class=\"centered\">",
"        28.6",
"       </td>",
"       <td class=\"centered\">",
"        32.8 to 57.9",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Perineural invasion",
"       </td>",
"       <td class=\"centered\">",
"        16 to 47.2",
"       </td>",
"       <td class=\"centered\">",
"        10 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Host factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate of recurrence",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate of metastasis",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CLL and SLL",
"       </td>",
"       <td class=\"centered\">",
"        25 to 100",
"       </td>",
"       <td class=\"centered\">",
"        18 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ transplantation",
"       </td>",
"       <td class=\"centered\">",
"        10 to 54",
"       </td>",
"       <td class=\"centered\">",
"        6 to 31",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Copyright &copy; 2006 by the American Society for Dermatologic Surgery, Inc. Published by Blackwell Publishing. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: A systemic review of the English literature. Dermatol Surg 2006; 32:1309. DOI: 10.1111/j.1524-4725.2006.32300.x. Reprinted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1837=[""].join("\n");
var outline_f1_50_1837=null;
var title_f1_50_1838="Tolerance to chronic B agonist";
var content_f1_50_1838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tolerance to chronic beta agonist therapy in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of patients without an exacerbation of asthma over time in patients treated with as needed or regular (continuous) beta agonist therapy. The likelihood of exacerbation was greater in the patients treated with continuous beta agonist, suggesting the development of tolerance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Taylor, DR, Sears, MR, Herbison, GP, et al, Thorax 1993; 48:134.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1838=[""].join("\n");
var outline_f1_50_1838=null;
var title_f1_50_1839="Rx MS mild symptoms I";
var content_f1_50_1839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with mild mitral stenosis (MS) and mild symptoms (NYHA functional class II) - Part I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_50_1839=[""].join("\n");
var outline_f1_50_1839=null;
  